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Introduction
Parts of this chapter have been published as:
1. Rik Vandenberghe, Katarzyna Adamczuk, Patrick Dupont, Koen Van
Laere, Gaël Chételat. Amyloid PET in clinical practice: Its place in the
multidimensional space of Alzheimer’s disease. 2013 Neuroimage Clin
26:497-511.
2. Rik Vandenberghe, Katarzyna Adamczuk, Koen Van Laere. The interest
of amyloid PET imaging in the diagnosis of Alzheimer’s disease. 2013
Curr Opin Neurol 26:646-655.
1.1 Pathological hallmarks of Alzheimer’s dis-
ease
Cognitive and behavioral decline due to neurodegenerative disease is highly
prevalent across the world. Apart from the pervasive personal and familial
impact, the public health burden may become unsurmountable for healthcare
systems over the next decades [1, 2] unless more efficacious interventions to pre-
vent, halt or slow down Alzheimer’s disease (AD) [3] are discovered. The ability
to characterize directly in humans the underlying pathophysiological processes
is fundamental to progress in AD research and therapy. The initial abnor-
malities in AD probably occur at the functional level, involving synaptic and
neuronal dysfunction, possibly initiated by abnormalities in soluble amyloid
β42 (Aβ42). The exact temporal relationship between the diverse structural
alterations that follow is still a matter of active neuropathological and in vivo
research.
The principal structural changes are:
• Aβ amyloid aggregates, which may take different forms [4]: According
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to some authors, diffuse plaques should not be considered as pathologi-
cal since they are not associated with synapse loss or neuronal loss, key
features of Alzheimer’s disease [5]. Others have suggested that diffuse
amyloid plaques are related to the presymptomatic stage of AD [6]. In
contrast to diffuse plaques, neuritic plaques stain with thioflavine S or
Bielschowsky, indicative for the presence of tau pathology invading or
surrounding the plaque. A time sequence analogous to that described
for neurofibrillary tangles (NFTs) has been developed to describe the
propagation of amyloid, starting in neocortical areas (phase 1) and then
spreading to allocortical regions including, among other regions, entorhi-
nal cortex, cornus ammonis 1 (CA1), anterior and posterior cingulate
(phase 2), basal forebrain nuclei, diencephalic nuclei and striatum (phase
3), brain stem nuclei (phase 4) and further into the molecular layer of the
cerebellum (phase 5) [7]. At a certain stage the increase in β amyloid ag-
gregates may level off, also referred to as a ’growth arrest’ of the amyloid
plaques [8, 9].
• Neurofibrillary tangles (NFT) and neuropil threads [4]. Initially, neu-
rofibrillary tangles are mainly present in entorhinal and perirhinal cortex
spreading to the hippocampus (stage I/II). They subsequently spread to
inferior temporal and lateral temporal cortex (stage III/IV) and then be-
come widely distributed over neocortical association zones (stages V/VI)
[10, 4, 11]. These NFT stages correlate relatively well with neuronal loss
and with the severity of clinical symptoms [12, 13, 14, 15, 16, 17, 18].
• Loss of synaptic density [19, 20, 21, 22], starting in the dentate gyrus and
correlated to episodic memory scores [21].
• Neuronal loss, starting in entorhinal cortex [23], and correlated to cogni-
tive scores [15].
1.2 Why is Aβ pathology particularly interest-
ing?
1.2.1 Long accumulation phase of Aβ peptides
There is a general consensus that Aβ amyloid aggregation is a fundamental
feature of AD [24]. The interesting characteristic of this process is that it
begins years before clinical symptoms. Studies in Alzheimer’s disease muta-
tion carriers showed that increased amyloid load can be detected by amyloid
positron emission tomography (PET) tracers 15 years before expected symp-
tom onset [25, 26] and by cerebrospinal fluid (CSF) Aβ42 levels 25 years before
the symptoms [26] (Figure 1.1). These fundamental findings showed that Aβ
accumulation could be used as an early biomarker for AD-related changes. This
is in agreement with one of the most influential current AD models [27, 28],
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Figure 1.1: Biomarkers’ changes as a function of years from expected Alz-
heimer’s disease symptom onset. Standardized differences between mutation
carriers and non-carriers indicated that decreasing CSF Aβ42 and increasing
PET Aβ are the earliest detectable changes, followed by increasing CSF tau,
hippocampal atrophy and hypometabolizm, and cognitive decline (CDR-SOB:
Clinical Dementia Rating - Sum of Boxes). Adapted from [26].
which assumes that CSF alterations in Aβ42, amyloid aggregation, volume loss
on structural magnetic resonance image (MRI) and cognitive decline follow an
orderly temporal sequence, initiated by changes in amyloid and culminating
in the clinical expression of cognitive symptoms. On the contrary, alternative
models emphasize the partial independence of the different in vivo measures of
Alzheimer’s disease [29, 30, 31, 32]. Therefore, the definite role of Aβ accumu-
lation in AD-related neurodegeneration needs further clarification. So far, we
can conclude that (1) change in Aβ level occurs early in the disease, making it
a useful early AD biomarker, and (2) together with other factors it contributes
to the disease progression.
1.2.2 Amyloid−positive cognitively normal elderly
Neuropathological studies show that a substantial portion of healthy older sub-
jects has increased levels of amyloid β in their brains without cognitive deficits
[33, 34, 35, 36]. Concordantly, PET scans with amyloid tracers show that a
proportion of healthy older subjects has a positive amyloid scan, which can be
indistinguishable from what is seen in clinically probable AD (see for review
[37]). The proportions of subjects with increased Aβ in their brain are vari-
able in different studies and strongly dependent on the age of the subjects. The
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prevalence of a positive amyloid scan below the age of 60 years in the absence of
clinical symptoms is observed in around 13% of subjects [38], so that a positive
scan is more likely to be related to the clinical symptoms compared with the
older age group. At the other end of the age spectrum, a third of cognitively
intact subjects above the age of 78 [39, 40] has a positive amyloid scan, and
50% above the age of 82 [41]. As a consequence, the specificity in terms of a
clinical disease diagnosis necessarily will be relatively lower in this age group.
Nonetheless, an amyloid-positive finding has an important prognostic implica-
tion. Cognitively intact amyloid-positive subjects show more cognitve decline
during up to 10 years preceding the scan than amyloid-negative subjects, even
when matched for Apolipoprotein E ε4 status [42]. Increased Aβ load is asso-
ciated with a higher chance to convert to mild cognitive impairment (MCI) or
AD [43] and a greater rate of grey matter atrophy [44]. Similarly, cerebrospinal
fluid Aβ42 levels are also abnormal (lower) in a considerable proportion of the
cognitively intact elderly [45, 46, 47, 48, 49]. Asymptomatic mutation carriers,
in one of three genes - amyloid precursor protein (APP), presenilin 1 (PSEN1),
and presenilin 2 (PSEN2) - have lower CSF Aβ42 10 to 20 years before their
estimated age of symptom onset and before the detection of cognitive decline
[50]. In cognitively intact older adults reduced CSF Aβ42 is associated with
faster global and hippocampal grey matter atrophy [51] and worse cognitive
performance [52, 53]. Longitudinally, these subjects have faster and larger
cognitive decline [52, 54] and are at increased risk for future pathological Aβ
accumulation [49]. APOE ε4 status also plays a role in decreased CSF Aβ42
levels and in higher cortical Aβ deposition [48].
1.2.3 Preclinical Alzheimer’s disease
Preclinical AD, also termed asymptomatic AD, refers to the presence of AD-
related pathophysiological processes, such as amyloid aggregation, in individu-
als who currently do not manifest cognitive deficits [55, 56] (Figure 1.2). Ac-
cording to National Institute on Aging and Alzheimer’s Association (NIA-AA)
criteria, subjects in preclinical stage 1 have a positive amyloid biomarker, such
as amyloid PET scan or CSF Aβ42. In stage 2 they additionally have one or
more positive biomarkers for neurodegeneration, such as (a) hypometabolism in
an AD-like pattern on 18F-fluorodeoxyglucose-PET, or (b) elevated CSF tau or
phospho-tau levels, or (c) cortical thinning in typical AD areas or hippocampal
atrophy on structural MRI. In stage 3 individuals additionally have evidence
of subtle cognitive decline [55]. When these three stages of preclinical AD were
evaluated in a population-based sample of 450 cognitively normal subjects an
additional category was found to be necessary [39]. A SNAP category - sus-
pected non-AD pathophysiology, which denotes subjects with normal amyloid
biomarker but abnormal biomarker for neurodegeneration. In this sample 43%
of individuals were classified as stage 0 (normal AD biomarkers and no evidence
of subtle cognitive impairment), 16% as stage 1, 12% as stage 2, 3% as stage
3, and 23% as SNAP. Longitudinal follow-up studies of individuals in different
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Figure 1.2: The clinical course of Alzheimer’s disease. Preclinical Alzheimers’s
disease stage encompasses presympromatic autosomal dominant mutation car-
riers and asymptomatic biomarker positive individuals. Note that some indi-
viduals in the preclinical stage will not progress to clinical dementia. Adapted
from [55].
stages showed that in preclinical stages 1-3 subjects had greater risk for pro-
gression to MCI or dementia [57] and future cognitive decline and mortality
[58] than those in stage 0. Interestingly, the SNAP group had similar conver-
sion rate to MCI as the amyloid-positive group [57]. Subjects in stages 2 and
3 had higher rates of medial temporal neurodegeneration compared with the
other stages [59]. Such preclinical AD stages offer a window of opportunity for
early preventive action. According to a commonly held view, disease-modifying
therapies (e.g. anti-amyloid) may be most efficient in the earliest disease stages.
1.3 Biomarkers of brain Aβ amyloidosis
Modern techniques such as amyloid PET or CSF Aβ42 measurement allow one
to detect brain amyloidosis directly in vivo. These biomarkers have been ex-
tensively studied in patients with AD and MCI, and have been widely accepted
as biomarkers for the diagnosis of AD. Recommendations for the use of these
biomarkers were included in the diagnostic guidelines for AD and MCI, from
the NIA-AA [60, 61] and International Working Group (IWG) [62, 56, 63]. At
present time they should be used to increase the certainty of AD dementia
diagnosis as underlying cause of AD or MCI, but not yet for routine diagnostic
purposes.
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1.3.1 Amyloid positron emission tomography
The amyloid PET tracers developed to date belong to various chemical classes.
According to a postmortem study of homogenized brain tissue in AD and con-
trols, thioflavin T derivatives (such as 11C-Pittsburgh compound B (PIB) and
its derivative 18F-flutemetamol), stilbenes (18F-florbetapir and 18F-florbetaben,
among others), and benzofuranes (18F-NAV4694) share a common high-affinity
binding site that explains most of the signal in AD [64]. At the time of writing
three 18F-labeled tracers were approved by the Food and Drugs Administra-
tion (FDA) and European Medicines Agency (EMA) for estimation of amyloid
plaques in patients evaluated for cognitive decline: 18F-flutemetamol [65, 66]
(Figure 1.3), 18F-florbetaben [67], and 18F-florbetapir [68]. The majority of
the currently available 18F-ligands has been compared in vivo with 11C-PIB
[31, 69]: Neocortical values for retention of 18F-amyloid ligands correlate well
with neocortical values of retention of 11C-PIB. For 18F-florbetapir [70, 71], the
regression slope is less steep than for other ligands, suggesting a smaller dy-
namic range [31, 69]. For the 18F-ligands in general, correlation in subcortical
white matter is much lower, and only 18F-AZD4694 has a high correlation value
with 11C-PIB also in white matter [72]. Test-retest values (% difference be-
tween two time points divided by the average obtained at the two time points)
of standardized uptake value ratios (SUVRs) for a composite cortical volume of
interest with cerebellum as reference have been reported for 18F-flutemetamol
(1.5%, S.D. 0.7) [73], 18F-florbetapir (2.4%, S.D. 1.41) [74], 18F-florbetaben
(6.2%, range 0.6-12.2) [75] and 18F-NAV4694 (7.5%, S.D. 6.5) [76]. Fleiss’ κ
has been reported for 18F-flutemetamol (0.86-0.96) [73, 77], 11C-PIB (0.90)
[78], 18F-florbetapir (0.58-0.76) [74, 79] and 18F-florbetaben (0.60 [80]; 0.89-
0.94 [81]). Cohen’s effect sizes to discriminate AD from healthy controls vary
from study to study, even for the same compounds, ranging between 1.3 and
3.8 [78, 80, 75, 82, 72, 81]. So far no published studies are available that have
directly compared performance between 18F-amyloid ligands within the same
subjects in vivo which would be highly informative for the clinician.
1.3.2 Cerebrospinal fluid Aβ42
CSF assay is commonly used in clinical workup to measure markers of AD
pathology: Aβ42, total tau protein (t-tau), and tau phosphorylated at threo-
nine 181 (p-tau). CSF Aβ42 reflects fibrillar brain Aβ deposits as was shown
by postmortem samples [83] and cortical biopsies [84]. Lower levels of Aβ42
in CSF are observed in clinically probable AD [85, 86, 87, 58] and MCI pa-
tients [88] compared with controls (Figure 1.4), and they predict progression
to clinically probable AD in MCI and older controls with high accuracy up to
10 years before the onset of severe cognitive symptoms qualifying for demen-
tia due to Alzheimer’s [89, 46, 90, 58]. Amyloid peptide in the CSF can be
detected by means of different methods. In one of the common procedures,
after collection of the CSF (with or without a priori fasting), the sample is
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Figure 1.3: Amyloid PET scan with 18F-flutemetamol tracer. (A) On the
left side standardized uptake value ratio image of AD patient, on the right
side healthy control (HC). (B) Areas with increased amyloid deposition in AD
compared with HC. Voxel-level Puncor = 0.001. Areas outlined in blue: voxel-
level P = 0.05 corrected for whole brain volume. Adapted from [66].
analyzed for the presence of Aβ42 peptide by enzyme-linked immunosorbent
assay (ELISA). Analysis is usually performed with the commercially available
ELISA kits or with in-house developed assays. In principle, amyloid peptide
is captured by a first monoclonal antibody, then the sample is incubated with
a second biotinylated antibody. The biotinylated antibody is detected by the
pereoxidase-labeled streptavidin and after addition of the substrate solution
the sample will develop a color, whose intensity is a measure of the target
peptide concentration. The high within and between-laboratory variability in
the CSF biomarker levels due to assay-related pre-analytical and analytical
factors is an important issue [91, 92, 93]. The cut-off values, which are used
to dichotomize individuals in the AD or non-AD CSF pattern, are affected by
this variability. Several studies have investigated the agreement between CSF
Aβ42 assay and amyloid PET, showing that CSF Aβ42 is inversely correlated
with cortical uptake of different amyloid tracers in AD, MCI and healthy older
adults (with 11C-PIB [94, 95, 96, 97, 50], with 18F-florbetapir [98, 99], and
with 18F-flutemetamol [100]). Dichotomization based on 11C-PIB is highly
concordant with that based on CSF Aβ42 [101]. When 18F-florbetapir and
14 Chapter 1
Figure 1.4: Cerebrospinal fluid Aβ42 levels in different populations. Cogni-
tively normal subjects (CN), Alzheimer’s disease patients (AD), and individu-
als with stable and progressive mild cognitive impairment (sMCI and pMCI).
Adapted from [99].
CSF Aβ42 were compared, discordance occurred more frequently but overall
they were consistent in the majority of subjects [98]. Regardless of the good
correlation and similar discriminative power for amyloid positivity, CSF Aβ42
and amyloid PET provide partially independent information and measure dif-
ferent aspects of AD amyloid pathology [102, 103]. In CSF a soluble amyloid
β protein is measured [104], whereas PET measures an aggregated (insoluble)
form of amyloid β [105]. For a more in-depth discussion of the relationship
between soluble Aβ42 in the brain and in CSF refer to Chapter 7 page 100.
1.4 Genetic effects on amyloid load
The process of Aβ accumulation, as all other biological processes in our body,
is influenced by a variety of factors. Except age, genetics is a second main risk
factor for increased brain amyloid load in AD, MCI and cognitively intact older
subjects. Downstream to the Aβ accumulation, cognitive reserve, environmen-
tal factors or brain diseases may influence how one’s brain responds to the Aβ
pathology [55].
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1.4.1 Polymorphism of apolipoprotein E
The strongest genetic factor modulating brain amyloid levels is the apolipopro-
tein E (APOE) gene. The APOE gene is located on chromosome 19. Its
two single nucleotide polymorphisms (SNP) at loci rs429358 and rs7412 cause
amino acid substitutions at codons 112 and 158 in the ApoE protein. These
SNPs make up three possible alleles: ε2, ε3, ε4. The most common and neu-
tral form is ε3, ε2 is less common and may have a protective effect on amyloid
accumulation [106]. The APOE ε4 is a dose-dependent risk factor for late-
onset and early-onset AD [107, 108]. The lifetime risk for AD is 30-40% in
people with one ε4 allele, in ε4 homozygotes it is as high as 90%, and in ε4
non-carriers it is around 9% [109, 110]. The conversion risk from HC to AD
or MCI conferred by the APOE ε4 is greater in women than in men [111]. In
a dose-dependent manner, APOE ε4 is associated with increased brain amy-
loid deposition in AD, MCI and healthy older adults as evidenced by amyloid
PET scan [112, 113, 114] and Aβ42 in CSF [115, 116, 117, 48]. The major-
ity of neuropathological studies showed that APOE ε4 AD patients have more
pronounced amyloid pathology compared with non-ε4 patients [118]. The detri-
mental effect of APOE ε4 on amyloid deposition is consistent among studies
in cognitively intact older adults, however, in clinical AD patients the effect on
amyloid load is less consistent [119]. This effect is more pronounced in specific
regions, namely in the lateral and medial frontal cortex, temporoparietal cor-
tex, and posterior cingulate-precuneus [112, 113, 114]. Throughout the disease
progression this regional pattern remains unchanged, only the amyloid deposi-
tion becomes stronger [112, 114]. The mechanism through which the ε4 variant
affects amyloid burden is probably related to the impaired clearance of soluble
Aβ. One of the potential mechanisms could be that the ε4 isoform competes
with soluble Aβ peptides for the same receptors/transporters responsible for
the metabolism of soluble Aβ species [120, 121].
1.4.2 Other genetic factors
A family history of AD is associated with increased brain amyloid levels and
increased risk for developing AD [122, 123], beyond what can be explained
by APOE alone. Subjects with a maternal family history of late onset AD
in particular, have higher amyloid tracer binding in well-established areas of
amyloid deposition, compared with subjects without or with paternal family
history [124]. These individuals also manifest decreased CSF Aβ42 levels and
this is independent from the effect of APOE ε4 [125].
Among non-APOE susceptibility genes for AD, several genetic variants
identified by genome wide association studies influence brain amyloid levels.
For instance, SNP rs6656401 [126] and rs6701713 in the CR1 gene, and two
other SNPs in ABCA7 (rs3764650) and CD2AP (rs9349407), plus several newly
identified variants [127], were associated with neuritic plaque burden at au-
topsy. In terms of genetic interactions, the minor allele in BIN1 (rs7561528 or
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rs744373) together with the common allele in PICALM (rs7851179) [128], as
well as the common allele in CR1 (rs3818361) together with the minor allele in
APOE [129], were associated with higher amyloid PET burden. One SNP in
an intronic part of the DHCR24 gene (rs7551288) revealed a protective effect
against amyloid accumulation [130].
The non-APOE risk genes have small observed effects and they do not ex-
plain the whole genetic variation associated with late onset AD [131]. There-
fore, new genetic variants explaining the missing heritability remain to be
found. For instance, one of the potential candidate genes could be the brain
derived neurotrophic factor (BDNF). Given the prominent role of BDNF in
neuroplasticity and a failure of neural plasticity as a potential common theme
in AD [17], BDNF could theoretically be linked to AD-related processes at
the molecular, neuronal or systems level. Thus, BDNF polymorphisms (for in-
stance at SNP rs6265) could influence the resilience against β amyloid related
changes.
1.5 Functional brain activity and amyloid load
Task-related fMRI can reveal adaptive changes in cognitive brain circuits during
cognitive processing which may provide resilience against the functional impact
of amyloid pathology. Brain resilience and functional reorganisation may gain
importance in the field as AD therapies may increasingly target multiple facets
of AD. To the best of our knowledge, three studies combined amyloid PET and
task-related fMRI within the same subjects in MCI or AD.
1.5.1 Language and associative-semantic system
The first study focused on changes in the language circuit in early-stage clin-
ically probable AD and how this is related to amyloid ligand retention [132].
This study built on a preceding study in amnestic MCI. In amnestic MCI, the
earliest changes in the language network occur in the posterior part of the left
superior temporal sulcus (STS) (Figure 1.5) and these changes correlate with
subclinical changes in written word identification speed, in line with the critical
role of this region in lexical-semantic retrieval [133]. In early-stage AD hypoac-
tivity is also seen in left posterior temporal cortex during associative-semantic
versus visuoperceptual processing. These fMRI changes in the left posterior
STS in AD correlate with oﬄine measures of confrontation naming: clinically
probable AD subjects with hypoactivity in this region are impaired on con-
frontation naming [132]. There is no correlation between 11C-PIB levels in this
region and the clinical deficit [132]. fMRI activity levels to the homotopical
right side show increased activity in those patients who had preserved naming
on the confrontation naming, suggestive of a compensatory increase [132].
Introduction 17
Figure 1.5: Earliest functional changes in the language system. Higher
activity in the posterior superior temporal sulcus in the associative-semantic
task compared with the visuoperceptual task: in controls compared with MCI
(red), for words more than pictures (blue), and for words and pictures (green).
Uncorrected P < 0.001. Adapted from [133].
1.5.2 Memory domain
Other studies focused on the episodic memory domain. In a study with MCI
subjects, the effect of a positive amyloid scan on hippocampal fMRI activ-
ity, hippocampal volume, and global cognition was evaluated cross-sectionally
and longitudinally. At baseline, amyloid-positive MCI subjects had increased
hippocampal activation during associative face-name memory encoding task
and smaller hippocampal volumes. Longitudinally, these subjects continued
to show increased hippocampal activation and decreased hippocampal volumes
[134].
A combined 11C-PIB-fMRI studies in healthy older adults revealed that
amyloid-positive cases have increased activation in task-positive regions during
an episodic memory encoding task of natural scenes, namely in ventrolateral
prefrontal, lateral occipital, lateral parietal, posterior inferior temporal cortices,
and the right parahippocampal/hippocampus [135, 136]. This increased activ-
ity was positively correlated with memory measures [135] and more detailed
memory encoding [136]. Amyloid-positive subjects also had decreased deacti-
vation in task-negative regions: posteromedial, medial prefrontal, and lateral
temporoparietal cortices [135, 136]. Along the same lines, during encoding
of associations between faces and names, the precuneus and temporoparietal
cortex, partially overlapping with the posterior nodes of the default mode net-
work, were less deactivated in amyloid-positive subjects compared to amyloid-
negative subjects [137]. Deactivation in precuneus-posterior cingulate area is
inversely related to hippocampal activation [138].
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1.6 Aims of the thesis
In this PhD project we aimed to investigate different effects related to brain
amyloid load in the cognitively intact older population. We combined diverse
but complementary techniques, such as amyloid imaging- and fluid-biomarkers,
functional MRI of the language and associative-semantic system, neuropsycho-
logical tests, and genetics to explain the variance in amyloid burden, topogra-
phy, and effects on brain function.
Aim 1: Influence of BDNF and APOE polymorphisms on brain amy-
loid load
The first aim of this doctoral research project was to test whether genetic poly-
morphisms could influence the level of amyloid load in cognitively intact older
individuals, and whether they could provide resilience against increased amy-
loid deposition. In particular, we evaluated if the BDNF val carriers were able
to compensate for the presence of amyloid in a better way than met carriers,
and if this was dependent on the APOE status (Chapter 3).
Aim 2: Effect of amyloid load on the language and associative-
semantic system
The second aim of this doctoral research project was to investigate through
which mechanisms cognitively intact volunteers are able to maintain their cog-
nitive status despite a high amyloid load. By means of amyloid imaging and
associative-semantic fMRI we investigated whether the increased amyloid load
in cognitively intact older adults induced early functional changes in the lan-
guage and associative-semantic system, and whether these adaptive changes
in the language network differed between BDNF met carriers and non-carriers
(Chapter 4).
Aim 3: Comparison of two amyloid imaging biomarkers for preclini-
cal Alzheimer’s disease
The third aim of this doctoral research project was to test which amyloid
PET tracer was most suitable to identify subjects with abnormal (AD-like)
levels of amyloid deposition. More specifically, we evaluated whether the 18F-
flutemetamol amyloid ligand was as accurate as its parent molecule 11C-PIB in
detecting cognitively intact older subjects with high amyloid load (Chapter 5).
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Aim 4: Comparison between different CSF Aβ isoforms for detection
of preclinical Alzheimer’s disease
The fourth aim of this doctoral research project was to evaluate the added
value of the various Aβ isoforms and their ratios via the intermediary of 18F-
flutemetamol PET and also compared this to the ratio between Aβ42 and total
tau. More specifically, we evaluated which of the following, Aβ42, Aβ40, Aβ38
isoforms, total tau, the Aβ42 ratios over Aβ40, Aβ38 and ttau, were most
accurate in detecting cognitively intact older subjects with elevated amyloid
load defined by a positive 18F-flutemetamol PET (Chapter 6).
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2
Experimental techniques
2.1 Positron emission tomography
In this project we utilized two positron emission tomography tracers which bind
to cortical neuritic plaques [139, 140, 141, 142]: 18F-flutemetamol [66, 65] and
11C-PIB [105]. These and other amyloid tracers are described in Section 1.3.1.
Basic principles, acquisition, processing, and statistical analysis of a PET scan
are described in the following part of this chapter.
2.1.1 Principles, acquisition, and reconstruction
Positron emission tomography is an imaging technique which relies on spatial
detection of radioactively labelled molecules. In a cyclotron 14N is bombarded
with protons to produce 11C and 18O is bombarded with protons to produce
18F (as fluoride ions). Such unstable radioisotopes (11C, 18F) are later coupled
to a molecule of interest. The radio-labelled molecule (tracer) is injected into
the blood stream and is distributed according to its physiological function. To
reach the steady state a proton inside a radionuclide nucleus is converted into
a neutron while releasing a positron and an electron neutrino, this is called
a beta+ decay. Within few millimetres the emitted positron collides with an
electron. As a consequence their masses annihilate and two photons of 511 keV
are produced, which travel in opposite directions at approximately 180 degrees.
Photons are detected in the scintilation crystals of a PET camera connected to
the photomultipliers, which convert photons into an electric current and then
amplify and measure it. An electronic coincidence circuit evaluates timing of
the absorbed photons and only the pairs of photons which arrive near simul-
taneously at the opposite PET camera crystals (coincidence pairs) are passed
through. The number and place of origin of the coincident detections along the
same line are recorded. It is important to note, that photons interact with the
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tissue through which they travel, thereby attenuating their kinetic energy. Usu-
ally, a low dose CT scan is acquired before the PET scan to measure densities
of different tissues and to estimate a fraction of lost signal. This is used then to
correct for the attenuation effects before the PET image is reconstructed. Two
other common interactions with tissue are scattered and random coincidences.
During a scattered coincidence a travelling photon interacts with an electron
and changes its direction. Photons are then detected by two scintilators which
are not opposite to each other. A random coincidence occurs when photons
from two different annihilation events are picked up by opposite scintilator
crystals within the time window of a coincidence. Both scatter and random
events lead to wrong predictions of the line of response and place of origin of
the true coincidence. This blurs the image and introduces noise to the signal,
therefore, images must be corrected for these events before the reconstruction
[143].
Measured coincidences (i.e. counts) are assigned to a particular line of re-
sponse at a particular angle. All coincidences are then placed in 2D images
named sinograms, which represent counts measured for all projection lines at
each available angle. Sinograms are later reconstructed to visually interpretable
images by backprojection algorithms, which as the name says, project back a
value measured at a certain line to the whole line, for each angle. Many recon-
struction algorithms exist today, such as filtered back projection or iterative
reconstruction. One of the often applied iterative algorithms is ordered subsets
expectation maximization. This method a priori takes into account informa-
tion about noise in the signal and includes a non-negativity constraint. These
features together with the iterative mode generate superior quality images,
however at the cost of longer processing time [143, 144].
2.1.2 Preprocessing
Images corrected for attenuation, scatter, and random coincidences are re-
binned into time frames. Depending on the reconstruction method, time frames
are either specified in advance or rebinned after the reconstruction. When
defining the time frames one should take into account that each frame should
have a similar tracer distribution and sufficient counts. In case of a “dynamic”
scan, data is acquired from the start of tracer injection, with shorter frames
at the beginning gradually extending into longer ones e.g. 4 x 15 s, 4 x 60
s, 2 x 150 s, 12 x 300 s. For a “static” scan, acquisition is started from the
point in time when the tracer reaches a stable distribution e.g. after 90 min
for 18F-flutemetamol with 6 frames of 5 min. Since the PET scanning time
is longer some motion is inevitable and frames should be spatially aligned to
correct for potential head motion. Within the same imaging modality rigid
transformation (6 parameters: 3 rotation and 3 translation parameters) can
be used to align the frames. For further processing of a static scan a sum or
an average of the aligned frames is used. In order to perform group analysis,
an individual subject’s sum or average PET image should be spatially normal-
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ized to a common stereotactic space such as the Montreal Neurological Institute
(MNI) space. If volumetric T1-weighted MR scan is available, it can be utilized
to more precisely transform the PET image into the atlas space. MR images
have much higher resolution and contain more detailed information about the
anatomy. Also, the transformation will not depend on the tracer uptake, as in
the case of PET-based spatial normalization. PET and MR images must be
first coregistered to each other. These are two different modalities, therefore,
a more detailed method such as an affine transformation with 12 parameters
(additionally 3 zoom and 3 skew parameters) is advisable. The coregistered
MR is spatially normalized to the T1 template in MNI space. One option to do
this, recommended in Statistical Parametric Mapping (SPM) software [145], is
to use a unified segmentation approach. This generates three segmentations,
grey matter, white matter, and cerebrospinal fluid, and non-linear transforma-
tion parameters. The transformation parameters are then applied to the PET
scan to bring it to MNI space [144].
2.1.3 Signal quantification
To measure specific tracer retention the PET signal needs to be quantified ei-
ther by a full kinetic modelling or simplified models applied to each voxel. In
the process of kinetic modelling measured data are fitted to a mathematical
model to predict tracer behaviour. It requires measuring tracer concentration
in arterial blood plasma (input function - reflects the amount of tracer avail-
able for binding) and measuring tracer concentration in a target tissue e.g.
brain (output function at multiple time points). Tracers often form metabo-
lites outside the brain and the input function needs to be corrected for that.
To measure target concentration in the brain across time, a dynamic scan is
required. Lastly, a proper mathematical model needs to be selected. Such
complex but precise modelling is favoured for new tracers, whose behaviours
need to be studied in detail. Often, it is possible to simplify models by making
certain assumptions and validating the results versus the original full model.
An example of such simplified quantification is a reference tissue model. In-
stead of an input function it employs a reference region, which contains only
non-specifically bound and unbound tracer. A further simplification could be
to only use static images at later time points when tracer uptake is considered
at steady state. Standard uptake value ratios (SUVR) can be used to create
parametric images by dividing the tracer concentration in the tissue of inter-
est e.g. cerebral cortex by the uptake in the reference region e.g. cerebellar
grey matter. In this way signal is corrected for the non-specifically bound and
unbound tracer [144].
Important confounds that PET images may suffer from are partial volume
effects (PVE). They arise from a low spatial resolution of the PET images,
which is about 4 to 8 mm of full width at half maximum (FWHM). When the
structures of interest are smaller than the sampling resolution, e.g. cerebral
grey matter, the measured signal is an average of the tracer uptake in a target
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and surrounding tissues. PVE pose a concern especially when the effect of
interest is a decrease in tracer binding. For example, a lower signal may stem
from a true decreased tracer concentration or from atrophy in the grey matter.
One of the common partial volume correction methods uses a volumetric MR
image [146]. Grey matter, white matter, and cerebrospinal fluid segmentations
are used to estimate different tissue fractions per voxel in order to determine
corrected tracer concentration per unit volume of grey matter [144, 146].
2.1.4 Statistical analysis
Before entering the statistical analysis, images should be spatially smoothed.
Smoothing improves the signal-to-noise ratio, reduces inter-subject anatomical
variability (even after spatial normalization subjects’ brains slightly differ in
shape and size), and it is required by the Random Field Theory which is used
to correct for multiple comparisons during the statistical analysis. The size of
the smoothing kernel should correspond to the size of the expected effect.
To explore tracer binding differences or its relationship to different variables
between subjects, images must be statistically analysed. Voxel-based analysis
will identify which voxels show significant change in tracer binding. SPM per-
forms a statistical test in every voxel of the brain. The dependent variable
is the voxel value of the image and independent variables or covariates, such
as age or genotype, are the same across all voxels. Since a statistical test is
performed in each voxel of the brain, correction for multiple comparisons must
be employed to correct for false positive findings. In SPM family-wise error
(FWE) correction is used based on Random Field Theory. FWE correction
estimates the likelihood of finding a significant group of voxels just by chance,
taking into account the number of resolution elements (not voxels) in the whole
brain volume. FWE corrected P values are generated for the voxel-level: the
highest Z value, for the cluster-level: the cluster of voxels above a certain Z
value, and for the set-level: set of clusters above a certain Z value [147]. Sig-
nificance is often tested at the combined voxel- and cluster-levels [148]. One
can also restrict the analysis to a particular volume of interest, hereby reduc-
ing number of statistical tests. In another approach, one can calculate a mean
value in cerebral cortex or in volumes of interest, and this can be analysed by
standard statistics. These values can also be used to dichotomize subjects in
tracer positive (increased uptake) or tracer negative (decreased uptake), and
they may be used to predict changes in other variables.
2.2 Magnetic resonance imaging
2.2.1 Basic principles
Magnetic resonance imaging is a powerful technique to visualize anatomy and
physiology of the human body. It can be used to study anatomical and func-
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tional organization of the brain. It measures the protons in tissues (hydrogen
atoms), which spin around their axis creating a magnetic dipole. In the absence
of an external magnetic field (B0), protons (or spins) are randomly oriented
resulting in a net magnetization close to zero. When an external magnetic field
is applied during MR scan (the static magnetic field in the MRI scanner is typ-
ically 1.5 or 3 Tesla), a small majority of spins aligns with the direction of the
magnetic field generating a net magnetization (longitudinal magnetization).
The aligned spins precess along the direction of the magnetic field with the
Larmor frequency, which is proportional to the strength of B0. The precessing
spins are out of phase, therefore the transverse magnetization perpendicular
to the direction of the magnetic field is zero. When a radiofrequency (RF)
pulse is applied at the Larmor frequency the aligned spins tilt away by 90◦ (or
another flip angle can be used) and they start precessing in phase. Hence, the
longitudinal magnetization decreases and transverse magnetization increases.
As soon as the RF pulse is terminated spins return to the low energy state and
the net magnetisation becomes once again parallel to the B0. This process,
which is termed relaxation, is characterized by two time constants. The T1
time constant describes the time point at which longitudinal magnetization re-
covers to 63% of its original value. A simultaneous but separate time constant
is T2, it describes the time point at which transverse magnetization drops to
63% of the original value. T2 depends on the spin-spin interactions in the
surrounding microenvironment. Different tissues, such as grey matter, white
matter, bone, fat, cerebrospinal fluid, have distinct T1 and T2 time constants.
By manipulating the time of read out of the signal, adapted to specific T1
and T2 constants, one can visualize distinct tissue classes. To spatially localize
the protons three magnetic gradients are superimposed on the main magnetic
field. Gradients change the strength of the magnetic field in different spatial
locations, therefore each spin has slightly different precession frequency and
can be precisely localized. The transverse magnetization induces alternating
current in receiver coils placed around individual’s head in the xy-plane. This
current is translated into sine (coils along y) and cosine (coils along x) waves.
The combination of particular phase and frequency of each wave identifies a
spatial location. In the final step frequency spectra are transformed into the
spatial domain [143, 149].
2.2.2 Functional MRI principles and acquisition
Functional MRI (fMRI) is used to create images of brain activity in response
to a particular task or during rest, indirectly by detecting blood oxygenation
changes. Active neurons have increased demand for oxygen supply. To meet
this need blood flow and volume in arterioles and venules surrounding active
neurons increase. The composition of the blood changes in such a way that the
relative amount of oxyhemoglobin to deoxyhemoglobin increases. This hemody-
namic response to neuronal activity reaches its peak after around 6 seconds and
then comes back to the original state. Oxyhemoglobin is diamagnetic (it has
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weak magnetic properties) and deoxyhemoglobin is paramagnetic (it distorts
the local magnetic field resulting in a signal decrease). The difference between
oxy- and deoxyhemoglobin levels is the source of the blood oxygenation level
dependent (BOLD) contrast, which is used in fMRI. Deoxyhemoglobin causes
faster dephasing of spins (spin-spin interactions) and combined with field inho-
mogeneity leads to faster signal loss described by time constant T2*. A higher
oxy- to deoxyhemoglobin ratio gives increased signal on the T2*-weighted im-
ages. Such images should be acquired by a fast imaging technique as echo
planar imaging (EPI). During the EPI sequence a whole xy-plane is acquired
after a single RF pulse thanks to rapidly changing gradients. Typically for an
fMRI sequence, the time between two RF pulses should be longer (TR, e.g.
3000 ms) and time between RF pulse and data collection should be short (TE,
e.g. 30 ms) [149].
2.2.3 Preprocessing
Similarly as for the PET data, fMRI scans need to be preprocessed to correct
for some of the noise induced during data acquisition. An fMRI scan usually
takes a longer time and is composed of many EPI volumes (images), therefore,
to correct for potential head motion volumes are realigned to the first (or any
other) acquired volume. The structural T1-weighted image is coregistered to
the mean of the realigned fMRI images. This structural scan is then normalized
to the T1 template in MNI space by a unified segmentation approach in SPM,
producing three segmentations and transformation parameters. The transfor-
mation parameters are then applied to the fMRI scans to bring them to MNI
space. The spatially normalized fMRI scans are smoothed with a Gaussian
kernel, for the reasons explained before in Section 2.1.2. Depending on the de-
sign of fMRI study, slice-time correction may be necessary (taking into account
that not all slices were acquired at the same time point of the hemodynamic re-
sponse). In this project we used block design, which is considered less sensitive
to the slice-time errors. In block design different tasks (conditions) are shown
consecutively for few tens of seconds and they are repeated several times. Thus,
the signal for a given condition is averaged over a wider time range, and addi-
tionally slice-time errors have similar effects on all conditions. The fMRI signal
needs to be corrected for non-relevant frequencies coming from physiological
or non-physiological sources. Examples of the physiological noise are periodic
spin motions, such as breathing, heart beats, blood vessels pulsation. Scanner
related drifts are one example of the non-physiological noise. Therefore, low
and high-pass filters must be applied to remove too low or too high frequencies
[143, 149].
2.2.4 Signal modelling and statistical analysis
In comparison to the PET images, where each voxel contains direct information
about a metabolic process, specific brain activity cannot be directly deduced
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from the preprocessed fMRI images. To interpret the fMRI signal, a specific
question must be asked about a cognitive process and by comparison of the
fMRI signal between the condition of interest and a control condition one can
obtain meaningful images. Those images are statistical maps which show re-
gions with significant signal change in response to a cognitive task. The analysis
of fMRI images is done in two steps.
In the first step, variance in the fMRI signal is modelled at the individual
subject level (fixed effects). It is assumed that the measured signal can be ex-
plained by a set of explanatory variables and an error term. In SPM the general
linear model and standard least squares are used to estimate the contribution
of each explanatory variable (condition) to the response variable for each voxel.
Technically, an image is created containing a parameter estimate (β) in each
voxel, which evaluates the contribution of a given condition to the fMRI signal
in that specific voxel, these are β-images. To explore differences between con-
ditions contrast images are created. A contrast image is a difference between
β-images weighted for the variance in each voxel. To assess the significance of
a contrast a t statistic is applied to each voxel and an image with all t-values
is created.
In this project we were interested in specific activations from associative-
semantic processing for words and pictures. The associative-semantic task was
derived from the Pyramids and Palm Trees test [150], a classical neuropsy-
chological test of associative-semantic processing for words and pictures. We
created contrast of interest by comparing the associative-semantic condition
with the visuoperceptual control condition. The control and task conditions
were matched in terms of difficulty, visual stimulation, and number of right
and left button presses. Thus, we believe that this contrast specifically probes
associative-semantic language areas.
In the second-level analysis, the individual contrast images are used for a
random effects analysis. Hence, it allows for inferences about the population
from which the subjects were drawn. Statistical tests as linear regression,
two-sample t test, factorial analysis of variance, etc. can be employed at this
level. Since the statistical test is applied to each voxel a correction for multiple
comparisons must be performed. Different approaches for this are explained in
Section 2.1.2.
2.3 Neuropsychological tests
2.3.1 Conventional tests
All participants included in this project underwent a conventional neuropsy-
chological protocol which probed several cognitive domains. General cognitive
functions, including orientation, memory, attention, language, and calculation,
were tested by the Mini Mental State Examination [151], and Clinical De-
mentia Rating score [152]. Verbal episodic memory was examined by the Rey
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Auditory Verbal Learning Test [153]. Language domain was assessed by the
Boston Naming Test [154, 155], the Letter Verbal Fluency and the Animal Ver-
bal Fluency [156]. Executive functions were tested with the Raven’s Standard
Progressive Matrices [157] and the Trail Making Test [158]. We used validated
Dutch versions of all the tests.
2.3.2 Experimental language tests
Subjects who participated in the experiments described in Chapter 3 and
Chapter 4 underwent three experimental neuropsychological tests: confronta-
tion naming [159], lexical decision [160], and speeded word identification [133].
We have chosen these tests since they activate language related temporal ar-
eas, some of which are involved in the early language impairment in AD
[161, 162, 163, 132]. All the tests were in Dutch. The confrontation naming
task tested word-finding abilities. Subjects were asked to read aloud presented
words belonging to different categories. The lexical decision task measured
lexical-orthographic retrieval. Subjects were asked to decide with a button
press if a presented word exists or not. The speeded word and picture identi-
fication task examined visual identification and higher-order lexical processes.
Subjects were asked to read a word or name a picture, which were presented
at various durations. In all 3 tasks we measured subjects’ reaction times and
accuracies.
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3.1 Abstract
Aside from apolipoprotein E (APOE), genetic risk factors for β amyloid de-
position in cognitively intact individuals remain to be identified. Brain de-
rived neurotrophic factor (BDNF) modulates neural plasticity, which has been
implicated in Alzheimer’s disease. We examined in cognitively normal older
adults whether the BDNF codon 66 polymorphism affects β amyloid burden
and the relationship between β amyloid burden and cognitive scores, and how
this relates to the effect of APOE. Amyloid load was measured by means of
18F-flutemetamol PET in 64 community-recruited cognitively intact individu-
als (mean age 66, S.D. 5.1). Recruitment was stratified according to a facto-
rial design with APOE (ε4 allele present vs absent) and BDNF (met allele at
codon 66 present vs absent) as factors. Individuals in the four resulting cells
were matched by the number of cases, age, and gender. Among the APOE ε4
carriers, BDNF met positive subjects had a significantly higher amyloid load
than BDNF met negative subjects, while BDNF met carrier status did not
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have an effect in APOE ε4 non-carriers. This interaction effect was localized to
precuneus, orbitofrontal cortex, gyrus rectus, and lateral prefrontal cortex. In
the APOE ε4/BDNF met carriers, a significant inverse relationship existed be-
tween episodic memory scores and amyloid burden but not in any of the other
groups. This hypothesis-generating experiment highlights a potential role of
BDNF polymorphisms in the preclinical phase of β amyloid deposition and also
suggests that BDNF codon 66 polymorphisms may influence resilience against
β amyloid-related effects on cognition.
3.2 Introduction
In a variable proportion of cognitively intact older subjects, in vivo amyloid
imaging has revealed increased cerebral Aβ deposition, sometimes to a degree
identical to that seen in patients with clinically probable Alzheimer’s disease
(AD) [164, 165, 166, 132, 167, 168, 169]. This finding has attracted a lot of
interest as it may be a possible marker for preclinical Alzheimer’s disease [55].
The only genetic risk factor proven to be associated with increased amyloid
load in a cognitively intact population is the apolipoprotein E (APOE) ε4 allele
[114, 166, 113, 117, 43], which is also a strong risk factor for Alzheimer’s disease
[107, 170]. Beyond what can be explained by APOE alone, a family history
of AD is associated with increased brain amyloid levels in cognitively intact
older adults [125]. According to a recent study, polymorphisms of complement
component (3b/4b) receptor-1 (CR1 ) modulate the effect of APOE ε4 on brain
amyloid levels [129]. These findings suggest a complex interaction between
genetic variants and brain amyloid deposition in preclinical AD [55].
A failure of neural plasticity has been put forward as a unifying theme
spanning across the multiple pathways that lead to clinical AD [171, 172, 17,
173, 174]. Brain derived neurotrophic factor (BDNF), a neurotrophin with
high affinity for tyrosine kinase B receptors (TrkB), has been implicated in
neural plasticity [175, 176] as well as in memory, both in humans [177] and in
animal models [178, 179, 180]. In humans, a common single nucleotide polymor-
phism (SNP) in the 5’ prodomain of the BDNF gene which results in valine
to methionine substitution at codon 66 (val66met), affects memory function
[181, 182, 183, 184, 185, 186, 187], hippocampal volume and fMRI responses
[183, 188]. The met allele occurs in approximately 35% of the Caucasian popu-
lation [189]. Given the prominent role of BDNF in neuroplasticity and a failure
of neural plasticity as a potential common theme in AD [17], the BDNF-TrkB
pathway could theoretically be linked to a host of AD-related processes at the
molecular, neuronal or systems level.
The original hypothesis underlying the design of our study was that BDNF
polymorphisms might influence the resilience against β amyloid related changes
[132]. We hypothesized that BDNF val carriers would be able to compensate
for the presence of β amyloid in a better way than met carriers. Such resilience
might be manifest as a difference between genetic strata in how Aβ load affects
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cognitive scores and also as a difference in compensatory mechanisms at the
brain systems level [132]. As a first step, we examined whether there were any
direct effects of the BDNF codon 66 polymorphism on amyloid retention in cog-
nitively intact older adults, measured by means of 18F-flutemetamol positron
emission tomography (PET) [65, 66, 73, 190].
3.3 Subjects and methods
3.3.1 Subjects
The main cohort consisted of 64 community-recruited older adults between 50
and 75 years of age (mean age = 66, S.D. = 5.1, range 53-74) (Table 3.1).
The study exclusion criteria were a Mini Mental State Examination [151] score
lower than 27, a Clinical Dementia Rating score [152] higher than 0, signif-
icant neurological or psychiatric history, significant brain lesions on struc-
tural MRI, and below-normal test scores on conventional neuropsychological
assessment (Table 3.1). Inclusion was stratified per age bin (50-59, 60-64, 65-
69, 70-75) for two genetic factors: BDNF (met allele present or absent) and
APOE (ε4 allele present or absent). The cells of this 2 x 2 factorial design
were prospectively matched for number of cases, gender, age, education and
handedness (Edinburgh Handedness Inventory) (Table 3.1). BDNF and APOE
variants were genotyped by sequencing at the Genetic Service Facility (GSF,
www.vibgeneticservicefacility.be) of the VIB Department of Molecular Genet-
ics.
The genetic distribution among all subjects who underwent screening, was
10% BDNF met +ve/APOE ε4 +ve, 16% BDNF met -ve/APOE ε4 +ve, 33%
BDNF met +ve/APOE ε4 -ve, and 41% BDNF met -ve/APOE ε4 -ve. Af-
ter genetic stratification, the genetic distribution of the final cohort (n = 64)
was as follows: 25% were BDNF met +ve/APOE ε4 +ve, 23% BDNF met
-ve/APOE ε4 +ve, 25% BDNF met +ve/APOE ε4 -ve, and 27% were BDNF
met -ve/APOE ε4 -ve.
The protocol was approved by the Ethics Committee University Hospitals
Leuven (EudraCT: 2009-014475-45) and written informed consent was obtained
from all subjects in accordance with the Declaration of Helsinki.
3.3.2 Image acquisition
18F-flutemetamol PET imaging for the main cohort was performed at the Uni-
versity Hospitals Leuven. The acquisition procedure has been described before
[65, 66, 73, 190]. Images were acquired on a 16-slice Siemens Biograph PET/CT
scanner (Siemens, Erlangen, Germany). The PET tracer was injected intra-
venously as a bolus (mean activity 150.6 MBq, S.D. 8 MBq, range 137.9-192.5
MBq) in an antecubital vein. Image acquisition started 90 min after tracer
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Demographic data and neuropsychological test scores
Genetic groups P
BDNF met +ve BDNF met -ve BDNF met +ve BDNF met -ve
APOE ε4 +ve APOE ε4 +ve APOE ε4 -ve APOE ε4 -ve
Gender (M/F) 7/9 9/6 8/8 10/7 0.8
Age (years) 65.4 (5.5) 66.5 (4.3) 65.3 (5.5) 65.8 (5.4) 0.9
Education (years) 13.3 (3.0) 12.5 (2.2) 13.9 (2.2) 14.7 (3.6) 0.2
Handedness (%) 95.0 (14.5) 100.0 (0.0) 96.7 (7.7) 100.0 (0.0) 0.2
MMSE (/30) 29.0 (0.9) 28.7 (1.1) 29.3 (0.6) 28.9 (0.9) 0.3
AVLT DR (/15) 11.4 (2.4) 10.3 (3.6) 11.3 (2.8) 10.6 (2.2) 0.6
AVLT TL (/75) 48.9 (7.8) 50.1 (8.6) 51.1 (12.3) 49.0 (9.1) 0.9
BNT (/60) 53.1 (5.4) 51.9 (6.5) 52.6 (4.8) 54.2 (3.2) 0.6
AVF (# words) 18.6 (4.7) 19.9 (5.3) 21.8 (5.5) 21.2 (4.2) 0.3
LVF (# words) 33.5 (11.8) 31.1 (8.1) 33.6 (9.9) 37.4 (9.8) 0.4
RPM (/60) 39 (8.6) 42.1 (9.2) 44.3 (7.3) 46.5 (7.5) 0.07
TMT B/A 2.9 (1.0) 2.5 (0.6) 2.6 (1.0) 2.5 (1.1) 0.5
Table 3.1: Values represent means and standard deviations (in parenthesis)
unless stated otherwise; gender is expressed in number of individuals. Abbre-
viations: M = male; F = female; MMSE = Mini Mental State Examination;
AVLT = Rey Auditory Verbal Learning Test; DR = delayed recall; TL = total
learning; BNT = Boston Naming Test; AVF = Animal Verbal Fluency Test;
LVF = Letter Verbal Fluency Test; RPM = Raven’s Progressive Matrices;
TMT = Trail Making Test part B divided by part A.
injection and lasted for 30 min. Prior to the PET scan, a low-dose computed
tomography (CT) scan was performed for attenuation correction. Random and
scatter corrections were also applied. Images were reconstructed using Ordered
Subsets Expectation Maximization (OSEM; 4 iterations x 16 subsets).
A high-resolution T1-weighted structural MRI was obtained on a 3T Philips
Intera system equipped with an 8-channel receive-only head coil (Philips SEN-
Sitivity Encoding head coil), using a 3D turbo field echo sequence (coronal
inversion recovery prepared 3D gradient-echo images, inversion time 900 ms,
TR = 9.6 ms, TE = 4.6 ms, flip angle 8◦, field of view = 250 x 250 mm, 182
slices; voxel size 0.98 x 0.98 x 1.2 mm3).
3.3.3 Image analysis
All analyses were performed using Statistical Parametric Mapping 8 (SPM8,
http://www.fil.ion.ucl.ac.uk/spm). The PET data were reconstructed as 6
frames of 5 minutes and realigned to the first frame to correct for potential
head motion. Subsequently, the 6 frames were summed to create one summed
image. The individual’s T1-weighted structural image was then co-registered
to his/her PET summed image. This MR image was subsequently normalized
to the SPM8 T1 template in Montreal Neurological Institute (MNI) space using
a unified segmentation approach. Next, this normalization matrix was applied
to the individual’s co-registered PET summed image.
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From the spatially normalized images (voxel size 2 x 2 x 2 mm3) standard-
ized uptake value ratios (SUVR) were calculated with cerebellar grey matter
as reference region, resulting in SUVR images. The cerebellar grey matter
reference region was defined as areas 91 to 108 of the Automated Anatomical
Labelling atlas (AAL) [191]. The cerebellar reference region was resliced to each
individual’s normalized PET summed image. In order to exclude white matter
(WM) content, it was masked by the normalized and modulated subject-specific
grey matter (GM) map, with the threshold for masking set at 0.3.
We also defined a composite cortical volume of interest. This was com-
posed of 5 bilateral cortical areas, i.e. frontal, parietal, anterior cingulate, pre-
cuneus/posterior cingulate and lateral temporal defined as AAL areas 3-10,
13-16, 23-28, 31-32, 35-36, 57-70, 81-82, 85-90. The composite cortical VOI
was resliced to each individual’s normalized PET summed image. In order to
exclude WM content, it was masked by the normalized and modulated subject-
specific GM map, with the threshold for masking set at 0.3.
In one of the subjects the structural T1 image was missing due to a con-
traindication for MRI. This individual’s PET summed image was normalized
to the group mean normalized PET summed image created from the 63 remain-
ing subjects. The AAL-derived cerebellar and composite cortical VOIs were
co-registered to this normalized PET summed image and were masked with
the mean normalized modulated GM map (thresholded at 0.3) created out of
the 63 normalized modulated GM maps. This individual’s SUVR image was
calculated based on this normalized PET summed image with the cerebellar
grey matter reference region.
As a secondary measure we also worked on partial volume corrected (PVC)
data. PVC was based on the MRI using the modified Müller-Gärtner method
[146]. This method determines tracer concentration per unit volume of GM.
In the modified method, we use probabilistic segmentation instead of binary
maps. The normalized unmodulated GM and WM segmentations were used to
estimate different tissue fractions per voxel. PVC was applied to the normalized
PET summed images. The remaining of the procedures were identical to those
outlined above.
We also tested for any group differences in tracer retention in the cerebel-
lar reference region, as this could cause spurious differences in cortical SUVR
values. We calculated the standardized uptake values (SUV) in the cerebellar
grey matter region. SUV values were defined as the ratio of mean activity
concentration in cerebellar grey matter in the normalized PET summed image
[MBq] to the injected activity concentration [MBq/kg] per total body weight
[kg].
Lastly, we evaluated whether similar results could be obtained when pons
was used as reference region for the SUVR images1. For this purpose pons was
manually drawn on the SPM8 T1-template (13 axial slices of 2 mm) and then
1The analyses with pons as reference region were added to the thesis after publication of
the article.
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for each individual it was corrected to match the subject-specific anatomical
boundaries of the pons based on the subject’s spatially normalized MR image.
3.3.3.1 Statistical analysis
We statistically analyzed all SUVR images using two approaches: one was
based on the global composite cortical VOI, the other was voxel-based. In
the global composite cortical analysis our primary outcome measure was mean
SUVR value calculated in the composite cortical VOI (SUVRcomp). We used
SUVRcomp as the dependent variable and performed a factorial ANOVA with
BDNF (2 levels: met allele present vs absent) and APOE (2 levels: ε4 allele
present vs absent) as between-subjects factors. In addition, we performed a
confirmatory non-parametric Kruskal-Wallis ANOVA on the 4 genetic groups
with SUVRcomp as the dependent variable.
In the voxel-based analysis, using SPM8, we analysed SUVR images by
means of a factorial ANOVA with BDNF (2 levels: met allele present vs absent)
and APOE (2 levels: ε4 allele present vs absent) as between-subjects factors.
The significance threshold was set at a cluster-level of P < 0.05 family-wise
error (FWE) corrected for the entire brain search volume, with the voxel-level
threshold set at uncorrected P < 0.001.
The composite cortical and voxel-based analyses were also performed using
pons as reference region.
The partial-volume corrected data were analyzed using a factorial ANOVA
with BDNF (2 levels: met allele present vs absent) and APOE (2 levels: ε4
allele present vs absent) as between-subjects factors.
Differences in the SUV values in the cerebellar grey matter VOI were anal-
ysed by a factorial ANOVA with 2 between-subjects factors: BDNF (2 levels:
met allele present vs absent) and APOE (2 levels: ε4 allele present vs absent).
3.3.4 Relationship to episodic memory test scores
To assess the relationship between 18F-flutemetamol retention and episodic
memory measures, we conducted a linear regression analysis with either AVLT
delayed recall score (DR) or total learning score (TL) as dependent variable
and SUVRcomp as independent variable. This analysis was performed across
the entire group as well as within each genetic group separately. To evalu-
ate whether the relationship was specifically observed with episodic memory
scores, we also performed a linear regression analysis with other tests from our
cognitive battery: Boston Naming Test (BNT), Animal Verbal Fluency Test
(AVF) and total score on Raven’s Progressive Matrices (RPM).
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Figure 3.1: Distribution of 18F-flutemetamol retention levels for the different
genetic groups. X axis: age in years; Y axis: SUVRcomp.
3.4 Results
The four genetic groups did not differ in age, gender, years of education or
neuropsychological test scores (Table 3.1).
3.4.1 Effect of APOE and BDNF polymorphisms on SUVR
3.4.1.1 Global composite cortical analysis
Our primary outcome measure, SUVRcomp, differed significantly between the
four genetic groups (F (3,60) = 5.37, P = 0.002) (Figure 3.1). The main effect
of APOE was significant: APOE ε4 carriers had significantly higher ligand re-
tention than APOE ε4 non-carriers (F (1,60) = 7.14, P = 0.01). The main effect
of BDNF genotype was not significant (F (1,60) = 1.02, P = 0.32). The inter-
action between BDNF and APOE on ligand retention was significant (F (1,60)
= 7.94, P = 0.007): BDNF met +ve/APOE ε4 +ve carriers had significantly
higher ligand retention (mean SUVRcomp = 1.37, S.D. = 0.21) than BDNF met
-ve/APOE ε4 +ve carriers (mean SUVRcomp = 1.23, S.D. = 0.12) (P = 0.01),
while amyloid ligand retention in APOE ε4 non-carriers did not differ between
BDNF met +ve (mean SUVRcomp = 1.17, S.D. = 0.06) and BDNF met -ve
cases (mean SUVRcomp = 1.24, S.D. = 0.11) (P = 0.2) (Figure 3.2 A and B).
Non-parametric analysis confirmed these results. The four genetic groups
differed significantly in SUVRcomp (H (df 3, N 64) = 11.35, P = 0.01). The
main effect of APOE was significant: APOE ε4 carriers had significantly higher
ligand retention than APOE ε4 non-carriers (H (df 1, N 64) = 5.25, P = 0.02).
The main effect of BDNF genotype was not significant (H (df 1, N 64) = 0.04,
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Figure 3.2: Effects of BDNF and APOE genotypes on amyloid deposition mea-
sured by SUVRcomp. (A) SUVRcomp in the different genetic subgroups. (B)
Further differentiation depending on APOE and BDNF subgroups.
P = 0.85). Planned comparisons revealed that BDNF met +ve/APOE ε4 +ve
carriers exhibited higher ligand retention (mean rank = 19.1) than BDNF met
-ve/APOE ε4 +ve carriers (mean rank = 12.6) (P = 0.048). Amyloid ligand
retention also tended to be higher in BDNF met +ve (mean rank = 13.8) than
in BDNF met -ve (mean rank = 19.9) APOE ε4 non-carriers (P = 0.07).
Analysis of partial volume corrected data confirmed these results. PVC
SUVRcomp was significantly different between the four genetic groups (F (3,59)
= 4.64, P = 0.006). The main effect of APOE was significant: APOE ε4 carriers
had significantly higher ligand retention than APOE ε4 non-carriers (F (1,59) =
6.96, P = 0.01). The main effect of BDNF genotype was not significant (F (1,59)
= 0.55, P = 0.46). The interaction between BDNF and APOE on ligand
retention was significant (F (1,59) = 6.7, P = 0.01): BDNF met +ve/APOE ε4
+ve carriers had significantly higher ligand retention (mean SUVRcomp = 1.56,
S.D. = 0.39) than BDNF met -ve/APOE ε4 +ve carriers (mean SUVRcomp =
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1.36, S.D. = 0.24) (P = 0.02), while amyloid ligand retention in APOE ε4
non-carriers did not differ between BDNF met +ve (mean SUVRcomp = 1.24,
S.D. = 0.09) and BDNF met -ve cases (mean SUVRcomp = 1.35, S.D. = 0.18)
(P = 0.19).
SUV values in cerebellar grey matter did not differ between genetic groups
(F (3,60) = 0.54, P = 0.66). There was no difference between APOE ε4 carriers
and non-carriers (F (1,60) = 0.21, P = 0.65), between BDNF met carriers and
non-carriers (F (1,60) = 0.55, P = 0.46) and neither was there any interaction
(F (1,60) = 0.79, P = 0.38).
3.4.1.2 Voxel-based analysis
The whole-brain voxel-wise analysis confirmed the findings from the composite
cortical analysis. There was a significant main effect of APOE: APOE ε4
carriers had significantly higher 18F-flutemetamol retention than APOE ε4 non-
carriers in the posterior cingulate (cluster peak -14, -20, 40, Z = 4.26, extent of
voxels (ext.) 178 mm3, corr. cluster-level P = 0.025) (Figure 3.3A). There was
no main effect of BDNF genotype (corr. cluster-level P > 0.7). The interaction
effect of APOE and BDNF was significant in precuneus (cluster peak 10, -40,
42, Z = 4.71, ext. 437 mm3, corr. cluster-level P = 0.0001), left orbitofrontal
cortex (cluster peak -8, 64, -14, Z = 4.69, ext. 387 mm3, corr. cluster-level P =
0.0003), right orbitofrontal cortex (cluster peak 16, 68, -2, Z = 4.37, ext. 240
mm3, corr. cluster-level P = 0.006), left gyrus rectus (cluster peak -8, 22, -18, Z
= 4.62, ext. 252 mm3, corr. cluster-level P = 0.004), right gyrus rectus (cluster
peak 16, 28, -28, Z = 4.35, ext. 209 mm3, corr. cluster-level P = 0.012), right
middle frontal gyrus (cluster peak 34, 46, 28, Z = 4.14, ext. 316 mm3, corr.
cluster-level P = 0.001) and right inferior frontal sulcus (cluster peak 50, 38, 6,
Z = 3.88, ext. 281 mm3, corr. cluster-level P = 0.002) (Figure 3.3 B). Simple
effects revealed that BDNF met +ve/APOE ε4 +ve carriers had higher ligand
retention than BDNF met -ve/APOE ε4 +ve carriers in posterior cingulate
(cluster peak at 2, -32, 42, Z = 4.25, ext. 388 mm3, corr. cluster-level P =
0.0003), gyrus rectus (cluster peak at -4, 34, -26, Z = 4.44, ext. 196 mm3,
corr. cluster-level P = 0.016), insula (cluster peak at 36, 8, -12, Z = 4.89, ext.
311 mm3, corr. cluster-level P = 0.001) and posterior middle temporal cortex
(cluster peak at 62, -62, 4, Z = 4.23, ext. 168 mm3, corr. cluster-level P =
0.03). There was no difference between BDNF met +ve/APOE ε4 -ve carriers
and BDNF met -ve/APOE ε4 -ve carriers (corr. cluster-level P > 0.9).
3.4.1.3 Relationship between β amyloid load and episodic memory
Across the entire sample, SUVRcomp did not correlate with AVLT DR (P =
0.38) or TL (P = 0.16). When analysed per genetic group, a highly significant
and negative correlation was seen only in the group of BDNF met +ve/APOE
ε4 +ve carriers (DR r = -0.62, P = 0.01, and TL r = -0.58, P = 0.02) (Fig-
ure 3.4 A and B, red lines). In the other groups the correlation remained far
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Figure 3.3: Statistical parametric map of the main effect of APOE (A) and the
interaction effect between APOE and BDNF (B). (A) Main effect of APOE
genotype: increased 18F-flutemetamol retention in APOE ε4 +ve carriers com-
pared to APOE ε4 -ve carriers in the posterior cingulate. (B) Interaction effect
between BDNF and APOE: increased 18F-flutemetamol retention in the pre-
cuneus, orbitofrontal cortex, gyrus rectus, middle frontal gyrus, and inferior
frontal sulcus. Images are displayed at voxel-level P < 0.001, only clusters that
reached corrected cluster-level P < 0.05 are shown. SPM t maps are projected
onto axial, sagittal, and coronal sections of the SPM8 standard single subject
T1 template and as SPM8 glass brain views.
below significance (P > 0.49) (Table 3.2). A formal pairwise comparison how-
ever of the regression slopes between groups did not reach significance (P >
0.05) [192].
None of the other cognitive test scores showed any correlation with β amy-
loid when tested across the entire sample (P > 0.17) or per group (Table 3.2).
3.4.1.4 Analyses with pons as reference region2
With pons as reference region, similar results were obtained. SUVRcomp dif-
fered significantly between the four genetic groups (F (3,60) = 5.68, P = 0.0017).
The main effect of APOE was significant: APOE ε4 carriers had significantly
higher ligand retention than APOE ε4 non-carriers (F (1,60) = 8.60, P = 0.005).
The main effect of BDNF genotype was not significant (F (1,60) = 2.33, P =
0.13). The interaction between BDNF and APOE on ligand retention was sig-
nificant (F (1,60) = 6.04, P = 0.017): BDNF met +ve/APOE ε4 +ve carriers
had significantly higher ligand retention (mean SUVRcomp = 0.65, S.D. = 0.11)
than BDNF met -ve/APOE ε4 +ve carriers (mean SUVRcomp = 0.58, S.D. =
0.04) (P = 0.0074), while amyloid ligand retention in APOE ε4 non-carriers
2The analyses with pons as reference region were added to the thesis after publication of
the article.
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did not differ between BDNF met +ve (mean SUVRcomp = 0.56, S.D. = 0.04)
and BDNF met -ve cases (mean SUVRcomp = 0.58, S.D. = 0.05) (P = 0.51).
The voxelwise analysis with pons as reference region also yielded identical
results as the main analysis.
The linear regression analysis between AVLT DR or TL and SUVRcomp with
pons as reference region yielded the same results as when cerebellar cortex was
used as reference region.
Figure 3.4: Correlation between amyloid ligand retention and AVLT delayed
recall (DR) and total learning (TL) scores. (A) Negative correlation between
SUVRcomp values and AVLT DR scores in the BDNF met +ve/APOE ε4 +ve
group (red line). (B) Negative correlation between SUVRcomp values and AVLT
TL scores in the BDNF met +ve/APOE ε4 +ve (red line). SUVRcomp (Y
axis) plotted by AVLT DR or TL scores (X axis): BDNF met +ve/APOE
ε4 +ve (red triangles), BDNF met -ve/APOE ε4 +ve (blue squares), BDNF
met +ve/APOE ε4 -ve (red circles) and BDNF met -ve/APOE ε4 -ve (blue
diamonds). When the correlation does not reach significance, no regression
line is shown.
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Linear regression between SUVRcomp and cognitive test scores
in each of the four genetic groups.
BDNF met +ve BDNF met -ve BDNF met +ve BDNF met -ve
APOE ε4 +ve APOE ε4 +ve APOE ε4 -ve APOE ε4 -ve
r P r P r P r P
AVLT DR -0.62 0.01 0.14 0.61 -0.19 0.49 0.15 0.56
AVLT TL -0.58 0.02 0.18 0.51 -0.12 0.65 0.02 0.95
BNT -0.18 0.49 -0.03 0.91 -0.06 0.81 -0.07 0.78
AVF 0.04 0.88 0.21 0.44 0.11 0.69 -0.42 0.09
RPM -0.36 0.17 0.00 1.00 0.03 0.92 0.10 0.72
Table 3.2: Values represent correlation coefficient (r) and statistical signifi-
cance (P). Abbreviations: AVLT = Rey Auditory Verbal Learning Test; DR
= delayed recall; TL = total learning; BNT = Boston Naming Test; AVF =
Animal Verbal Fluency Test; RPM = Raven’s Progressive Matrices.
3.5 Discussion
Our study revealed two key novel findings. First, APOE ε4 carriers exhibited a
higher β amyloid load in the presence of one or two BDNF met alleles compared
to BDNF met non-carriers (Figure 3.1, 3.2). Second, an inverse relationship
between Aβ load and episodic memory exists in BDNF met/APOE ε4 carriers
but not in any of the other subgroups.
The interaction effect between BDNF and APOE on β amyloid load was
unexpected and needs further confirmation by independent studies. The genetic
stratification for APOE and BDNF prior to recruitment for scanning is a unique
feature of our cohort that was probably critical for obtaining this novel finding.
In the group of individuals volunteering for this study, after applying all non-
genetic criteria for in/exclusion, the proportion of BNDF met +ve/APOE ε4
+ve subjects was only 10%. After stratification this was raised to 25%. It is
this genetic combination that drives the interaction. Had we not strived for a
balanced factorial design with cells matched for numbers at recruitment, the
interaction effect would almost certainly have been missed. This means that
we had to genotype much higher numbers of subjects than were actually able
to enter the scanning phase of the study. Replication of the interaction effect
will probably also have to be based on samples enriched for the naturally least
frequent combination of BNDF met and APOE ε4 carriers.
Most of the subjects with raised amyloid were APOE ε4 carriers with BDNF
met allele at codon 66 (Figure 3.1). The number of subjects with raised amy-
loid is relatively low but impacts relatively strongly on the statistical outcome.
Non-parametric testing confirmed that BDNF met carriage affected Aβ load.
Our findings were obtained in a cohort stratified at recruitment for APOE
and BDNF polymorphisms according to a balanced factorial design with de-
mographically matched subjects. The stratification, the balanced design and
the fact that we only tested these two gene polymorphisms, reduces the risk of
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a false-positive. As a relatively low number of the 64 healthy subjects had a
raised Aβ load, the power of our study to determine an influence of genetics
is limited and any negative findings should be interpreted with caution. The
proportion of subjects with raised amyloid increases with age [166]. Further
studies in a higher age range will be needed to confirm whether the interaction
is present also in an older population.
We used the volumetric MRI scan for normalisation and the segmented gray
matter maps for definition of the cerebellar gray matter and the composite corti-
cal volume. The method we applied differs from the purely PET-based method
applied in the phase 2 study of 18F-flutemetamol [73]. As a consequence, we
cannot simply use the cut-off from the phase 2 study to discriminate positive
from negative cases in a binary manner. Furthermore, in a cognitively intact
population of older adults, a significant minority exhibits intermediary values.
While categorical discrimination between positive and negative individuals is
relevant for clinical purposes, a binary division in positive and negative cases
is not essential for the current scientific question.
The interaction effect was seen in frontobasal cortex, precuneus, and lateral
prefrontal cortex, which are well-established areas of predilection for amyloid
deposition in the initial phase of the disease [164, 193, 114, 165, 167, 168].
For posterior cingulate and precuneus this has been linked to their status as
a network hub [194, 195], including their centrality in the connections from
the hippocampal formation to parietal cortex [196, 197]. Why orbitofrontal
cortex regularly recurs as an area of predilection, is less clear. In any case,
numerous studies of the earliest changes in amyloid load in AD have reported
increased amyloid load in this region [10, 198, 199, 193, 114]. Orbitofrontal
cortex also shows hypometabolism on 18F-deoxyglucose PET early in the AD
disease course [200].
The original purpose of our factorial design was to evaluate the effect
of BDNF on functional reorganisation and plasticity [132] in response to β
amyloid related injury. We predicted that compared to BDNF met carriers
BDNF val status would confer a higher compensatory capacity for functional
reorganisation in the face of increased Aβ amyloid [132]. Given ample evi-
dence for a relationship between BDNF polymorphism and episodic memory
[181, 182, 183, 184, 185, 186, 187] and given the prominent role of episodic
memory decline in the earliest clinical stages of Alzheimer’s disease, we pri-
marily evaluated whether BDNF affected the relationship between Aβ depo-
sition and episodic memory. We found a strong negative correlation between
Aβ deposition and episodic memory encoding and recall in the BDNF met
+ve/APOE ε4 +ve carriers but not in any of the three other groups (Fig-
ure 3.4, Table 3.2). This finding is in line with our a priori hypothesis that
BDNF polymorphism may influence resilience against Aβ related injury. A
formal pairwise comparison however of the regression slopes of β amyloid load
versus episodic memory scores between the groups did not reach significance,
possibly due to the relatively small sample size. The relationship between cog-
nitive test scores in cognitively intact individuals and Aβ deposition is still a
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topic of active research, with some studies reporting an inverse relationship
and others an absence of any relationship [199, 201, 167, 202, 203]. Our find-
ings offer one possible explanation for this divergence between studies: if the
genetic composition differs between cohorts, this may cause differences in how
β amyloid load relates to episodic memory scores (Figure 3.4 A, B). The effect
of Aβ load on episodic memory scores in the BDNF met +ve/APOE ε4 +ve
group highlights the behavioural relevance of our findings.
Previous studies have shown the negative effect of BDNF codon 66 val to
met substitution on a number of parameters: It is associated with worse mem-
ory function [181, 183, 184, 185, 186, 187], lower fMRI responses in hippocampi
during both encoding and retrieval [183, 184], smaller volumes of hippocampi
[204, 205, 186, 188, 206], lateral prefrontal cortex [207, 188, 208], temporal neo-
cortex, cingulate, and insula [208], and amygdalae [209, 210], as well as age-
related volume reduction of other cortical areas which may be gender-dependent
[207]. The BDNF codon 66 met allele also affects white matter connectivity
[211]. Interestingly, a recent study reported effects of BDNF val66met poly-
morphism on brain metabolism in healthy controls, MCI and AD cases [212].
To the best of our knowledge our study is the first to directly examine how
the well-studied negative effects of BDNF met relate to subclinical Aβ amyloid
and its relationship to episodic memory.
An interaction effect between BDNF and APOE on amyloid ligand retention
has not been reported in previous genome-wide association studies (GWAS) of
clinically probable Alzheimer’s disease patients. In their conventional form,
GWAS make use of massively univariate single-locus tests. Such tests are
designed to search for single disease-associated polymorphisms [213] where each
gene variant is tested individually for association with a specific phenotype
(cases versus controls) [214]. GWAS in their classical form will miss interaction
effects between genes.
Apart from amyloid load, it is currently unknown how the interaction
between BDNF and APOE polymorphisms affects other contributors to the
pathogenesis of AD, such as synapse loss, cholinergic depletion, or neurofib-
rillary tangle formation. For this reason, it remains to be seen whether the
interaction effect between BDNF and APOE on amyloid burden we observed
in cognitively intact subjects can be extrapolated to genetic comparisons be-
tween clinically probable AD and controls.
Studies in animal models of AD offer us with several putative mecha-
nisms through which BDNF and the amyloid cascade may interact. Intra-
hippocampal injections of Aβ(1-42) in rats reduce the expression of BDNF and
also result in decreased BDNF levels in prefrontal cortex [215]. In amyloid
precursor protein (APP) double transgenic mice with both the Swedish and
the Indiana APP mutations, BDNF gene delivery to entorhinal cortex reverses
synapse loss and improves cell signalling, partially normalizes APP-related al-
terations in hippocampal and entorhinal gene expression, and restores learning
and memory [216]. In AD postmortem samples, BDNF protein expression as
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well as mRNA levels are decreased in hippocampi and other cortical areas
[217, 218, 219, 220, 221]. During the course of AD, BDNF serum concentra-
tion levels correlate with the severity of dementia: levels are increased in early
stages of AD and decreased in the advanced stages [222, 223]. It however is
difficult to speculate on the exact mechanism through which BDNF may inter-
act with APOE to increase amyloid burden as the relationship between APOE
and increased amyloid aggregation itself is still relatively poorly understood.
Both genes have been implicated in neural plasticity. This concept encom-
passes widely diverse processes [17]. Possibly, the efficacy with which neurons
dispose of toxic forms of Aβ may depend on pathways that are linked to lipid
metabolism and neuronal survival in which APOE and BDNF, respectively,
play pivotal roles.
In conclusion, we demonstrate an association between BDNF met allele and
PETmeasures of amyloid deposition in cognitively normal older adult APOE ε4
carriers. This finding provides empirical evidence for a role of the BDNF-TrkB
pathway not only in neural plasticity but also in the pathogenesis of Alzheimer’s
disease [17]. It underscores the opportunity to use brain imaging measurements
to help characterize the individual and epistatic effects of putative genetic risk
factors in the predisposition to AD. We however would like to emphasize that
the current study is hypothesis-generating and needs further replication.
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Functional changes in the language network in
response to increased amyloid deposition in
cognitively intact older adults
This chapter has been published as:
Katarzyna Adamczuk, An-Sofie De Weer, Natalie Nelissen, Patrick Dupont,
Stefan Sunaert, Karolien Bettens, Kristel Sleegers, Christine Van
Broeckhoven, Koen Van Laere, Rik Vandenberghe. Functional changes in the
language network in response to increased amyloid deposition in cognitively
intact older adults. Cereb Cortex 2014 doi:10.1093/cercor/bhu286.
4.1 Abstract
Word finding symptoms are frequent early in the course of Alzheimer’s dis-
ease and relate principally to functional changes in left posterior temporal cor-
tex. In cognitively intact older adults, we examined whether amyloid load
affects the network for language and associative-semantic processing. Fifty-six
community-recruited subjects (52-74 years), stratified for Apolipoprotein E and
Brain Derived Neurotrophic Factor genotype, received a neurolinguistic assess-
ment, 18F-flutemetamol PET, and a functional MRI of the associative-semantic
system. The primary measure of amyloid load was the cerebral-to-cerebellar
grey matter standardized uptake value ratio in a composite cortical volume
of interest (SUVRcomp). The primary outcome analysis consisted of a whole-
brain voxelwise linear regression between SUVRcomp and fMRI response during
associative-semantic versus visuoperceptual processing. Higher activity in one
region, the posterior left middle temporal gyrus, correlated positively with in-
creased amyloid load. The correlation remained significant when only the word
conditions were contrasted but not for pictures. According to a stepwise lin-
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ear regression analysis, oﬄine naming reaction times correlated positively with
SUVRcomp. A binary classification into amyloid-positive and amyloid-negative
cases confirmed our findings. The left posterior temporal activity increase may
reflect higher demands for semantic control in the presence of a higher amyloid
burden.
4.2 Introduction
Modern techniques such as amyloid positron emission tomography (PET) al-
low one to detect hallmark lesions related to Alzheimer’s disease (AD) directly
in vivo [224, 225, 226, 31, 69]. Depending on mainly age and Apolipoprotein
E (APOE) genotype, 10-30% of cognitively intact older adults have a positive
amyloid scan, which can be indistinguishable from what is seen in clinically
probable AD (for review see [37]). Longitudinally, increased Aβ load is asso-
ciated with greater risk of cognitive decline [227, 203, 43, 79] and grey matter
volume loss [44]. Amyloid PET has become one of the principal ways to define
the ’preclinical’ stage of AD, a term that refers to the AD-related pathogenetic
processes that happen before clinical symptoms become apparent [55]. In this
study we used 18F-flutemetamol [73] as our ligand. Previous studies have re-
vealed a high correlation between the cortical retention levels obtained with
this ligand and those obtained with 11C-Pittsburgh Compound B [73, 228] as
well as with neuritic plaque density based on Bielschowsky silver staining [229].
Word finding difficulties are frequent in clinically probable AD, even at a
pre-dementia stage [230, 231, 232, 133, 233, 234, 235]. The first language area
to become dysfunctional in early-stage AD and amnestic mild cognitive im-
pairment (MCI) is the left posterior superior temporal sulcus (STS) [132, 133].
Functional magnetic resonance imaging (fMRI) activity is lower in this region
during associative-semantic compared with visuoperceptual processing in mild
cognitive impairment (MCI) [133] and in clinically probable AD [132] com-
pared to controls. In these populations, fMRI activity levels positively correlate
with Boston Naming test scores [132] and with word identification speed [133].
Furthermore, in AD patients in whom naming is preserved, fMRI activity in
the homotopical right-sided STS is increased compared to controls [132]. Ac-
cordingly, we hypothesized that posterior temporal cortex may show adaptive
changes in the presence of increased amyloid burden also in cognitively intact
individuals. The study of functional changes related to amyloid burden in cog-
nitively intact subjects is important because it could explain why some brains
appear to be more resilient against Aβ related injury than others. This fac-
tor may determine which individuals show clinical manifestations of underlying
Alzheimer pathology and which remain cognitively intact despite the presence
of Alzheimer pathology in the brain [34, 35, 236, 19, 36, 237, 164]. Even during
the initial stages of neurodegenerative disease, the brain retains a potential for
plasticity [238, 239, 240, 241, 17, 242, 243, 162].
One of the genes that have been implicated in functional plasticity [175, 176]
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is Brain Derived Neurotrophic Factor (BDNF), both in humans [177] and in
animal models [179, 178, 180]. The presence of one or two met alleles on codon
66 is often considered to reduce the capacity for functional reorganisation. As
our second hypothesis, we examined whether adaptive changes occurring in
the language network in response to amyloid load differ between BDNF met
carriers and non-carriers and how this interacts with APOE ε4 genotype [244].
4.3 Materials and methods
The protocol was approved by the Ethics Committee University Hospitals Leu-
ven (EudraCT: 2009-014475-45) and written informed consent was obtained
from all subjects in accordance with the latest version of the Declaration of
Helsinki.
4.3.1 Participants
Subjects were recruited from the community via advertisement in local news-
papers and via a website for seniors, asking for healthy volunteers between 50
and 75 years of age for participation in a scientific study at the University
Hospital Leuven, Belgium, involving brain imaging. The relationship between
genotype (APOE versus BDNF) and amyloid levels in the present cohort has
been described by [244].
At screening, subjects underwent blood sampling for genotyping, Mini Men-
tal State Examination (MMSE), Clinical Dementia Rating score (CDR), and a
structured interview about medical history. Inclusion was stratified per age bin
(50-59, 60-64, 65-69, 70-75) for two genetic factors: BDNF (met allele present
or absent) and APOE (ε4 allele present or absent). The cells of this 2 x 2 fac-
torial design were prospectively matched for number of cases, gender, age, ed-
ucation and handedness (Edinburgh Handedness Inventory) [244]. BDNF and
APOE variants were genotyped by sequencing at the Genetic Service Facility
(GSF, www.vibgeneticservicefacility.be) of the VIB Department of Molecular
Genetics. The study exclusion criteria were an MMSE score below 27, a CDR
score above 0, neurological or psychiatric history, brain lesions on structural
MRI, left-handedness, non-native Dutch speaker, and below-normal test scores
on conventional neuropsychological assessment (< 1.9 SD on published norms
adapted for age, gender, and education) (Table 4.1). The conventional neu-
ropsychological test protocol consisted of the Rey Auditory Verbal Learning
Test, Boston Naming Test, Letter Verbal Fluency and Animal Verbal Fluency,
Raven’s Standard Progressive Matrices and the Trail Making Test (Table 4.1).
Fifty-six healthy, right-handed adults between 50 and 75 years of age (mean
age = 65, SD = 5.5, range 52-74) who fulfilled all criteria were included in the
study.
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Demographic data and neuropsychological test scores
Genetic groups P
BDNF met +ve BDNF met -ve BDNF met +ve BDNF met -ve
APOE ε4 +ve APOE ε4 +ve APOE ε4 -ve APOE ε4 -ve
Gender (M/F) 7/7 7/4 7/7 10/7 0.9
Age (years) 64.7 (5.9) 66.5 (4.7) 64.5 (6.0) 64.9 (5.5) 0.83
Education (years) 13.1 (2.7) 12.7 (1.8) 13.8 (2.2) 14.4 (3.6) 0.47
Handedness 94.3 (15.5) 100.0 (0.0) 96.2 (8.2) 100.0 (0.0) 0.24
MMSE (/30) 28.9 (0.9) 28.7 (1.1) 29.3 (0.6) 28.9 (0.9) 0.47
AVLT TL (/75) 48.7 (8.0) 47.5 (8.4) 51.2 (12.4) 50.0 (8.4) 0.79
AVLT DR (/15) 11.6 (2.2) 9.0 (3.3) 11.4 (2.7) 10.8 (2.1) 0.07
BNT (/60) 53.6 (4.6) 50.9 (7.4) 53.4 (3.9) 54.0 (3.3) 0.39
AVF (# words) 18.6 (4.7) 19.7 (5.2) 21.9 (5.8) 21.3 (4.3) 0.30
LVF (# words) 32.4 (12.1) 29.8 (7.9) 34.1 (10.3) 37.1 (10.0) 0.33
RPM (/60) 39.1 (9.2) 39.8 (8.7) 45.7 (6.6) 46.5 (7.5) 0.03
TMT B/A 2.9 (1.1) 2.4 (0.6) 2.5 (0.9) 2.5 (1.1) 0.50
Table 4.1: Values represent means and standard deviations. Gender is ex-
pressed in number of individuals. M = male; F = female; MMSE = Mini
Mental State Examination; AVLT = Rey Auditory Verbal Learning Test; TL
= total learning; DR = delayed recall; BNT = Boston Naming Test; AVF
= Animal Verbal Fluency Test; LVF = Letter Verbal Fluency Test; RPM =
Raven’s Progressive Matrices; TMT = Trail Making Test B divided by A. Last
column represents P-values for one-way between groups ANOVA. Bonferroni
corrected threshold for significance P < 0.006 corresponding to Pcorrected <
0.05.
4.3.2 Experimental language tests
Given our a priori hypothesis of early involvement of left posterior STS and
given its possible role in lexical-semantic retrieval [133], the experimental lan-
guage tests conducted outside the fMRI scanner consisted of confrontation
naming, lexical decision and speeded word identification (Table 4.2). Each
of these tests was presented by Presentation 14.8 (NeuroBehavioural Systems,
Albany, CA, USA) and was displayed on a 19-inch cathode ray tube monitor
(resolution 1024 x 768 pixels, refresh rate 75 Hz) 60 cm from subjects’ eyes.
4.3.2.1 Confrontation naming task
In a computerized version of the picture naming task from Laiacona and Capi-
tani [159], 60 white line drawings of concrete entities were presented on a black
background (picture size 9.68 deg x 7.74 deg [245]). The 60 items comprised 3
living (10 animals, 10 fruits and 10 vegetables) and 3 non-living (10 tools, 10
pieces of furniture, 10 vehicles) categories. Item order was randomized for each
individual. A trial started with the appearance of a fixation point displayed for
2 s before stimulus onset. A warning sound (177 ms duration) was presented
500 ms before stimulus onset. The stimulus was on the screen until the subject
provided a response, for a maximum duration of one minute.
Aβ load and the language system in older adults 49
Reaction times (RT) were measured for the correct responses from the on-
set of the stimulus to the onset of the naming response. Voice recordings
were manually analysed in the WavePad Sound Editor version 4.57 (http:
//www.nch.com.au/wavepad). Accuracy was measured as percentage correct
responses. Responses were considered correct if they were the picture’s domi-
nant name, a synonym, the name of a subordinate to the entity designated by
the dominant name, or else if it occurred in at least 3 out of 30 other healthy
controls viewing the picture for 2 s. Spontaneous, immediate auto-corrections
were allowed.
4.3.2.2 Lexical decision task
In a computerized version of the visual lexical decision test from the Dutch
version of the Psycholinguistic Assessment of Language Processing in Aphasia
(PALPA 24 [160]), words and non-words were presented as white letters (letter
height: 1 deg) on a black background. Stimuli consisted of 40 words with
high imageability (20 high and 20 low frequency words), 40 words with low
imageability (20 high and 20 low frequency words) and 80 non-words, randomly
divided into 4 blocks (literal transcription of PALPA 24 paper version). Each
stimulus was preceded by a fixation point for 1 s. Subjects were instructed to
use their dominant hand and respond by key press whether the stimulus was a
word or non-word. The stimulus was on the screen until the subject responded,
for a maximum duration of stimulus presentation of 30 s.
RTs were measured for correct responses from the onset of the stimulus to
the time of the button press. A’ was used as our accuracy measure [246].
4.3.2.3 Speeded word and picture identification
The purpose of the speeded word and picture identification task was to analyse
written word and picture identification under varying time constraints [133].
We derived a time-accuracy curve for stimulus presentation durations varying
between 30, 60, 90, 150, 200, 500, 800 or 2000 ms. Subjects were instructed
to read the word or name the picture. A trial consisted of a warning sound,
a forward mask (200 ms duration, 9.68 deg x 7.74 deg), followed by either a
word (letter height 1 deg) or a picture (9.68 deg x 7.74 deg [245]), which was
immediately followed by a backward mask (200 ms duration, 9.68 deg x 7.74
deg), and a fixation point for 3 s. For each individual subject, the onset (a),
steepness of the curve (b), and asymptote (c) of the time-accuracy function
for words and pictures were calculated by means of the equation: accuracy =
c*(1-e(a−∆t)/b) for ∆t ≥ a [247, 133]. Goodness of fit was estimated as the
sum of squared differences between the measured and calculated values (sum
of the squared errors).
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Experimental test scores
Genetic groups P
BDNF met +ve met -ve met +ve met -ve
APOE ε4 +ve ε4 +ve ε4 -ve ε4 -ve BDNF APOE int
Conf naming RT (ms) 1595 (288) 1507 (237) 1471 (333) 1450 (317) 0.27 0.50 0.68
Accu (%) 93.0 (3.3) 91.2 (8.1) 92.4 (5.3) 90.7 (5.0) 0.70 0.24 0.96
Lexical decision RT (ms) 1033 (146) 1118 (238) 1138 (211) 1154 (352) 0.29 0.44 0.60
Accu (A’) 0.99 (0.01) 0.99 (0.01) 0.99 (0.01) 0.98 (0.02) 0.95 0.38 0.45
Speeded id W a (ms) 25.2 (17.5) 21.2 (9.7) 21.6 (12.2) 19.9 (9.1) 0.48 0.42 0.75
b (ms) 17.4 (8.3) 25.5 (13.5) 22.7 (10.1) 19.2 (10.7) 0.85 0.42 0.05
c (%) 99.1 (1.3) 98.2 (1.8) 99.6 (0.6) 99.0 (1.7) 0.09 0.05 0.77
Table 4.2: Values represent means and standard deviations. Conf naming =
confrontation naming task; Speeded id W = speeded identification task for
words; RT = reaction times; Accu = accuracy. Last three columns represent
significance values for the main effect of BDNF, APOE, and interaction between
them. Bonferroni corrected threshold for significance P < 0.007 corresponding
to Pcorrected < 0.05.
4.3.3 Functional MRI
4.3.3.1 Stimuli and tasks
Stimuli were projected onto a screen (resolution of 1024 x 768 pixels, refresh
rate 60 hz) using Presentation 14.8 (NeuroBehavioural Systems, Albany, CA,
USA). The fMRI paradigm has been described in detail before [248, 249, 250,
132, 133, 251, 252]. In summary, the experimental design was factorial [248].
The first factor, task, had two levels: associative-semantic (Figure 4.1 blue and
purple) versus visuoperceptual judgement (Figure 4.1 cyan and yellow). The
second factor, input modality, also had two levels: printed words (Figure 4.1
blue and cyan) versus pictures (Figure 4.1 purple and yellow). The associative-
semantic condition was derived from the Pyramids and Palm Trees test [150],
a classical neuropsychological test of associative-semantic processing for words
and pictures. During a trial, a triplet of stimuli was presented for 5250 ms,
one stimulus on top (the sample stimulus) and one in each lower quadrant (the
test stimuli) at 4.6 deg eccentricity (mean picture size was 3.7 deg and mean
letter size 1.2 deg), followed by a 1500 ms interstimulus interval. Subjects
were asked to press a left- or right-hand key depending on which of the two
test stimuli matched the sample stimulus more closely in meaning. A given
triplet was presented in either the picture or the word format and this was
counterbalanced across subjects. In the visuoperceptual control condition, a
picture or word stimulus was presented in three different sizes (mean picture
size was 3.7 deg and mean letter size 1.2 deg). Subjects had to press a left- or
right-hand key depending on which of the two test stimuli matched the sample
stimulus more closely in size on the screen. An epoch, i.e. a block of trials
belonging to the same condition, consisted of four trials (total duration 27
s). The fifth condition consisted of a resting baseline condition during which a
fixation point was presented in the centre of the screen (Figure 4.1 red). During
each fMRI run (5 runs in total), a series of the 5 epoch types, was replicated
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Figure 4.1: Stimuli and tasks in fMRI experiment. Associative-semantic task
with words (blue) and with pictures (purple). Visuoperceptual task with words
(cyan) or pictures (yellow). Resting baseline with fixation point (red). Subjects
were asked to press a left- or right-hand key depending on which of the two
lower stimuli matched the upper stimulus more closely in meaning (blue, purple)
or in size on the screen (cyan, yellow). A given concept triplet was presented
in either the word or the picture format and this was counterbalanced across
subjects. Arrow in the top of the figure shows a timeline of one fMRI run, with
each condition indicated in its respective colour. The order of conditions was
randomized for each run and subject. Translation: deur = door, hek = fence,
raam = window.
3 times (Figure 4.1 timeline). The order of conditions was pseudorandom and
differed across runs of the same subject.
Prior to the fMRI session, visual acuity was tested in each participant.
Subjects were asked to read aloud a text written in font 12 at 40 cm distance
from their eyes. In case a correction to normal vision was necessary, subjects
received MR compatible glasses with lenses matched to the subjects’ sight
defect. Following this, subjects performed an oﬄine practice session of fMRI
task. In this session we determined which size difference (9%, 6%, 3%, or 1%)
for the visuoperceptual conditions was needed for each individual subject to
obtain comparable accuracies as for the associative-semantic conditions.
4.3.3.2 Image acquisition
Twenty-eight subjects were scanned on a 3T Philips Intera system equipped
with an 8-channel receive-only head coil (Philips SENSitivity Encoding head
coil). Twenty-eight subjects could not undergo the fMRI in the Intera system
because their body in the scanner lumen obstructed the beam from the projec-
tor to the screen. These subjects were scanned on a 3T Philips Achieva system
equipped with a 32-channel receive-only head coil (Philips SENSitivity Encod-
ing head coil) which used a screen placed behind the individual’s head for the
projection. There were no statistically significant differences of sex (P = 0.79)
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(chi-square test), genetic groups (P = 0.17), age (P = 0.49), or MMSE (P
= 0.92) (Kolmogorov-Smirnov comparison of two datasets) between subjects
scanned on the Intera versus the Achieva system. Scanner type was included
as a covariate of no interest for all analyses.
Sequence parameters were the same for both scanners. A high-resolution
T1-weighted structural scan was obtained using a 3D turbo field echo sequence
(coronal inversion recovery prepared 3D gradient-echo images, inversion time
900 ms, TR = 9.6 ms, TE = 4.6 ms, flip angle 8◦, field of view = 250 x 250 mm,
182 slices; voxel size 0.98 x 0.98 x 1.2 mm3). Functional MRIs were acquired
using T2* echo-planar images (50 transverse slices, voxel size 2.5 x 2.5 x 2.5
mm3 ; TR = 3000 ms, TE = 30ms, flip angle 90◦, field of view 200 x 200 mm).
4.3.3.3 Image analysis
All analyses were performed using Statistical Parametric Mapping 8 (SPM8,
http://www.fil.ion.ucl.ac.uk/spm). Functional MR scans of each subject were
realigned to correct for potential head motion. The structural MR image was
coregistered to the average of the realigned fMRI images. The structural MR
image was then normalized to the SPM8 T1 template in Montreal Neurological
Institute (MNI) space. The same normalization matrix was applied to the
coregistered fMRI scans. The normalized fMRI images (voxel size 3 x 3 x 3
mm3) were smoothed using a 6 x 6 x 6 mm3 Gaussian kernel. A high-pass filter
with a Full Width at Half Maximum of 270 s and a low-pass filter consisting of
a canonical hemodynamic response function (HRF) were applied. The epoch-
related response was modeled by a canonical HRF convolved with a boxcar.
4.3.4 Flutemetamol PET
4.3.4.1 Image acquisition
As described before [65, 66, 73, 190], images were acquired on a 16-slice Siemens
Biograph PET/CT scanner (Siemens, Erlangen, Germany). The PET tracer
was injected intravenously as a bolus (mean activity 151.2 MBq, SD 8.3, range
137.9 - 192.5 MBq) in an antecubital vein. Image acquisition started 90 min
after tracer injection and lasted for 30 min. Prior to the PET scan, a low-
dose computed tomography scan was performed for attenuation correction.
Random and scatter corrections were also applied. Images were reconstructed
using Ordered Subsets Expectation Maximization (4 iterations x 16 subsets).
4.3.4.2 Image analysis
The PET data were reconstructed as 6 frames of 5 minutes and realigned
to the first frame to correct for potential head motion. Subsequently, the
6 frames were summed to create one summed image. The individual’s T1-
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weighted structural image was then coregistered to this PET summed image.
This MR image was subsequently normalized to the SPM8 T1 template. The
same normalization matrix was then applied to the individual’s coregistered
PET summed image. From the spatially normalized PET images (voxel size 2
x 2 x 2 mm3), standardized uptake value ratios (SUVR) were calculated in a
voxelwise manner with cerebellar grey matter (GM) as reference region. The
cerebellar grey matter reference region was defined as areas 91 to 108 of the
Automated Anatomical Labelling atlas (AAL) [191]. The cerebellar reference
region was resliced to each individual’s normalized PET summed image. In
order to exclude most of the white matter (WM) content, it was masked by
the normalized and modulated subject-specific GM map, with the threshold
for masking set at > 0.3.
Our primary PET outcome measure was the mean SUVR in a composite
cortical volume of interest (VOI) (SUVRcomp). This composite VOI consisted
of 5 bilateral cortical regions: frontal (AAL areas 3-10, 13-16, 23-28), parietal
(AAL 57-70), anterior cingulate (AAL 31-32), posterior cingulate (AAL 35-
36) and lateral temporal (AAL 81-82, 85-90). The composite cortical VOI
was resliced to each individual’s normalized PET summed image. In order
to exclude most of the WM content, it was masked by the normalized and
modulated subject-specific GM map, with the threshold for masking set at >
0.3.
While we used SUVRcomp as a continuous variable in our primary analysis,
we also conducted a secondary analysis where amyloid load was treated as a
binary variable and cases were classified as amyloid-positive versus -negative
based on an SUVRcomp cut-off. Such a binary approach is closer to the way in
which Sperling et al. (2011) conceptualized preclinical AD. The SUVRcomp cut-
off for binary classification was derived from an independent dataset [73] which
contained 27 scans from AD patients (mean age 70, SD 7.0) and 15 scans from
healthy older controls (HC) (mean age 69, SD 7.6). 18F-flutemetamol scans
from the Vandenberghe et al. (2010) study were re-analyzed using the MRI-
informed PET analysis method described above. The cut-off was defined based
on the statistical distance between the AD group and the HC as described in
Vandenberghe et al. (2010). This gave a SUVRcomp cut-off equal to 1.38. Note
that this cut-off is lower than the cut-off defined by Vandenberghe et al. (2010)
or Thurfjell et al. (2014) for a purely PET-based approach, probably due to
exclusion of more white matter signal in the MRI-informed method in the
amyloid-negative cases. Because of this difference, we also verified our binary
case classification using the PET-based method and cut-off from Thurfjell et
al. (2014) (cut-off equal to 1.57).
We verified our findings using partial volume corrected (PVC) data. PVC
was based on the MRI using the modified Müller-Gärtner method [146, 244].
This method makes use of probabilistic segmentation and determines tracer
concentration per unit volume of GM. The normalized unmodulated GM and
WM segmentations were used to estimate different tissue fractions per voxel.
PVC was applied to the normalized PET summed images. The remaining
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procedures were identical to those outlined above.
4.3.5 Statistical analysis
4.3.5.1 Analysis of behavioural data obtained during fMRI
RTs and accuracies (% correct responses) were analyzed by means of a four-
factor repeated-measures ANOVA, with stimulus modality (2 levels: pictures vs
words) and task (2 levels: associative-semantic vs visuoperceptual) as within-
subject factors and, as between-subject factors, BDNF (2 levels: codon 66
met carriers vs non-carriers) and APOE (2 levels: ε4 carriers vs non-carriers)
genotype (Table 4.3). Pairwise comparisons were performed using Bonferroni
post hoc tests.
4.3.5.2 Whole-brain voxelwise analysis
All voxelwise analyses were performed using SPM8. For each subject, param-
eter estimates were generated modelling each of the 5 conditions. We then
created the following contrast images, averaging across runs:
1. (Associative-semantic task with words + Associative-semantic task with
pictures) - (Visuoperceptual task with words + Visuoperceptual task with
pictures)
2. Associative-semantic task with words - Visuoperceptual task with words
3. Associative-semantic task with pictures - Visuoperceptual task with pic-
tures
4. (Associative-semantic task with words - Visuoperceptual task with words)
- (Associative-semantic task with pictures - Visuoperceptual task with
pictures) and inversely.
5. (Associative-semantic task with words + Associative-semantic task with
pictures) - baseline
6. (Visuoperceptual task with words + Visuoperceptual task with pictures)
- baseline.
7. Visuoperceptual task with words - baseline.
8. Visuoperceptual task with pictures - baseline.
The first-level contrast images were then used for second-level whole-brain anal-
ysis.
Our primary outcome analysis consisted of a whole-brain voxelwise linear
regression analysis with SUVRcomp as independent variable, and fMRI response
in contrast 1 (main effect of task) as dependent variable. The statistical map
was thresholded at a significance threshold of voxel-level Puncorrected < 0.001
combined with a cluster-level Pcorrected < 0.05, family-wise error (FWE) cor-
rected for the whole brain volume.
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As a secondary outcome analysis, we examined for each of the 10 regions
that constitute the composite cortical VOI, the correlation between regional
SUVR and the main effect of task (contrast 1) across the whole brain.
Furthermore, we examined whether any significant correlations with amy-
loid load were found for contrasts 2-8.
As a further secondary outcome analysis, we performed a whole-brain voxel-
by-voxel linear regression between SUVR images and fMRI images representing
associative-semantic minus visuoperceptual activity (contrast 1) using Biolog-
ical Parametric Mapping (BPM) [253]. The BPM is a toolbox for multimodal
image analysis which is based on a voxel-wise use of the SPM’s general linear
model. This allows comparison of different imaging modalities within voxels.
As a further secondary analysis, we categorized the cases into amyloid-
positive versus amyloid-negative and compared the main effect of task between
the two groups (contrast 1) using a two-sample t test.
We also tested if there was any difference in fMRI response between the
four genetic groups by means of a factorial ANOVA with BDNF (2 levels: met
allele present vs absent) and APOE (2 levels: ε4 allele present vs absent) as
between-subject factors and the main effect of task (contrast 1) as dependent
variable.
All whole-brain voxelwise analyses were thresholded at a significance thresh-
old of voxel-level Puncorrected < 0.001 combined with a cluster-level Pcorrected
< 0.05, FWE corrected for the whole brain volume. In the BPM analysis we
used threshold of voxel-level Puncorrected < 0.001 combined with cluster size of
at least 10 voxels.
4.3.5.3 Relationship to oﬄine measures of linguistic performance
When our primary analysis revealed clusters of significant correlation between
SUVRcomp and fMRI response during associative-semantic versus visuopercep-
tual processing (contrast 1), we examined in further detail whether mean fMRI
response in these clusters correlated with a pre-specified set of oﬄine measures
of linguistic performance. Clusters of voxels exhibiting a significant correla-
tion between SUVRcomp and fMRI response (contrast 1) were extracted using
the MarsBaR 0.43 toolbox (http://marsbar.sourceforge.net/). Given the pro-
posed role of the posterior STS in lexical-semantic retrieval [133], the principal
measures that we selected a priori were 1) Reaction times during the con-
frontation naming task, 2) Reaction times during the lexical decision task, 3)
The b parameter from the speeded word identification task. For each of these
parameters, we performed a stepwise linear regression analysis with this pa-
rameter as dependent variable and the independent variables: fMRI response
during the associative-semantic minus the visuoperceptual condition (contrast
1), SUVRcomp, age, education level, BDNF genotype, and APOE genotype.
Probability to enter the model was set at P < 0.05 with probability to remove
set to P > 0.1. This analysis was performed outside SPM in a VOI-based
56 Chapter 4
manner using STATISTICA 11 (http://www.statsoft.com/) as SPM software
does not include stepwise linear regression.
In an additional, binary approach, we examined which of these neurolinguis-
tic measures differed between the amyloid-positive and the amyloid-negative
class (two-sample t test).
4.4 Results
4.4.1 Analysis of behavioral scores during fMRI
The main effect of task was significant: subjects responded more accurately
during the associative-semantic conditions than during the visuoperceptual con-
ditions (F (1,52) = 17.4, P = 0.0001), albeit with longer RTs (F (1,52) = 24.9,
P = 0.000007) (Table 4.3). The main effect of modality was also significant:
subjects responded more slowly (F (1,52) = 21.3, P = 0.00003) and less ac-
curately (F (1,52) = 5.7, P = 0.02) for pictures than for words (Table 4.3).
The interaction between task and modality was significant (F (1,52) = 11, P
= 0.002): the associative-semantic task was performed more accurately with
words than with pictures (P = 0.00008), while there was no difference between
words and pictures for the visuoperceptual task (P = 1). There was no main ef-
fect of BDNF and APOE genotypes on accuracy or RT (P > 0.2) (Table 4.3).
The three-way interaction between task, modality and APOE genotype was
significant for accuracies (F (1,52) = 8.2, P = 0.006) (Table 4.3). According to
a posthoc analysis, APOE ε4 non-carriers performed the associative-semantic
task more accurately with words than with pictures (P = 0.0006), while there
was no difference between the two input-modalities for the visuoperceptual task
(P = 0.35). No such difference was seen in the APOE ε4 carriers (P = 0.23).
We did not find any significant interactions for reaction times (P > 0.05).
Performance during fMRI experiment
Reaction time (ms) Accuracy (% correct)
BDNF met+ met- met+ met- all met+ met- met+ met- all
APOE ε4+ ε4+ ε4- ε4- groups ε4+ ε4+ ε4- ε4- groups
Sem W 2653 2852 2679 2725 2717 88.8 85.5 90.7 89.0 88.8
(395) (326) (300) (449) (376) (7.4) (4.7) (4.2) (9.0) (7.0)
Sem P 2885 2839 2771 2858 2840 80.2 83.5 82.6 81.3 81.7
(530) (332) (293) (462) (417) (8.7) (7.9) (9.5) (9.0) (8.7)
Visuo W 2343 2570 2474 2457 2451 81.2 75.7 75.1 80.7 78.5
(404) (407) (381) (357) (382) (10.3) (15.8) (16.0) (15.6) (14.4)
Visuo P 2633 2765 2534 2647 2636 76.3 71.7 81.2 85.0 79.3
(611) (447) (426) (382) (468) (13.9) (17.8) (15.2) (14.5) (15.5)
Table 4.3: Values represent means and standard deviations. Sem W =
associative-semantic task with words; Sem P = associative-semantic task with
pictures; Visuo W = visuoperceptual task with words; Visuo P = visuopercep-
tual task with pictures.
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4.4.2 Whole-brain voxelwise analysis
4.4.2.1 Univariate contrast between fMRI conditions
The contrast between the associative-semantic minus the visuoperceptual con-
ditions (main effect of task, contrast 1) revealed a distributed semantic network
consistent with previous findings [248, 133, 132] (Figure 4.2A). The interaction
between task and input modality (contrast 4) revealed word-specific activa-
tion during the semantic compared to the visuoperceptual task in left STS,
extending from posterior to more anterior portions of the STS (cluster peak
coordinates -66, -36, 9, extent (ext) = 113 voxels, cluster level Pcorrected =
0.0001) (Figure 4.2B). Picture-specific semantic activation (inverse of contrast
4) occurred bilaterally in ventral occipitotemporal cortex extending to superior
occipital gyrus (right cluster peak coordinates 33, -45, -21, ext = 1756 vox-
els, cluster level Pcorrected < 0.0001 and left cluster peak coordinates -39, -51,
-15, ext = 1286 voxels, cluster level Pcorrected < 0.0001) and in right inferior
frontal gyrus (cluster peak coordinates 48, 12, 27, ext = 141 voxels, cluster
level Pcorrected < 0.0001) (Figure 4.2C).
4.4.2.2 Linear regression between fMRI response and amyloid load
In a whole-brain analysis, the posterior third of the left middle temporal gyrus
(MTG) (Figure 4.3A) exhibited a significant positive correlation between fMRI
response during the associative-semantic versus the visuoperceptual task (con-
trast 1) and SUVRcomp: activity levels were higher with a higher amyloid load
(-57, -45, 9, ext = 64 voxels, cluster level Pcorrected = 0.006) (Figure 4.3A-E).
No other regions showed a correlation, even when we lowered the significance
threshold to cluster-level Pcorrected < 0.25. The MTG belonged to the amodal
network, as evidenced by the conjunction analysis of contrast 2 and 3 (Fig-
ure 4.4A versus B and C).
When we restricted the contrast between the associative-semantic and the
visuoperceptual task to the words (contrast 2) and examined the correlation
with amyloid load in the whole-brain analysis, SUVRcomp correlated positively
with fMRI response during the associative-semantic minus visuoperceptual con-
trol condition for words in the same region (-60, -48, 9, ext = 49 voxels, cluster
level Pcorrected = 0.02). For pictures, there was no correlation (contrast 3)
(cluster-level Pcorrected > 0.6). No other regions showed a correlation, even
when we lowered the significance threshold to cluster-level Pcorrected < 0.10.
Neither were any correlations with SUVRcomp found for contrast 4-8.
Analysis of partial volume corrected data confirmed these results. PVC
SUVRcomp positively correlated with fMRI response during the associative-
semantic minus the visuoperceptual condition (contrast 1) in the posterior third
of the left MTG (-54, -39, 12, ext = 87 voxels, cluster level Pcorrected = 0.001).
Analysis restricted only to the word conditions showed that SUVRcomp cor-
related positively with fMRI response during the associative-semantic minus
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Figure 4.2: fMRI activity during associative-semantic processing. (A) Main
effect of associative-semantic task minus visuopercetual task (contrast 1). (B)
Interaction effect of task and modality: effect of semantic words (contrast 4,
i.e. (associative-semantic task with words - visuoperceptual task with words) -
(associative-semantic task with pictures - visuoperceptual task with pictures)).
(C) Interaction effect of task and modality: effect of semantic pictures (inverse
of contrast 4, i.e. (associative-semantic task with pictures - visuoperceptual
task with pictures) - (associative-semantic task with words - visuoperceptual
task with words)). Shown activations are significant at the threshold of voxel
level Puncorrected = 0.001 combined with cluster level Pcorrected = 0.05. The
colour scales indicate the T -values for the contrasts. MNI coordinates are
indicated in the left upper corner and orientation of the brain in the right
upper corner.
visuoperceptual control condition for words (contrast 2) in the same region
(-54, -36, 9, ext = 45 voxels, cluster level Pcorrected = 0.028). No correlation
was found between SUVRcomp and the fMRI response during the associative-
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Figure 4.3: Correlation between fMRI response during associative-semantic
processing and amyloid load. (A) Area in the left posterior MTG of significant
correlation between SUVRcomp and fMRI response during associative-semantic
minus visuoperceptual condition (contrast 1) (cluster peak -57, -45, 9, ext = 64
voxels, cluster level Pcorrected = 0.006). The colour scale indicates the T -values.
MNI coordinates are indicated in the left upper corner and orientation of the
brain in the right upper corner. (B) Plot of correlation between SUVRcomp (X
axis) and mean fMRI contrast values in the left MTG VOI during associative-
semantic minus visuoperceptual condition (contrast 1) (Y axis) (r = 0.63, P <
0.0001). (C) Bar plot depicting mean fMRI contrast values (Y axis) in the left
posterior MTG during each condition (X axis). Error bars: standard error;
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Sem W: associative-semantic task with words (blue); Sem P: associative-
semantic task with pictures (purple); Visuo W: visuoperceptual task with words
(cyan); Visuo P: visuoperceptual task with pictures (yellow); Rest: resting
baseline condition (red). (D) Correlation of SUVRcomp (X axis) with mean
fMRI contrast values during associative-semantic word processing (contrast
2) in the left MTG VOI (Y axis) (r = 0.59, P < 0.0001). (E) Correlation
of SUVRcomp (X axis) with mean fMRI contrast values during associative-
semantic picture processing (contrast 3) in the left MTG VOI (Y axis) (r =
0.47, P = 0.00025). Black lines: linear regressions; red triangles: BDNF met
+ve/APOE ε4 +ve; blue squares: BDNF met -ve/APOE ε4 +ve; red circles:
BDNF met +ve/APOE ε4 -ve; blue diamonds: BDNF met -ve/APOE ε4 -ve.
semantic minus visuoperceptual condition when only pictures were used (con-
trast 3) (cluster level Pcorrected > 0.07).
Among the regions which constituted the composite cortical VOI, average
SUVR in each of the regions besides the left and right anterior cingulate and
left lateral frontal region contributed to the correlation of fMRI response during
contrast 1 and SUVRcomp (cluster level Pcorrected < 0.038).
Biological parametric mapping indicated a significant correlation within-
voxels between fMRI activity and SUVR in the posterior left MTG (cluster
peak coordinates -60, -54, 12, ext = 18 voxels, voxel level Puncorrected = 0.0001,
Z = 3.65, r = 0.50).
4.4.2.3 Binary classification
We evaluated whether similar results would be obtained had we used a binary
approach: amyloid-positive versus amyloid-negative group (Figure 4.5). Eight
subjects (14%) were classified as positive (Figure 4.5). fMRI performance pa-
rameters did not differ between the amyloid-positive and the amyloid-negative
group (Table 4.4). In a whole-brain voxelwise analysis, the amyloid-positive
group exhibited a higher fMRI response compared to the amyloid-negative
group during the associative-semantic minus visuoperceptual conditions (con-
trast 1) in the posterior third of the MTG (-54, -42, 9, ext = 55 voxels, cluster-
level Pcorrected = 0.013) (Figure 4.5B red cluster). This was also true for
the contrast between the associative-semantic minus visuoperceptual task pre-
sented as words (contrast 2) (-57, -45, 6, ext = 59 voxels, cluster-level Pcorrected
= 0.008) (Figure 4.5B green cluster). Overlap between clusters is shown in dark
orange (Figure 4.5B). We did not find any significant differences elsewhere and
neither did we find any significant between-group differences for other contrasts.
When we applied the Thurfjell et al. (2014) method and cut-off for binary
classification, 4 cases were positive. The between-group differences remained
essentially the same: the amyloid-positive group had higher fMRI response
compared to the amyloid-negative group during the associative-semantic versus
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visuoperceptual condition (-60, -48, 9, ext = 54 voxels, cluster-level Pcorrected
= 0.014).
Figure 4.4: Modality specificity of amyloid sensitive VOI (left MTG). (A) Func-
tional left MTG VOI belongs to the amodal associative-semantic network (con-
junction of contrast 2 and 3) (MTG cluster pick -63, -45, 3, ext = 51 voxels,
voxel level Pcorrected = 0.000002). Overlap is shown in purple. (B) Left MTG
VOI did not belong to the word specific associative-semantic areas (contrast
4) (voxel level Pcorrected > 0.16) and (C) neither to the picture specific se-
mantic areas (inverse of contrast 4) (voxel level Pcorrected > 0.18). The left
MTG VOI is shown in blue. The hot colour scales indicate the T -values of
associative-semantic network (A), word specific associative-semantic regions
(B), and picture specific associative-semantic regions (C). Orientation of the
brain is indicated in the right upper corner. All P -values were FWE corrected
for multiple comparisons in a small volume.
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Figure 4.5: Amyloid-positive versus amyloid-negative group. (A) Older healthy
amyloid-positive subjects had higher amyloid deposition compared to amyloid-
negative subjects in typical regions for increased amyloid load (precuneus,
anterior and posterior cingulate, lateral prefrontal, lateral parietal, and lat-
eral temporal, ext = 39779 voxels, cluster level Pcorrected < 0.0001). The
hot colour scale indicates the T -values for the differences. (B) Older healthy
amyloid-positive subjects had increased fMRI response compared to amyloid-
negative subjects during the associative-semantic minus visuoperceptual con-
ditions (contrast 1) in the posterior third of the MTG (-54, -42, 9, ext =
55 voxels, cluster level Pcorrected = 0.013; in red), and during the associative-
semantic minus visuoperceptual task presented as words (contrast 2) also in the
MTG (-57, -45, 6, ext = 59 voxels, cluster level Pcorrected = 0.008; in green).
Overlap between clusters is shown in dark orange. Results are thresholded at
voxel level Puncorrected = 0.001 combined with cluster level Pcorrected = 0.05.
MNI coordinates are indicated in the left upper corner and orientation of the
brain in the right upper corner.
4.4.3 Genotype effect on fMRI response and relationship
between fMRI response and SUVR
BDNF and APOE genotype did not affect the activity patterns during the
associative-semantic versus visuoperceptual conditions (cluster level Pcorrected
> 0.8). Nor was there an effect of BDNF or APOE genotype on the correla-
tion between mean fMRI response in the left posterior MTG (contrast 1) and
SUVRcomp (P > 0.1) (BDNF met carriers r = 0.64, P = 0.0002; BDNF non-
carriers r = 0.61, P = 0.0005; APOE ε4 carriers r = 0.71, P = 0.00006; APOE
ε4 non-carriers r = 0.40, P = 0.03) (Figure 4.6).
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Figure 4.6: Effect of BDNF and APOE genotype on fMRI response. (A) The
difference between correlations for BDNFmet carriers (red full circles) and non-
carriers (blue full circles) (P = 0.86). (B) The difference between correlations
for APOE ε4 carriers (red empty circles) and non-carriers (blue empty circles)
(P = 0.11). Y axes: mean fMRI response during the associative-semantic
minus the visuoperceptual condition (contrast 1) in functional left MTG VOI.
X axes: SUVRcomp. Lines show linear regressions.
4.4.4 Relationship with oﬄine language measures
According to a stepwise regression analysis, variance in RT during the con-
frontation naming task was partly explained by SUVRcomp (r = 0.27, P =
0.04), rather than fMRI response (contrast 1; P = 0.62), age (P = 0.34), edu-
cation (P = 0.57), BDNF (P = 0.21), or APOE status (P = 0.42) (Figure 4.7).
Response latencies during confrontation naming were longer in the amyloid-
positive compared to the amyloid-negative group (P = 0.047) (Table 4.4).
There were no differences for any of the other experimental language tests
and neither did the conventional neuropsychological test scores differ between
the amyloid-positive and -negative class (Table 4.4).
4.5 Discussion
In cognitively intact older adults, a higher amyloid burden was associated with
subclinical alterations of the network for language and associative-semantic
processing. Activity in left posterior middle temporal gyrus was higher with
a higher amyloid load (Figure 4.3A, B). Higher amyloid levels were correlated
with slower confrontation naming (Figure 4.7). Our posterior temporal find-
ings are based on a whole-brain search without prior restriction of the search
volume. They were in agreement with our a priori hypothesis about posterior
temporal cortex, although the exact location was in the amodal posterior MTG
(Figure 4.4A) adjacent to the word-specific posterior STS found before in MCI
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Figure 4.7: Results of a stepwise regression analysis. RT during the confronta-
tion naming task (Y axis) was best predicted by the SUVRcomp (black circles)
(r = 0.27, P = 0.04), and not by fMRI response from contrast 1 (red circles)
(P = 0.62), age (blue circles) (P = 0.34), education (green circles) (P = 0.57),
BDNF (purple circles) (P = 0.21), or APOE (cyan circles) (P = 0.42) sta-
tus. X axis represents values of the predictor variables. Grey dashed line =
SUVRcomp cut-off of 1.38.
[133] and AD [132] patients.
While we used the SUVRcomp as a continuous variable for the primary
outcome analysis, we also conducted a secondary analysis where amyloid load
was treated as a binary variable and cases were classified as amyloid-positive
versus -negative based on an SUVRcomp cut-off. Such a binary approach is
closer to the way in which Sperling et al. (2011) conceptualize preclinical AD.
The findings based on a binary approach were entirely in line with the findings
obtained with the linear regression approach (Figure 4.5).
During the visuoperceptual control conditions subjects engaged in an active
comparison of the size-on-the-screen of a picture or a word. It is highly plausi-
ble that the meaning of this word or picture is automatically activated to some
degree during the visuoperceptual condition too. A lower-level control condi-
tion with consonant letter strings or scrambled pictures [254] would have been
necessary had we wanted to isolate the regions activated during word and pic-
ture processing in the visuoperceptual condition. In any case, we did not find a
correlation between amyloid load and the activity pattern during the visuoper-
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ceptual control conditions minus fixation baseline. This could suggest that the
network underlying activation of word and picture meaning during the visuop-
erceptual condition is relatively intact in preclinical AD and that the principal
changes are at the level of explicit associative-semantic processing.
Our findings are based on observational cross-sectional data, analyzed by
means of correlational analysis and between-group comparisons. One therefore
has to be careful in drawing conclusions about a causal link between the in-
crease in amyloid burden, the increase in left posterior temporal activity, and
the decrease in confrontation naming latencies. To adequately resolve this fun-
damental limitation, one would need to conduct interventional studies. This
is difficult since there are no proven amyloid-lowering interventions available.
Transcranial magnetic stimulation targeting the left posterior temporal cortex
could be an option to examine how altering activity within a subject affects
naming latencies and whether this depends on amyloid load.
We also observed right-hemispheric inferior frontal activation during the
associative-semantic versus the visuoperceptual task (Figure 4.2A), and this
was particularly pronounced for the pictures (Figure 4.2C). The right inferior
frontal activation could be related to the older age range of our individuals,
in line with the Hemispheric Asymmetry Reduction in Older Adults model
[255, 256]. However, one would need fMRI data over a wider age range including
also young adults to confirm this. In any case, no increase in right-hemispheric
activation was found as a consequence of increasing amyloid load in our dataset,
contrary to our original hypothesis [132].
Previous studies have investigated changes in task-related fMRI in AD prin-
cipally within the episodic memory domain. AD patients consistently show
lower hippocampal activation in episodic memory encoding tasks in compari-
son to controls and/or MCI subjects [257, 258, 259, 260, 138, 261]. Subjects
with late MCI also have decreased hippocampal activity during episodic mem-
ory encoding [258, 262] while subjects with early MCI compared to controls
show an increase in hippocampal activity during memory encoding [263, 264].
Young healthy presenilin 1 mutation carriers destined for early-onset AD ex-
hibit higher activity in the hippocampal formation in comparison to the non-
carrier controls [265, 266]. Subjects with a higher risk for AD due to family
history and APOE ε4 carrier status also have higher hippocampal activation
during encoding compared to non-carrier controls [267]. These studies led to a
model where the direction of functional changes in medial temporal cortex is
stage-dependent: in the preclinical AD stage and the early MCI stage, activity
during memory encoding in the hippocampus is increased compared to controls,
while in the late MCI and the clinically probable AD stage activity is decreased
compared to controls. Our findings indicate that a similar sequence may occur
in the language domain in left posterior temporal cortex. The current data show
increased activity during associative-semantic processing in preclinical AD ac-
cording to the National Institute on Aging and Alzheimer’s Association criteria
[55]. In a previous study in amnestic MCI, activity in left posterior STS was
decreased and correlated with the speed of written word identification [133]. In
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clinically probable AD, the same region also showed lower activity levels [132].
Our study is the first to report an increase in left posterior temporal cortex in
a stage that has been referred to as preclinical AD (Figure 4.3), similarly to
what has been described in the hippocampal formation for episodic memory
[261]. Taken together, this series of studies may suggest a similar sequence of
increased activity in posterior temporal cortex followed by activity decreases
as Alzeimer’s disease progresses to the clinical stages.
Initial functional imaging studies of language and semantic memory in clin-
ically probable AD have emphasized prefrontal increases which correlated pos-
itively with task performance [240, 242, 268]. These AD-related prefrontal
increases generalized across episodic and semantic memory tasks [268] and
presumably reflect general adaptive strategic processes [240, 268]. A series
of studies revealed functional changes also in temporal cortex, most notably
left inferior temporal cortex [161, 162], left and right middle temporal gyrus
[161, 162, 163] and left posterior superior temporal sulcus [132, 133]. Functional
differentiation exists within left temporal cortex even within nearby areas. For
instance, the posterior third of the left STS is activated during semantic pro-
cessing specifically for words [248, 133]. It has been principally implicated in
lexical-semantic [133] or lexical-phonological retrieval [269, 270]. In contrast, an
adjacent more inferior region, the posterior third of the left MTG, is activated
during semantic processing for both words and pictures (Figure 4.4A versus
B and C, Figure 4.3D-E). The left posterior middle temporal gyrus is one of
the most consistent hubs in the associative-semantic network [271, 252]. It has
been implicated in amodal semantic processing [248, 133] as well as in seman-
tic control [272, 273]. In the current study the correlation principally occurred
within the amodal posterior MTG region rather than the word-specific STS
(Figure 4.3A, Figure 4.4A). Our findings can be readily integrated in current
hypotheses that attribute to posterior MTG a role in cognitive control: regions
involved in semantic control may be the prime candidates for compensatory
processes in response to increases in amyloid load. Increased amyloid burden
in cortical areas may hamper normal neuronal functioning due to its neurotoxic
effects. In order to cope with such functional changes at the neuronal level, de-
mands for cognitive control may increase and this may account for the increase
in MTG activity levels. Cognitively normal older persons may have increased
Aβ levels yet intact neuropsychological performance [237, 164], possibly due
to ongoing compensatory processes. As the disease advances, mechanisms re-
sponsible for maintaining constant level of increased activation may become
exhausted, resulting in the first cognitive symptoms. Thus early word finding
difficulties in the course of AD might arise due to failure of semantic control
processes, followed by a gradual activity decrease in other language areas, e.g.
areas directly involved in word processing like posterior STS.
We did not find any effect of genetic polymorphisms of APOE or BDNF on
the language network in our cohort. In AD, APOE ε4 status has been associ-
ated more closely with episodic memory deficits than with language symptoms
[274, 275, 276, 277]. Healthy older controls with a family history of Alzeimer’s
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disease and at least one APOE ε4 allele, have increased fMRI activation during
a semantic memory task (famous versus unfamiliar names) in bilateral tem-
poroparietal areas, posterior cingulate and precuneus, posterior middle and
superior temporal regions, and left hippocampal complex [278]. It is not that
we did not find any effect of APOE. As reported before, APOE genotype ex-
erted an effect on the amyloid burden in our cohort: a higher amyloid load
in APOE ε4 carriers was present in posterior cingulate, a region outside the
network that our paradigm is activating [244].
As of yet, the relationship between BDNF and language has been princi-
pally studied during development and early adulthood [279, 280, 281] and in
schizophrenia [282]. Contrary to our hypothesis, the regression between fMRI
response and amyloid load was not influenced by BDNF status. In the same
cohort we previously reported that BDNF exerted a direct effect on amyloid
load in interaction with APOE: BDNF met carriers had increased levels of Aβ
in typical regions of predilection in comparison to the BDNF met non-carriers
with APOE ε4 [244]. In summary, contrary to our prediction, the effect of
BDNF in our cohort is situated at the level of amyloid aggregation rather than
at the level of fMRI response.
Our findings highlight the critical role of left posterior temporal cortex
in AD-related processes. Changes in left posterior superior temporal sulcus
lead to lexical-semantic retrieval deficits which may explain the word finding
difficulties in clinical AD [132] and the subclinical slowing in word identification
speed in MCI [133]. The changes we observed in this study in the posterior
middle temporal gyrus may reflect higher demands for semantic control in those
subjects who are cognitively intact despite a high amyloid burden.
To conclude, our cross-sectional data indicate that a higher amyloid load in
cognitively intact individuals has functional consequences for the network me-
diating language and associative-semantic processing. The converging evidence
obtained in cognitively intact older adults, amnestic MCI and AD may suggest
a sequence of events similar to that proposed for the hippocampal formation in
episodic memory. The initial compensatory role of increased neuronal activity
may precede later deterioration.
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Amyloid imaging in cognitively normal older
adults: Comparison between 18F-flutemetamol
and 11C-Pittsburgh Compound B
This chapter has been published as:
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Dupont, Koen Van Laere, Rik Vandenberghe. Amyloid imaging in cognitively
normal older adults: Comparison between 18F-flutemetamol and
11C-Pittsburgh Compound B. Eur J Nucl Med Mol Imaging 2015
doi:10.1007/s00259-015-3156-9.
5.1 Abstract
Preclinical, or asymptomatic, Alzheimer’s disease (AD) refers to the presence of
positive AD biomarkers in the absence of cognitive deficits. This research con-
cept is being applied to define target populations for clinical drug development.
In a prospective community-recruited cohort of cognitively intact older adults,
we compared two amyloid imaging markers within subjects: 18F-flutemetamol
to 11C-Pittsburgh compound B (11C-PIB).
In 32 community-recruited cognitively intact older adults aged between
65 and 80 years, we determined the concordance between binary classifica-
tion based on 18F-flutemetamol versus 11C-PIB according to semiquantita-
tive assessment (standardized uptake value ratio in composite cortical volume,
SUVRcomp) and, alternatively, according to visual reads. We also determined
the correlation between 18F-flutemetamol and 11C-PIB SUVR and evaluated
how this was affected by the reference region chosen (cerebellar grey matter
versus pons) and the use of partial volume correction (PVC) in this popula-
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tion.
Binary classification based on semiquantitative assessment was concordant
between 18F-flutemetamol and 11C-PIB in 94% of cases. Concordance of blinded
binary visual reads between tracers was 84%. The Spearman correlation be-
tween 18F-flutemetamol and 11C-PIB SUVRcomp with cerebellar grey matter
as reference region, was 0.84, with a slope of 0.98. Correlations in neocortical
regions were significantly lower with pons as reference region. PVC improved
the correlation in striatum and medial temporal cortex.
For the definition of preclinical AD based on 18F-flutemetamol, concordance
with 11C-PIB was highest using semiquantitative assessment with cerebellar
grey matter as reference region rather than pons.
5.2 Introduction
Biomarkers for Aβ accumulation in the brain play a central role in the Na-
tional Institute on Ageing and Alzheimer’s Association (NIA-AA) research
definition of preclinical Alzheimer’s disease (AD) [55]. Preclinical AD, also
termed asymptomatic AD, refers to the presence of AD-related pathophysio-
logical processes, such as amyloid aggregation, in individuals who do not have
cognitive deficits [55, 56]. Cognitively intact individuals who are amyloid-
positive are at increased risk for cognitive decline [57, 58]. Recent methods for
defining amyloid-positivity include positron emission tomography (PET) amy-
loid imaging and Aβ42 in cerebrospinal fluid assay. It is still largely unknown
how the choice of a particular amyloid biomarker may affect the discrimina-
tion between amyloid-positive and amyloid-negative healthy subjects. This is
important since an amyloid-positive status may define potential candidates for
experimental (e.g. anti-amyloid) therapies in clinical drug development.
18F-labeled tracers currently approved by the Food and Drugs Administra-
tion (FDA) and European Medicines Agency (EMA) for estimation of amy-
loid plaques in patients evaluated for cognitive decline are 18F-flutemetamol
[65, 66], 18F-florbetaben [67], and 18F-florbetapir [68]. The cortical retention
of 18F-flutemetamol has been compared to 11C-Pittsburgh compound B (11C-
PIB) [105] in clinical populations such as amnestic mild cognitive impairment
(aMCI) patients together with clinically probable AD patients [73], or aMCI
and clinically probable AD together with healthy controls [228], but not in
cohorts consisting exclusively of cognitively intact older adults. This is cru-
cial since the discriminative value of a tracer may also depend on the popu-
lation under study. The concordance between two tracers may be better in a
mixed sample of patients and controls then in a group consisting exclusively
of cognitively normal controls. In cognitively intact older adults ligand re-
tention values may lie closer to threshold than in patients with probable AD
and it has been hypothesized that 11C-PIB could potentially outperform 18F-
labelled tracers under such conditions [283]. Other 18F-labelled amyloid tracers
(18F-florbetaben [67], 18F-florbetapir [68], 18F-AZD4694 [76]) have also been
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compared with 11C-PIB within subjects, again mostly in clinical patient popu-
lations combined with cognitively intact older adults [31, 72]. For these tracers,
no direct comparisons have been performed in cohorts consisting exclusively of
cognitively intact older adults. Cognitively intact older adults who are amyloid-
positive constitute the target population for a number of current clinical drug
development programmes. The success of targeted molecular therapies may
critically depend on the presence of the drug target. Accurate ascertainment
of amyloid-positivity prior to inclusion may constitute one of the factors that
determines the success of trials in preclinical AD (importance of high speci-
ficity), as well as the cost of screening for eligible subjects (importance of high
sensitivity). Moreover, in cognitively intact older adults where amyloid levels
are slightly to markedly elevated, the precise analysis method is essential. This
may be less of an issue in patients with clinically probable AD who are well
within the abnormal range. None of the studies comparing 18F-flutemetamol
and 11C-PIB have evaluated the effect of reference region, magnetic resonance
image (MRI) versus PET-based normalization or partial volume correction on
the concordance between those tracers in cognitively normal older adults.
Therefore, the aim of this study was to directly compare 18F-flutemetamol
to 11C-PIB within the same subjects in a prospective community-recruited
cohort of cognitively intact older adults. We evaluated concordance between
18F-flutemetamol versus 11C-PIB binary classifications based on semiquanti-
tative assessment and visual reads, as well as the correlations between the
semiquantitative measures. We also estimated the impact of different image
analysis methods on amyloid quantification.
5.3 Materials and methods
5.3.1 Participants
Thirty-two cognitively intact older controls (mean age 72 years, SD 5) partici-
pated in this study (Table 5.1). They were recruited through advertisement in
local newspapers and through websites for seniors as part of a larger longitu-
dinal study, asking for healthy volunteers between 65 and 80 years of age for
participation in a scientific study at the University Hospital Leuven, Belgium,
involving brain imaging. At screening, subjects underwent a detailed interview
about medical history, a Mini Mental State Examination, a Clinical Dementia
Rating, general physical and neurological examination, blood sampling, and
a conventional neuropsychological assessment. Inclusion criteria were age be-
tween 65 and 80 years, MMSE ≥ 27, CDR = 0, and normal test scores on
neuropsychological assessment. Inclusion was stratified for two genetic factors:
BDNF (met allele present or absent) and APOE (ε4 allele present or absent),
as this cohort was part of a larger 18F-flutemetamol study in healthy controls
of the interactions between these polymorphisms [244, 284]. Exclusion criteria
were neurological or psychiatric history and brain lesions on structural MRI.
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Demographic and neuropsychological characteristics
Gender (male/female) 21/11
ApoE ε4 13 (41%)
Age (years) 72 (4.5) 65-80
Education (years) 12.6 (3.2) 8-20
MMSE (/30) 29.1 (1.1) 27-30
AVLT TL (/75) 44.4 (7.1) 33-69
AVLT DR (/15) 8.8 (2.3) 5-13
AVLT %DR 78.5 (12.5) 55-100
BNT (/60) 54.3 (4.1) 41-60
AVF (# words) 24.6 (5.2) 16-40
LVF (# words) 35.0 (11.9) 14-61
RPM (/60) 35.5 (10.0) 15-54
TMT B/A 2.3 (0.6) 1.3-3.8
Table 5.1: Second column: Mean (SD). Third column: Range. MMSE = Mini
Mental State Examination; AVLT = Rey Auditory Verbal Learning Test; TL
= total learning; DR = delayed recall; BNT = Boston Naming Test; AVF
= Animal Verbal Fluency Test; LVF = Letter Verbal Fluency Test; RPM =
Raven’s Progressive Matrices; TMT = Trail Making Test part B divided by
part A.
The protocol (EudraCT: 2009-014475-45) was approved by the Ethics Com-
mittee University Hospitals Leuven. Written informed consent was obtained
from all subjects in accordance with the Declaration of Helsinki.
5.3.2 Amyloid PET
PET scans were acquired on a 16-slice Siemens Biograph PET/CT scanner
(Siemens, Erlangen, Germany). Tracers were injected as a bolus in an an-
tecubital vein (18F-flutemetamol mean activity 150 MBq, SD 5 MBq, range
134-162 MBq; 11C-PIB mean activity 363 MBq, SD 33 MBq, range 255-420
MBq). The 18F-flutemetamol scan acquisition started 90 min after tracer in-
jection and lasted for 30 min [66, 73, 244, 284]. The 11C-PIB scan was obtained
within 30 days from the 18F-flutemetamol scan (mean 2 days, median 0 days,
range -22 to 21 days). Three subjects could not come to the clinic within the
30 days period due to personal or health reasons and they received a 11C-PIB
scan within 32, 39, and 118 days from the 18F-flutemetamol scan. Dynamic
11C-PIB scan acquisition extended from 0 to 70 min post tracer injection.
Prior to PET acquisition, a low-dose computed tomography scan of the head
was performed for attenuation correction. Random and scatter correction were
applied. The 18F-flutemetamol measurement was rebinned into 6 frames of
5 min and the 11C-PIB measurement between 40 and 70 min post injection
was also rebinned into 6 frames of 5 min each. Images were reconstructed us-
ing Ordered Subsets Expectation Maximization (4 iterations x 16 subsets). A
structural T1-weighted MRI was acquired on a 3T Philips Achieva scanner (3D
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turbo field echo sequence, 32-channel Philips SENSitivity Encoding head coil:
coronal inversion recovery prepared 3D gradient-echo images, inversion time
900 ms, TE/TR 4.6/9.6, flip angle 8◦, voxel size 0.98 x 0.98 x 1.2 mm3 [284]).
The 18F-flutemetamol and the 11C-PIB scans were preprocessed using Sta-
tistical Parametric Mapping 8 (SPM8, http://www.fil.ion.ucl.ac.uk/spm). The
individual images of the 6 frames were realigned and summed for both data
sets separately. The individual’s 18F-flutemetamol and 11C-PIB PET summed
images were co-registered to the subject’s T1-weighted MRI. 18F-flutemetamol
and 11C-PIB PET summed images were spatially normalized to the Montreal
Neurological Institute (MNI) space using MRI. This was done in two steps.
First, the MR image was spatially normalized to the SPM8 T1 template in
MNI space using a unified segmentation approach. This generated the non-
linear transformation parameters, as well as grey matter (GM), white matter
(WM) and cerebrospinal fluid images. Next, these transformation parameters
were applied to the individual’s co-registered 18F-flutemetamol and 11C-PIB
PET summed images to spatially normalize them to MNI space.
5.3.2.1 Semiquantitative analysis of amyloid PET
To measure specific tracer retention, standardised uptake value ratio (SUVR)
images were calculated from the spatially normalized summed 18F-flutemetamol
images and from the spatially normalized summed 11C-PIB images (voxel size
2 x 2 x 2 mm3) with the cerebellar GM used as reference region. The spatially
standardised volumes of interest (VOIs) were identical for 18F-flutemetamol
and for 11C-PIB image analysis. The cerebellar GM was defined based on the
automated anatomical labelling (AAL) atlas (areas 91-108) and masked inclu-
sively with subject-specific GM maps, with the threshold for masking set at >
0.3 [244, 284]. This reference region was used both for 18F-flutemetamol and
for 11C-PIB images. As a secondary analysis, we also used pons as a refer-
ence region: this region was manually drawn on the SPM8 T1-template (13
axial slices of 2 mm) and then for each individual it was corrected to match
the subject-specific anatomical boundaries of the pons based on the subject’s
spatially normalized MR image.
Our primary PET outcome measure was the mean SUVR in the compos-
ite cortical VOI (SUVRcomp) with cerebellar GM as reference region. The
composite VOI consisted of 5 bilateral cortical areas [244, 284]. The spatially
standardised VOIs were based on the AAL template. We also calculated mean
SUVR in each of these regions separately and additionally in medial temporal
(AAL 37-42), and occipital cortex (AAL 43-54), and striatum (AAL 71-74).
The AAL VOIs were masked inclusively with subject-specific GM maps, with
the threshold for masking set at > 0.3 [244, 284]. Mean SUVR was also esti-
mated in subcortical WM (SWM), which was defined based on subject-specific
WM maps thresholded at > 0.5.
The cut-offs for SUVRcomp for binary classification were defined based on
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independent datasets re-analyzed using the MRI-based PET analysis method
described above. The cut-offs were defined based on the statistical distance
between the AD group and the HC as described in Vandenberghe et al. (2010),
that is: factor = Mean SUV Rcomp AD − Mean SUV Rcomp HCSD SUV Rcomp AD + SD SUV Rcomp HC , SUV Rcomp cut-
off = Mean SUV Rcomp AD−factor×SD SUV Rcomp AD. 18F-flutemetamol
cut-off was estimated based on the Vandenberghe et al. (2010) dataset [73],
and was equal to 1.38. The 11C-PIB cut-off was calculated based on 37 clini-
cally probable AD subjects and 23 age-matched healthy controls (datasets from
Nelissen et al. (2007) [132], Vandenberghe et al. 2010 [73], and Ahmad et al.
2014 [285]) and was equal to 1.22. Note that the used 1.38 18F-flutemetamol
cut-off is lower than the cut-off defined by Vandenberghe et al. (2010) or Thur-
fjell et al. (2014) for a purely PET-based approach, probably due to exclusion
of more white matter signal by the current MRI-based method in the amyloid-
negative cases. We also verified our binary case classification using the purely
PET-based method with narrow VOIs and SUVR cut-offs with reference to
cerebellar GM as used by Thurfjell et al. (2014). For this method, the cut-off
with the neuropathological modified Consortium to Establish a Registry for
Alzheimer’s Disease score as standard-of-truth was 1.57 [229].
In addition, we evaluated how cut-offs and concordance changed when we
defined the cut-off of one tracer based on receiver operating characteristic
(ROC) analysis with the categorization by the other tracer as standard-of-
truth (SoT)1. We did this with the categorization based on 11C-PIB as SoT
and, separately, with the categorization based on 18F-flutemetamol as SoT.
As a further secondary analysis, we performed a semiquantitative analysis
based on partial volume corrected (PVC) data. PVC was based on the MRI
using the modified Müller-Gärtner method [146, 244, 284].
5.3.2.2 Visual reads
18F-flutemetamol and 11C-PIB scans were visually evaluated by 3 indepen-
dent readers blinded to all subject information: two certified nuclear medicine
physicians (reader 1 K.V.L, reader 2 K.G.) and a certified psychiatrist (reader 3
M.V.), experienced in reading amyloid scans. All readers had successfully com-
pleted the GE Healthcare electronic reader training program for 18F-flutemeta-
mol images. The visual read was done on summed orthogonal PET images in
native space, scaled to the image maximum intensity value and displayed with
a modifiable rainbow (NIH) colour scale. Each reader received an individually
randomized list of 18F-flutemetamol and 11C-PIB images which were evaluated
in separate sessions. Readers were asked to assign scans as positive or negative
and to rate their overall confidence in classifying the image on a scale from 1
to 5 (5 being the highest confidence). The final assignment was based on a
majority verdict.
1The ROC analyses were added to the thesis after publication of the article.
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5.3.3 Statistical analysis
The primary analyses were intended to evaluate in cognitively intact older
adults:
1. The concordance between binary classification based on 18F-flutemetamol
versus 11C-PIB according to semiquantitative SUVRcomp assessment.
2. The concordance of binary visual reads of 18F-flutemetamol versus 11C-
PIB.
3. The correlation between 18F-flutemetamol and 11C-PIB SUVRcomp. Nor-
mality of data distribution was tested using the Shapiro-Wilk test. Cor-
relations were evaluated using (a) Spearman rank correlation coefficients
ρ if distributions deviated from normality, and (b) using slopes of lin-
ear regression m. The agreement between 18F-flutemetamol and 11C-PIB
SUVRcomp was tested by a Bland-Altman analysis [286].
The secondary analyses evaluated in cognitively intact older adults:
1. The agreement between readers of the visual classification. This was
analysed by means of Fleiss’ Kappa (κ).
2. Readers’ confidence in visual binary classification of the PET scans. This
was analysed by three-factor repeated measures ANOVA, with reader (3
levels: reader 1 vs 2 vs 3) and tracer (2 levels: 18F-flutemetamol vs 11C-
PIB) as within-subject factors, and concordance of binary visual reads (2
levels: concordant vs discordant) as between-subject factor.
3. The correlation between 18F-flutemetamol and 11C-PIB SUVR in a set
of 9 separate regions.
4. The correlation between 18F-flutemetamol and 11C-PIB SUVR values
using the pons as reference region.
5. The correlation between PVC-corrected 18F-flutemetamol and PVC-correc-
ted 11C-PIB SUVR values.
Statistical analyses were performed in Statistica 11 (http://www.statsoft.com/)
and Matlab R2013b (http://www.mathworks.com).
5.4 Results
Regional and composite SUVR values of 18F-flutemetamol (W = 0.68-0.86, P <
0.002) and 11C-PIB (W = 0.69-0.87, P < 0.006) were not normally distributed.
Therefore in the subsequent analyses we used Spearman ρ coefficient.
Binary classification based on semiquantitative cut-offs was concordant be-
tween 18F-flutemetamol versus 11C-PIB in 94% of the cases (Figure 5.1A).
Based on 18F-flutemetamol SUVRcomp 5 out of 32 subjects (16%) were as-
signed to the amyloid-positive category (Figure 5.1A, 5.2). Based on 11C-
PIB SUVRcomp, 7 out of 32 subjects (22%) were assigned to the amyloid-
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positive category (Figure 5.1A, 5.2). Two cases were discordant between 18F-
flutemetamol and 11C-PIB (cases 8 and 31, Figure 5.1A, 5.2). These subjects
were assigned to the amyloid-negative category based on 18F-flutemetamol and
to the amyloid-positive category based on 11C-PIB.
Concordance of binary visual reads between tracers was 84% (Figure 5.1B).
Based on 18F-flutemetamol scans 3 out of 32 subjects (9%) were assigned to
the amyloid-positive category (Figure 5.1B, 5.2). According to 11C-PIB scans,
6 out of 32 subjects (19%) were assigned to the amyloid-positive category (Fig-
ure 5.1B, 5.2). Out of 5 discordant cases, one subject was read as positive for
18F-flutemetamol but negative for 11C-PIB (case 24, Figure 5.1B, 5.2, 5.3), and
4 were read as positive for 11C-PIB but negative for 18F-flutemetamol (cases
17, 19, 29, 31, Figure 5.1B, 5.2). Fleiss’ κ for inter-reader agreement was 0.86
for 18F-flutemetamol, and 0.93 for 11C-PIB.
When we analysed readers’ confidence in visual classification of 18F-fluteme-
tamol and 11C-PIB scans we found a significant main effect of reader (F2,62 =
12.3, P = 0.00003): reader 1 (r1) and 3 (r3) were more confident than reader
2 (r2) (r1 > r2 P = 0.0001, r3 > r2 P = 0.0006) (Figure 5.4A). We also found
a significant main effect of concordance of visual classification: readers were
more confident when classifying concordant cases compared with discordant
cases (F1,30 = 5.1, P = 0.03) (Figure 5.4B). No other effects were found.
18F-flutemetamol and 11C-PIB SUVR values were highly correlated in the
composite cortical VOI, in all neocortical VOIs and in subcortical white mat-
ter (Table 5.2; Figure 5.5). The correlations in striatum and medial temporal
cortex were weaker (Table 5.2; Figure 5.5). The slopes of linear regression
Figure 5.1: Concordance between binary semiquantitative (A) and visual (B)
classifications of 18F-flutemetamol and 11C-PIB scans. (A) Dashed lines =
SUVR cut-offs. (B) Red = positive scan; green = negative scan. Values in red
and green cells = confidence levels of the readers.
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were close to 1 in all neocortical regions and subcortical white matter (Ta-
ble 5.2; Figure 5.5). Slopes in striatum and medial temporal cortex were lower
(Table 5.2; Figure 5.5). The Bland-Altman analysis [286] showed a good agree-
ment between 18F-flutemetamol and 11C-PIB SUVRcomp, with a systematic
bias towards higher 18F-flutemetamol SUVR values (Figure 5.6).
Figure 5.2: Representative summed PET images of the discordant cases be-
tween 18F-flutemetamol and 11C-PIB scans based on semiquantitative and vi-
sual classification. For the sake of comparison we also displayed two positive
cases who were concordantly classified by semiquantitative and visual approach.
Brain sections show axial slices at -4, 10, 24, 38 MNI z coordinates. On the
right side of the brain sections SUVRcomp values (at the top) and results of
visual reads (VIS R, at the bottom, + positive scan, - negative scan) are shown.
Images are scaled to a maximum intensity in an image.
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Figure 5.3: Detailed view on case 24. Left upper corners show MNI coordinates.
Right upper corners show brain orientation. Images are scaled to a maximum
intensity in an image.
Figure 5.4: Analysis of readers’ confidence in visual binary classification of 18F-
flutemetamol and 11C-PIB scans. (A) Main effect of reader. (B) Main effect of
concordantly versus discordantly classified cases.
When we applied the Thurfjell et al. (2014) PET-based processing method
and autopsy derived SUVR cut-off with reference to cerebellar GM, 4 out of
32 18F-flutemetamol scans (13%) were classified as amyloid-positive. In three
cases, the MRI-informed and the purely PET-based processing methods yielded
discordant classification: two subjects were classified as amyloid-negative based
on the PET-based method and as amyloid-positive based on the MRI-informed
method (case 19 and 29, Figure 5.1B, 5.2, SUVRcomp based on purely PET-
based processing method 1.45 and 1.47 respectively), one subject showed the
inverse pattern (case 31, Figure 5.1B, 5.2, SUVRcomp based on purely PET-
based processing method 1.61). The correlation between 18F-flutemetamol and
11C-PIB scans analysed by the purely PET-based processing method was high
in composite cortical VOI and in all neocortical VOIs (Table 5.2).
We also performed an ROC analysis to evaluate whether a different cut-off
was obtained when one of the tracers was evaluated against the categorization
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Figure 5.5: Regional correlations between 18F-flutemetamol and 11C-PIB SU-
VRs. WM = white matter.
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Region-wise correlations between 18F-flutemetamol and 11C-PIB SUVRs for
different analysis methods
MRI-informed method PET-based method
Cerebellar GM Pons Cerebellar GM Cerebellar GM
& PVC
Region m ρ m ρ m ρ m ρ
Composite cortical 0.98 0.84 0.49 0.69 0.96 0.90 0.72 0.86
Lateral frontal 0.91 0.87 0.49 0.76 0.91 0.89 0.72 0.85
Lateral temporal 1.03 0.83 0.47 0.70 1.03 0.87 0.73 0.75
Lateral parietal 1.00 0.90 0.50 0.63 0.97 0.92 0.74 0.92
Anterior cingulate 0.90 0.81 0.54 0.79 0.89 0.90 0.73 0.82
Posterior cingulate 0.99 0.86 0.56 0.78 0.98 0.83 0.72 0.92
Lateral occipital 1.03 0.77 0.43 0.72 0.94 0.86 0.67 0.84
Striatum 0.84 0.60 0.52 0.81 0.95 0.87 - -
Medial temporal 0.84 0.66 0.53 0.79 0.99 0.68 0.76 0.70
Subcortical WM 0.99 0.82 0.90 0.96 0.98 0.95 - -
Table 5.2: GM = grey matter; WM = white matter; PVC = partial volume
correction; m = slope of linear regression; ρ = Spearman correlation coefficient.
All correlations reached P ≤ 0.0001, except for the correlation in striatum with
cerebellar GM as reference region P = 0.0003. Bold font shows significant
differences at P< 0.05 for comparison ofm and ρ with columns 2-3, respectively.
Not corrected for multiple comparisons.
by the other tracer as standard-of-truth. The SUVRcomp cut-offs for opti-
mal agreement between the tracers defined based on ROC analysis were 1.3
for 18F-flutemetamol (Area under the ROC curve (AUC) 0.983, 95% CI 0.861
- 1.0, sensitivity 86%, specificity 100%) and 1.22 for 11C-PIB (AUC 0.993,
95% CI 0.877 - 1.0, sensitivity 100%, specificity 96%)2. Seven cases were de-
fined as amyloid-positive based on 18F-flutemetamol cut-off and also based on
11C-PIB cut-off. There were two discordant cases between 18F-flutemetamol
and 11C-PIB classifications: one classified as amyloid-negative based on 18F-
flutemetamol and as amyloid-positive based on 11C-PIB (case 31) and one in
an opposite fashion (case 16). The obtained cut-off values were essentially the
same as those derived from the independent datasets.
When pons was used as reference region, the correlation between 18F-
flutemetamol and 11C-PIB SUVRs was weaker in the composite cortical VOI
and in neocortical VOIs. This difference was statistically significant in the
lateral parietal VOI (P = 0.007) (Table 5.2). The correlation however was
stronger in striatum, medial temporal cortex, and subcortical WM when pons
was used as reference region than when cerebellar GM was used. This differ-
ence was statistically significant in subcortical WM (P = 0.004) (Table 5.2).
With pons as reference region, the slopes of linear regression were close to 0.5
and were significantly less steep than with cerebellar GM as reference region
in all VOIs (P < 0.0001) except for subcortical WM where slope was 0.9 (Ta-
ble 5.2). When pons was used as reference region for 18F-flutemetamol and
cerebellar grey matter was used as reference region for 11C-PIB, correlations
2The ROC analyses were added to the thesis after publication of the article.
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Figure 5.6: Agreement between 18F-flutemetamol and 11C-PIB SUVRs based
on Bland-Altman analysis.
between SUVRs in all VOIs were weaker than when either pons or cerebellar
grey matter were used for both of the tracers3. Statistically significant differ-
ences were found in medial temporal (P = 0.006) and subcortical WM (P =
0.02) VOIs, compared with correlations with pons as reference region for both
tracers.
PVC did not significantly alter ρ and slopes for the correlation between
18F-flutemetamol and 11C-PIB SUVR values in the composite cortical VOI or
any of the neocortical VOIs (Table 5.2). In striatum, medial temporal cortex
and subcortical WM, PVC improved ρ or slope significantly (Table 5.2).
5.5 Discussion
To our knowledge this is the first study comparing 18F-flutemetamol to 11C-
PIB in a cohort consisting exclusively of cognitively intact older adults, without
patients with cognitive deficits. Our results provide evidence for a close corre-
spondence between the two amyloid tracers even at this preclinical stage.
We detected a few more amyloid-positive cases with 11C-PIB scan (7 out
of 32) than with 18F-flutemetamol scan (5 out of 32). This differs from previ-
ous comparisons that included only AD and MCI [73] or AD, MCI, together
with HC [228], where concordance between 18F-flutemetamol and 11C-PIB was
100%. In the Hatashita et al. study [228] the cut-offs for semiquantitative
assessment were not defined independently from the test sample and this may
3These analyses were added to the thesis after publication of the article.
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also have contributed to this complete concordance. In our study the cut-offs
were based on independent datasets. One of the discordant subjects (case 8)
lay within 1.5% test-retest variability of SUVRcomp values [73], therefore only
case 31 should be considered meaningfully discordant.
The values in the discordant cases in our study were around the cut-off,
except for case 24 (see below). Near-threshold values may render the binary
division between amyloid-positive and -negative cases in cognitively normal in-
dividuals more difficult. Amyloid accumulation is a progressive process and the
amyloid-positive cases are distributed over range of continuous values rather
than bimodally. Hence, among cognitively normal controls a binary classifica-
tion into positive and negative subjects is somewhat artificial. Individuals with
the intermediate amyloid levels may either remain at this level or may be head-
ing towards further pathological amyloid aggregation [287]. Subjects around
the cut-off may be accumulating amyloid at a higher rate than those subjects
who are further removed from the cut-off [287] and in this sense may be of
special interest for potentially disease-modifying drug trials. To investigate the
prevalence and the meaning of these cases with sufficient power a joint lon-
gitudinal approach including different centres would be necessary. In such an
approach a standardized quantification of amyloid deposition, such as centiloid
scale [288], would facilitate the comparison. Values close to threshold probably
explain the higher rate of discordance in visual reads in our study compared
to what has been found in AD and MCI [73, 228]. We however met one excep-
tion: in case 24, 18F-flutemetamol SUVR was far removed from the cut-off and
nevertheless the 18F-flutemetamol scan was read as positive by all 3 readers
with relatively high confidence. When evaluating this scan in retrospect, the
outcome of the read may have been determined by the fact that tracer reten-
tion was similarly low in white matter and in neocortex. As a consequence, the
pattern of gyral indentation was lost and the cortical surface relatively even.
This was not true for the 11C-PIB scan. The similarity in 18F-flutemetamol
retention between neocortex and white matter and the even appearance of the
surface may have led to the positive read despite the low neocortical SUVR.
This underscores the usefulness of semiquantitative measures when evaluating
normal control 18F-flutemetamol scans. The overall confidence of readers in
visual evaluation of scans was high, however, the confidence of all readers was
lower when evaluating discordant cases compared with concordant cases. This
indicated that a subset of scans in this population is particularly difficult to
read.
As a further difference with previous comparative studies [73], the correla-
tion between 18F-flutemetamol and 11C-PIB SUVR values in subcortical white
matter (Table 5.2) was higher than previously observed (in [73] r = 0.36). The
definition of the white matter VOI may have been more accurate in the current
study as it was based on the MRI. A white matter VOI that is defined based
on PET may be affected by spill-over between grey and white matter and this
may differ between 18F-flutemetamol and 11C-PIB, yielding lower correlations
in previous studies [73].
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We also evaluated how differences in the analysis method affected the con-
cordance and the correlation with 11C-PIB. PVC did not substantially alter
correlations between 18F-flutemetamol and 11C-PIB in neocortical VOIs, but
affected the correlation in striatum and medial temporal cortex in a positive
sense. The latter area is known to be particularly susceptible to partial volume
effects. Second, using pons as a reference region resulted in substantially lower
correlations between 18F-flutemetamol and 11C-PIB in neocortical regions (Ta-
ble 5.2). Only in striatum, medial temporal cortex, and subcortical WM did
pons as a reference region yield better correlations (Table 5.2). Finally, the cor-
relations of SUVRs were the same when 18F-flutemetamol and 11C-PIB scans
were analysed with a purely PET-based method [229] compared to our MRI-
based method [244] (Table 5.2). It however is worth noting that the slopes
for the correlations between 18F-flutemetamol and 11C-PIB were substantially
lower for the purely PET-based method than when MRI was used to indepen-
dently define the regions to be used for analysis of the two PET modalities.
Practical implications
The FDA and EMA approvals of amyloid imaging are for visual reads and
are restricted to patients with cognitive decline. For research use in cogni-
tively intact individuals, our findings suggest that semiquantitative assessment
would be preferable above visual reads. In cognitively intact older individuals
cerebellar grey matter would be the preferred reference region compared with
pons. PVC would be advantageous for evaluation of medial temporal cortex
and subcortical regions. Concordance between 18F-flutemetamol and 11C-PIB
was better when regions were based on MRI rather than for PET based regions.
5.5.1 Conclusion
Our study of amyloid markers in asymptomatic older adults provides evidence
that semiquantitative measures of 18F-flutemetamol with cerebellar grey matter
as a reference are closely similar to what one would obtain if 11C-PIB was used,
in particular if MRI is used to define the regions of interest. Concordance for
visual reads tended to be less convincing in this population.
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Diagnostic value of cerebrospinal fluid Aβ
ratios in preclinical Alzheimer’s disease
This chapter has been submitted for publication:
Katarzyna Adamczuk, Jolien Schaeverbeke, Hugo MJ Vanderstichele, Johan
Lilja, Natalie Nelissen, Koen Van Laere, Patrick Dupont, Kelly Hilven, Koen
Poesen, Rik Vandenberghe. Diagnostic value of cerebrospinal fluid Aβ ratios
in preclinical Alzheimer’s disease. Under revision.
6.1 Abstract
In this study of preclinical Alzheimer’s disease (AD) we assessed the added
diagnostic value of using cerebrospinal fluid (CSF) Aβ ratios rather than Aβ42
in isolation for detecting individuals who are positive on amyloid positron emis-
sion tomography (PET).
Thirty-eight community-recruited cognitively intact older adults (mean age
73, range 65-80 years) underwent 18F-flutemetamol PET and CSF measure-
ment of Aβ1-42, Aβ1-40, Aβ1-38, and total tau (ttau). 18F-flutemetamol re-
tention was quantified using standardized uptake value ratios in a composite
cortical region (SUVRcomp) with reference to cerebellar grey matter. Based on
a prior autopsy validation study, the SUVRcomp cut-off was 1.57. Sensitivities,
specificities and cut-offs were defined based on receiver operating characteristic
analysis with CSF analytes as variables of interest and 18F-flutemetamol posi-
tivity as the classifier. We also determined sensitivities and CSF cut-off values
at fixed specificities of 90% and 95%.
Seven out of 38 subjects (18%) were positive on amyloid PET. Aβ42/ttau,
Aβ42/Aβ40, Aβ42/Aβ38, and Aβ42 had the highest accuracy to identify amylo-
id-positive subjects (area under the curve (AUC) ≥ 0.908). Aβ40 and Aβ38
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had significantly lower discriminative power (AUC = 0.571). When specificity
was fixed at 90% and 95%, Aβ42/ttau had the highest sensitivity among the
different CSF markers (85.71% and 71.43%, respectively). Sensitivity of Aβ42
alone was significantly lower under these conditions (57.14% and 42.86%, re-
spectively).
For the CSF-based definition of preclinical AD, if a high specificity is re-
quired, our data support the use of Aβ42/ttau rather than using Aβ42 in
isolation.
6.2 Introduction
Preclinical [55, 58], or asymptomatic [63], Alzheimer’s disease (AD) is char-
acterized by the presence of AD-related pathophysiological processes in the
absence of cognitive deficits. Evidence of brain amyloidosis is a requirement
common to all 3 National Institute on Ageing and Alzheimer’s Association
(NIA-AA) stages of preclinical AD [55]. This can be detected directly in vivo
by means of either β-amyloid (Aβ) protein quantification in cerebrospinal fluid
(CSF) or positron emission tomography (PET) amyloid imaging [55, 100, 102].
Apart from Aβ1-42, other Aβ isoforms (e.g. Aβ1-40, Aβ1-38) have evoked
interest from a clinical-diagnostic perspective, as either a separate biomarker
tool or when combined (ratio) with Aβ1-42 [289, 290, 291]. Using ratios of
Aβ isoforms (Aβ1-42/Aβ1-38, Aβ1-42/Aβ1-40) may have added value for the
discriminaton between AD and normal pressure hydrocephalus [292], cerebral
amyloid angiopathy [293], frontotemporal dementia [294], and Lewy body de-
mentia [295], and also between mild cognitive impairment (MCI) due to AD
and non-AD MCI [296]. In cognitively intact individuals, Aβ38 or Aβ40 do
not correlate with amyloid PET positivity, in contrast with Aβ42 [101, 102].
In this study of preclinical AD, we assessed the added value of using ratios
of Aβ42 to other C-terminal Aβ isoforms or to total tau for discriminating
amyloid-positive versus amyloid-negative cognitively intact healthy controls,
with an autopsy-validated 18F-flutemetamol cut-off score [229] as standard-of-
truth. The cut-off value was derived from the 18F-flutemetamol phase 3 study
using a binarized measure of postmortem brain neuritic plaque density [297]
(overall mean Bielschowsky score below or above 1.5 [229]).
6.3 Methods
6.3.1 Participants
Thirty-eight cognitively intact older controls (mean age 73 years, SD 5 years,
Table 6.1) were recruited, from 10/09/2012 until 04/04/2014, through ad-
vertisement in local newspapers and through websites for seniors, asking for
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healthy volunteers between 65 and 80 years of age for participation in a scien-
tific study at the University Hospital Leuven, Belgium, involving brain imaging.
At screening, subjects underwent a detailed interview about medical history, a
Mini Mental State Examination (MMSE), a Clinical Dementia Rating (CDR),
blood sampling, and a conventional neuropsychological assessment. Inclusion
criteria were age 65 - 80 years, MMSE ≥ 27, CDR = 0, and normal test scores
on neuropsychological assessment according to the published norms adapted
for age, gender, and education. Inclusion was stratified per age bin (65-69, 70-
74, 75-80) for two genetic factors: Brain-Derived Neurotrophic Factor (BDNF)
(met allele present or absent) and Apolipoprotein E (APOE) (ε4 allele present
or absent). The cells of this 2 x 2 factorial design were prospectively matched for
number of cases, age, sex, and education. This cohort was part of a larger 18F-
flutemetamol study in healthy controls about the interaction between BDNF
and APOE [244, 284]. Among the exclusion criteria were a neurological or psy-
chiatric history and focal brain lesions on structural magnetic resonance image
(MRI). Subjects who fulfilled all criteria underwent 18F-flutemetamol PET and
lumbal puncture. The protocol (EudraCT: 2009-014475-45) was approved by
the Ethics Committee University Hospitals Leuven. Written informed consent
was obtained from all subjects in accordance with the Declaration of Helsinki.
6.3.2 Amyloid PET
18F-flutemetamol PET was acquired on a 16-slice Siemens Biograph PET/CT
scanner (Siemens, Erlangen, Germany). The tracer was injected as a bolus in
an antecubital vein (mean activity 150 MBq, SD 5 MBq, range 134-162 MBq).
Scan acquisition started 90 min after tracer injection and lasted for 30 min
[66, 73, 244, 284]. Three adverse events were reported within 24 hours after
the scan. This includes 2 mild headaches, which were resolved the same and
the next day after the scan. One subject reported a rising heartbeat and a
warm feeling immediately after injection, which were resolved within 2 min.
Prior to PET acquisition, a low-dose computed tomography scan of the head
was performed for attenuation correction. Random and scatter correction were
applied. The 18F-flutemetamol measurement was rebinned into 6 frames of 5
min. Images were reconstructed using Ordered Subsets Expectation Maximiza-
tion (4 iterations x 16 subsets). The individual images of the 6 frames were
realigned and summed. Subsequently, the PET summed image was spatially
normalized to Montreal Neurological Institute (MNI) space using a fully auto-
mated PET-only method that made use of an adaptive template to account for
the different uptake patterns in negative and positive 18F-flutemetamol images
[298]. On spatially normalized images (voxel size 2 x 2 x 2 mm3) standard
uptake value ratios (SUVR) were calculated with cerebellar grey matter as ref-
erence region. Mean SUVR value was calculated in a composite cortical region
(SUVRcomp) consisting of 5 bilateral areas: frontal, parietal, anterior cingu-
late, precuneus-posterior cingulate and lateral temporal [229]. The composite
cortical region and the cerebellar grey matter reference region were defined as a
88 Chapter 6
Demographics and CSF biomarkers concentrations
[mean (SD, range)]
Gender (male/female) 22/16
Age (years) 73 (4.7, 65 - 80)
Education (years) 13.4 (3.1, 8 - 20)
APOE ε4 (n) 19 (50%)
BDNF met (n) 20 (53%)
MMSE (/30) 28.9 (1.0, 27 - 30)
AVLT TL (/75) 46.2 (8.4, 31 - 69)
AVLT DR (/15) 9.8 (2.5, 5 - 14)
AVLT %DR 83.7 (11.7, 55 - 108)
BNT (/60) 54.2 (4.2, 41 - 60)
AVF (# words) 24.0 (5.5, 14 - 40)
LVF (# words) 36.0 (10.8, 17 - 64)
RPM (/60) 36.1 (9.8, 15 - 53)
TMT B/A 2.4 (0.5, 1.5 - 3.8)
Aβ38 (pg/mL) 2401 (654, 1057 - 3505)
Aβ40 (pg/mL) 8933 (2456, 3640 - 13273)
Aβ42 (pg/mL) 996 (430, 351 - 1859)
ttau (pg/mL) 360 (134, 126 - 660)
Aβ42/Aβ38 0.412 (0.119, 0.136 - 0.596)
Aβ42/Aβ40 0.110 (0.030, 0.044 - 0.148)
Aβ42/ttau 3.015 (1.246, 0.749 - 5.128)
Table 6.1: APOE = Apolipoprotein E; MMSE = Mini Mental State Examina-
tion; AVLT = Rey Auditory Verbal Learning Test; TL = total learning; DR
= delayed recall; BNT = Boston Naming Test; AVF = Animal Verbal Fluency
Test; LVF = Letter Verbal Fluency Test; RPM = Raven’s Progressive Matrices;
TMT = Trail Making Test part B divided by part A; ttau = total tau.
combination of narrow automated anatomic labeling-type regions [191] outlined
on the ICBM-152 template masked with a grey matter probability mask [229].
Images were analyzed by an experienced medical imaging specialist blinded to
all study information.
To estimate the SUVRcomp cut-off for detecting amyloid-positivity in vivo
using the above described method, a receiver operating curve (ROC) analysis
has been performed by Thurfjell et al. (2014) on an independent dataset of 68
SUVRcomp values (quantified based on the above described method) with the
autopsy results as a standard-of-truth [229]. The autopsy data were classified
following Vemuri’s modification of the Consortium to Establish a Registry for
AD criteria [299, 297]. Eight cortical regions (precuneus, midfrontal cortex,
superior temporal cortex, middle temporal cortex, inferior parietal cortex, an-
terior cingulate gyrus, posterior cingulate gyrus, and primary visual cortex)
were scored using an overall mean Bielschowsky score: 0 = 0 plaques, 1 = 1-5
plaques, 2 = 6-19 plaques, 3 ≥ 20 plaques. If the mean Bielschowsky score was
> 1.5 in at least one region, the brain was classified as amyloid-positve, if all
regions had ≤ 1.5, the brain was classified as amyloid-negative. The resulting
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SUVRcomp cut-off was 1.57 [229].
6.3.3 Lumbar puncture and CSF analysis
Lumbar punctures were carried out at the L4/5 level in the morning (10 am
- 2 pm) without fasting, on average 41 days after the PET scan (range 7 to
99 days). No adverse events were reported within 24 hours after the lum-
bar puncture. Thirteen milliliters (mL) of CSF was sampled in 4 fractions of
about 3 mL, each collected in a polypropylene tubes (Greiner Bio-one Cellstar,
VWR, Leuven, Belgium, total volume 15 mL), with discarding 1 mL to avoid
traumatic blood contamination. Samples were transported to the laboratory
medicine department immediately after the puncture and centrifuged within
30 min after collection (2600 RPM, 10 min, 4◦C). After centrifugation, super-
natants were transferred in polypropylene tubes and from there aliquoted in
1.5 mL polypropylene tubes (Kartell, Noviglio, Italy, volume CSF/tube 1 mL).
Samples were stored at -80◦C until batch analysis. The levels of CSF Aβ1-42,
Aβ1-40, Aβ1-38, and total tau (ttau) were measured in the first fraction with
a new generation of single analyte enzyme-linked immunosorbent assays (EU-
ROIMMUN, Lübeck, Germany) at ADx Ghent by two experienced laboratory
technicians blinded to all study information. The Aβ assays quantify the full
length of the C-terminus-specific Aβ isoforms (Aβ1-specific assay format). The
tau assay is designed with a capture antibody towards the central region and
one monoclonal antibody with an epitope at the amino-terminus of the protein.
The assay design includes lyophylised recombinant proteins as calibrators, run-
validation control samples (= calibrators added to a phosphate-buffered solu-
tion), as well as a qualification panel to evaluate the analytical performance(s)
in the lab. These novel immunoassays are free from matrix interference and
their intra-assay reproducibility has a coefficient of variation (CV) ≤ 5.0% with
an inter-assay reproducibility ≤ 8.3% [300].
6.3.4 Statistical analysis
In the primary analysis we compared diagnostic accuracy of different CSF Aβ
isoforms, their ratios, ttau and Aβ42/ttau to detect amyloid-positive older in-
dividuals. We used a ROC analysis with CSF analytes as variables of interest
and 18F-flutemetamol positivity defined based on autopsy-derived SUVRcomp
cut-off as a classifier. We also evaluated whether case classification changed
when we varied the cut-off by ± 1.5%, corresponding to the test-retest vari-
ability estimated for SUVRcomp [73]. The highest Youden index (sensitivity
+ specificity - 1) was used to estimate the optimal ROC cut-offs. Statistical
differences between ROC curves were evaluated according to the method of
DeLong et al. [301] for pairwise ROC comparisons.
Depending on the study, a high clinical specificity may be desirable even
if this implies a loss of sensitivity. We therefore also evaluated sensitivities
and cut-offs at a fixed prespecified specificity of 90% and 95%, respectively.
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We evaluated whether this changed case classification significantly (McNemar
test).
As a secondary analysis, we evaluated the continuous relationship between
the different CSF analytes and 18F-flutemetamol SUVRcomp values. We tested
whether a linear, polynomial (quadratic), exponential or hyperbolic relation
fitted best to these data. The model assumptions were assessed by evaluating
normality and homoscedasticity of residuals with q-q plots and plots of residuals
versus fitted values. The best fitting model was selected based on Akaike
information criterion (AIC) which is a measure of model fit. A lower AIC
indicates a better fit. CSF analytes were used as dependent variables and
18F-flutemetamol SUVRcomp as an independent variable.
Statistical analyses were performed in R version 3.1.1 (http://www.r-project.
org) and MedCalc version 14.8.1 (http://www.medcalc.org).
6.4 Results
Based on the autopsy-confirmed 18F-flutemetamol SUVRcomp cut-off, 7 out of
38 subjects (18%) were assigned to the amyloid-positive category (Figure 6.1A).
Case assignment did not change when we varied the cut-off according to the
known test-retest replicability.
Aβ42/ttau, Aβ42/Aβ40, Aβ42/Aβ38, and Aβ42 discriminated between
18F-flutemetamol positive and negative subjects with high accuracy (AUC >
0.908, Table 6.2, Figure 6.1B). Aβ38, Aβ40, and ttau showed a lower dis-
criminative power with AUC < 0.724 (Table 6.2). Aβ42/ttau, Aβ42/Aβ40,
Aβ42/Aβ38, and Aβ42 had significantly higher AUCs than Aβ38 or Aβ40
alone (Table 6.2, P < 0.003). There was no significant difference between ra-
tios Aβ42/ttau, Aβ42/Aβ40, Aβ42/Aβ38 on the one hand and Aβ42 alone, on
the other hand (Table 6.2, P > 0.32). The AUCs of the three ratios were not
statistically different from each other (Table 6.2, P > 0.30).
When specificity was fixed at 90%, Aβ42/ttau and Aβ42/Aβ40 had the
highest sensitivity and Aβ42/Aβ38 the second highest sensitivity (Table 6.3).
All three Aβ isoforms (Aβ42, Aβ40, Aβ38) used on their own detected signifi-
cantly fewer amyloid PET positive cases when specificity was fixed a priori at
90% than when the cut-off was based on the Youden index (Table 6.3), indica-
tive of a significant loss in sensitivity. This was not the case for Aβ42/ttau,
Aβ42/Aβ40, Aβ42/Aβ38 ratios, and ttau (Table 6.3).
When specificity was fixed at 95%, Aβ42/ttau had the highest sensitiv-
ity (Table 6.3). All Aβ isoforms, ttau, and all ratios detected significantly
less amyloid-positive cases when the specificity was fixed a priori at 95% com-
pared to the Youden index based cut-off, with one exception namely the ratio
Aβ42/ttau (Table 6.3). At a specificity of 95%, the number of amyloid PET
positive cases detected based on the ratio Aβ42/ttau did not differ significantly
from the number detected based on the Youden index based cut-off, although
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Figure 6.1: Distribution of 18F-flutemetamol SUVRcomp values and ROC curves
for different CSF analytes. (A) Distribution of 18F-flutemetamol SUVRcomp
values according to age, sex, and APOE genotype. Solid line = 1.57 SUVRcomp
cut-off, dashed lines = 1.57 SUVRcomp cut-off ± 1.5% corresponding to a test-
retest variability for SUVRcomp [73] (1.594 and 1.547). (B) ROC curves for
different CSF analytes, with 18F-flutemetamol positivity as classifier. Dots
represent optimal cut-offs for each analyte, corresponding to the highest Youden
index.
Diagnostic performance of different CSF analytes with 18F-flutemetamol
PET as autopsy validated standard-of-truth
AUC SE 95% CI Cut-offa Sensitivity Specificity
Aβ38 0.571 0.111 0.401 - 0.730 2909 100% 32.26%
Aβ40 0.571 0.112 0.401 - 0.730 10738 100% 29.03%
Aβ42*† 0.908 0.051 0.769 - 0.977 745 100% 74.19%
ttau 0.724 0.148 0.555 - 0.856 436 71.43% 80.65%
Aβ42/Aβ38*† 0.935 0.039 0.806 - 0.989 0.332 100% 87.10%
Aβ42/Aβ40*† 0.954 0.033 0.832 - 0.995 0.096 100% 80.65%
Aβ42/ttau*† 0.963 0.028 0.846 - 0.998 2.006 100% 87.10%
Table 6.2: Statistically significant differences of AUCs between analytes are
indicated by * and †. *P < 0.05 compared with Aβ40. †P < 0.05 compared
with Aβ38. No other differences of AUCs were found. aCut-off corresponding
to the highest Youden index. AUC = area under the ROC curve, SE = standard
error, CI = confidence interval. Analyte concentrations are described as pg/mL
or calculated as ratios between concentrations of two analytes.
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Clinical accuracy: estimated sensitivities and cut-off values at a fixed
specificity of 90% or 95%
Specificity of 90% Sensitivity 95% CI Cut-off % Difference P
Aβ38 14.29% 0.00 - 71.43 1446 65.79% <0.0001
Aβ40 14.29% 0.00 - 71.43 5602 65.79% <0.0001
Aβ42 57.14% 0.00 - 100.00 546 21.05% 0.008
ttau 57.14% 14.29 - 100.00 471 10.53% 0.125
Aβ42/Aβ38 71.43% 0.00 - 100.00 0.268 7.89% 0.250
Aβ42/Aβ40 85.71% 14.29 - 100.00 0.074 10.53% 0.125
Aβ42/ttau 85.71% 14.29 - 100.00 1.852 5.26% 0.500
Specificity of 95% Sensitivity 95% CI Cut-off % Difference P
Aβ38 14.29% 0.00 - 71.43 1342 68.42% <0.0001
Aβ40 14.29% 0.00 - 71.43 5254 71.05% <0.0001
Aβ42 42.86% 0.00 - 85.71 493 28.95% 0.001
ttau 42.86% 0.00 - 85.71 539 18.42% 0.016
Aβ42/Aβ38 28.57% 0.00 - 71.43 0.251 21.05% 0.008
Aβ42/Aβ40 57.14% 8.62 - 85.71 0.067 21.05% 0.008
Aβ42/ttau 71.43% 28.57 - 100.00 1.415 13.16% 0.063
Table 6.3: CI = confidence interval. % Difference = % of subjects who were
classified differently based on the cut-offs from fixed specificities compared with
the cut-offs corresponding to the highest Youden index (Table 6.2). P = sig-
nificance for the % Difference. Analyte concentrations are described as pg/mL
or calculated as ratios between concentrations of two analytes.
it was numerically lower.
Four CSF analytes, Aβ42/ttau, Aβ42/Aβ40, Aβ42/Aβ38, and Aβ42,
showed a significant correlation with the 18F-flutemetamol SUVRcomp values
(Figure 6.2). The linear model was rejected because it did not satisfy assump-
tions of the model. The hyperbolic model fitted best to the relationship be-
tween Aβ42 and 18F-flutemetamol SUVRcomp. The relationships between 18F-
flutemetamol SUVRcomp and Aβ42/ttau, Aβ42/Aβ40, Aβ42/Aβ38 were best
described by the exponential model. However, differences between the models
were small. There was no correlation between 18F-flutemetamol SUVRcomp
values and Aβ38, Aβ40, and ttau (Figure 6.2), in line with a previous study
[101].
6.5 Discussion
Overall, when sensitivity and specificity were combined, the ability to discrim-
inate amyloid-positive from amyloid-negative cognitively healthy older adults
was comparable between Aβ42 on its own and the ratio of Aβ42 over the iso-
forms examined or over total tau. However, when a high specificity of 90-95%
was imposed as a criterion, the sensitivity of Aβ42 alone diminished to 43-57%.
The sensitivity of the ratio over Aβ40 was acceptable at specificity of 90% (86%)
but at 95% it decreased to 57%. Under these requirements, the ratio over total
CSF Aβ isoforms for preclinical AD 93
Figure 6.2: Associations between the different CSF analytes and 18F-
flutemetamol SUVRcomp. Black lines represent fitting of the model, shown
only for the significant correlations.
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tau was the only measure which retained an acceptable sensitivity (71-86%).
A high specificity would for instance be desirable if the potential benefit of a
study drug depends on the amyloid-positivity of cognitively normal subjects
and the study drug has potentially noxious effects or a high cost. A favorable
trade-off in terms of sensitivity, as was the case only for Aβ42 over total tau,
would decrease the number of subjects needed to scan to reach a prespecified
number of positive cases.
6.5.1 Added value of Aβ isoforms Aβ38 and Aβ40
The shorter isoforms Aβ38 and Aβ40 on their own had no diagnostic value to
discriminate preclinical AD, in line with previous studies in cognitively intact
healthy controls [101], and also in clinical AD patients [302]. In the context of
preclinical AD, the added value of the Aβ isoforms mainly occurred when used
for calculating the ratio. The ratio over Aβ40 performed better than Aβ42
alone if a high specificity was required (Table 6.3).
The impact of using Aβ isoforms on the clinical accuracy is linked in part
to the context of use. In some studies comparing clinical AD with healthy
controls, the ratio of Aβ42 over Aβ38 or Aβ40 improved overall diagnostic ac-
curacy [303, 304], but in others it did not [302, 305]. For the discrimination be-
tween clinically probable AD and non-AD dementias, the discriminative value
of Aβ42/Aβ40 was similar to that of the ratio over total tau and better than
Aβ42 alone [306, 307]. In the MCI stage of the disease, the predictive value for
progression to dementia over a 4 year interval was higher for Aβ42/Aβ40 (AUC
= 0.866) than for Aβ42 alone (AUC = 0.768) [296]. In our study, Aβ42/Aβ40
still allowed acceptable sensitivity for a specificity of 90%, and more so than
Aβ42 in isolation.
The reason why ratios perform better than Aβ42 in isolation may be method-
ological: the normalization procedure may remove a portion of the pre-analytical
and analytical variability in the measurement of the protein levels that is in
itself unrelated to AD. In that case, as better standards will become available
for Aβ42 measurement, the benefit of using ratios will diminish. Alternatively,
the ratio may perform better than Aβ42 for biological reasons. Many autoso-
mal dominant forms of AD are associated with an increase in the ratio of Aβ42
over Aβ40 [308, 309]. Others, such as the Dutch and the Arctic APP mutation,
are associated with the inverse effect [308]. If the driving force in the initial
phases of sporadic AD is related to a disequilibrium between different isoforms
rather than the absolute amount of Aβ42 on its own, this could theoretically
explain why the ratio would be better.
6.5.2 Ratio of Aβ42 over total tau
For a fixed specificity of 95%, the highest sensitivity (71%) was obtained for
Aβ42 over total tau. Total tau is generally thought to reflect neuronal loss.
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Adding the separate measurement of a biomarker that increases with the inten-
sity of the neurodegenerative process may enhance specificity because AD is a
multidimensional disease [31, 310] so that adding a second dimension (neuronal
loss) improves accuracy of classification.
6.5.3 Potential study limitations
Our study has some limitations. The sample size was relatively low and
the number of amyloid-positive cases relatively small. For that reason, the
estimates of sensitivity and specificity may not be entirely stable. Second,
our standard-of-truth was 18F-flutemetamol positivity based on an autopsy-
validated cut-off. The autopsy study covered the different Thal stages 1-5
[142]. However, it remains possible, theoretically, that if measured in a popula-
tion restricted to cognitively intact older adults, the cut-off for distinguishing
moderate to high neuritic amyloid density from sparse to low density may
be lower than what is found in a mixed group including patients with ad-
vanced dementia along with dementia-free individuals [142]. Third, according
to the current study logic, a case who has low Aβ42 values but a normal 18F-
flutemetamol value would be considered a false-positive. We, however, cannot
exclude that this case is in a preclinical state preceding amyloid deposition
detectable by PET [101]. In the selection of subjects who have increased risk
of amyloid deposition but who have not yet reached the amyloid positivity
threshold, there could still be a role for Aβ isoforms beyond Aβ42, though this
remains to be demonstrated. The specificity required to define preclinical AD
based on biomarkers will depend on the type of clinical trial. Different ther-
apeutic strategies may target different preclinical stages of the disease. Our
findings are mainly relevant for those trials that target a phase where amyloid
aggregation has already occurred.
6.5.4 Conclusion
For selection of subjects with increased PET amyloid load, if a high specificity
is required, our data support the use of Aβ42 over total tau rather than using
Aβ42 alone or the ratios to other Aβ isoforms.
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7
General discussion
7.1 Preclinical AD in practice
In this project we define preclinical AD primarily based on amyloid PET scan in
accordance with the NIA-AA criteria [55]. Overall our findings agree with the
current model of preclinical AD [55, 311], however, we found several differences
and novelties related to this early disease stage based on our cohort.
When we pooled together all subjects included in this project the prevalence
of a positive amyloid scan was 19% (21 out of 112 subjects, Figure 7.1). This
is slightly lower compared with a recent meta-analysis of prevalence of amyloid
pathology in subjects with normal cognition [38]. In that meta-analysis study
amyloid positivity was observed in 25% of subjects between 52 and 82 years of
age. Out of all subjects in this age range, 30% were APOE ε4 carriers. This
meta-analysis was based on community-recruited cohorts and may be prone to
selection biases which may result in a higher prevalence rate. In a population-
based cross-sectional study of cognitively intact 50-89 years old adults fre-
quency of amyloid-positive individuals was similar to that in our study [312].
Among subjects between 50-79 years of age, they reported 15% of amyloid-
positive and neurodegeneration-negative cases and 5% of amyloid-positive and
neurodegeneration-positive cases. That gave in total 20% of amyloid-positive
subjects.
In the Mayo Clinic Study of Aging [312], in the older group between 80-89
years of age, 23.5% of subjects were amyloid-positive and neurodegeneration-
negative and 32% were amyloid-positive and neurodegeneration-positive, which
gave 55.5% of amyloid-positive subjects in total. Our cross-sectional study
did not include subjects older than 80 years, thus we do not have data on
frequency of amyloid positivity in this age range. Overall, above the age of 80
prevalence of AD and also amyloid positivity is high, but the impact of positive
amyloid biomarker on cognitive decline is probably lower in the older age range
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than in the younger subjects. Neuropathological studies have indicated that
the association between neuritic amyloid plaque density and the occurrence
of dementia is substantially lower above the age of 75 than at a younger age
[29, 313].
In our cohort, between 52 and 80 years of age, 46% of subjects were APOE
ε4 carriers. Within the amyloid-positive group, 71% of subjects were APOE ε4
carriers (15 of 21). Given that our cohort was enriched for APOE ε4 carriers
the percentage of amyloid-positive subjects may appear relatively low. On the
other hand, 50% of APOE ε4 carriers were also BDNF val carriers. Poten-
tially, val carries could have more effective mechanisms for reducing amyloid
accumulation (Chapter 3). Moreover, the whole cohort in our study, consisting
of four genetic groups, is quite different from the general population. Our sub-
jects were recruited from the community through advertisements in newspapers
and on the internet addressed to the 50+ community. Included subjects were
matched for number of factors, among them number of cases in each genetic
group resulting in different genotype frequencies than in the general population,
e.g. 25% of APOE ε4 and BDNF met carriers compared with less than 10%
in general population. Inversely, other community-recruited cohorts may have
selection biases of their own that may have resulted in a higher prevalence of
amyloid-positive cases in these studies. Therefore, we should apply with cau-
tion the expected prevalence of amyloid positivity in a specific age group based
on other community-recruited studies, to our community-recruited cohort. To
judge the prevalence in the general population, population-based studies, which
are relatively rare, remain the gold standard. Lastly, according to a detailed
interview performed during screening visit most of our subjects were educated,
cognitively and/or physically active, and taking medication or following a diet
for lowering cholesterol levels and blood pressure. These factors could also
contribute to some differences between our and other cohorts.
Subjects with intermediate levels of amyloid deposition presented a signif-
icant concern. This concern has been raised before [37]. Instead of a clear
bimodal distribution into amyloid-positive and amyloid-negative cases, a sig-
nificant proportion of values in cognitively intact older individuals is around
the cut-off (Figure 7.1). The intermediate cases contribute to the discordance
between 18F-flutemetamol and 11C-PIB binary classification based on semi-
quantitative assessment (Chapter 5). Two discordant cases were assigned to
the amyloid-negative category based on 18F-flutemetamol and to the amyloid-
positive category based on 11C-PIB. This suggests that either 18F-flutemetamol
is more resistant to the false positives or 11C-PIB is more sensitive at an early
stage of amyloidosis. A longitudinal follow up of these cases will clarify which
is the correct explanation. We could not formally compare the binary classifi-
cation between 18F-flutemetamol and CSF Aβ levels because we did not have
an independent cut-off for binary classification of CSF values at the time of
writing (Chapter 6).
Detection of the intermediate cases may depend on procedural details, such
as the method for amyloid quantification, chosen reference and target regions,
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Figure 7.1: Distribution of 18F-flutemetamol SUVRcomp values according to
age and APOE genotype in all included participants.
and method to define the cut-off, etc. It was suggested that by using the pons
instead of cerebellar grey matter as a reference region some of the variabil-
ity related to the white matter content in VOIs might be removed [314, 298]
and it might be more suitable for longitudinal studies [315]. In our analysis
method (Chapter 5), owing to the narrow MRI-based cortical VOIs which con-
tain less white matter, the cerebellar grey matter is a preferred reference region
compared with the pons.
The intermediate values may have a biological meaning. They could repre-
sent subjects on their way to increased amyloid deposition. It is important to
mention here, that the design of our study was cross-sectional and one cannot
directly determine from our data who will show further increase in amyloid
aggregation in the future or at which age a positive subject started to accu-
mulate amyloid prior to inclusion. Longitudinal studies showed that changes
in Aβ level begin as early as middle age and in some cases they increase over
time [300]. Amyloid accumulation is a progressive and dynamic process and
the amyloid-positive cases represent a range of continuous values rather than
a stationary amyloid-positive stage. Hence, binary classification into positive
and negative subjects is somewhat artificial, albeit useful in the clinical con-
text. In the same line, amyloid biomarkers could reflect different accumulation
phases. For instance, according to a neuropathological validation study, amy-
loid PET with 18F-flutemetamol is able to reliably discriminate between Thal
amyloid phases 1-2 versus 4-5, but not 1-2 versus 3 [316]. Thus, it probably
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reflects intermediate to advanced amyloid accumulation and is less sensitive to
only slightly elevated amyloid deposition. On the other hand, in this study
amyloid scans were assessed in a binary manner according to visual reads. If
scans were assessed on a continuous scale, e.g. SUVR scale, and values were
correlated to the Thal amyloid phases one potentially could detect more subtle
relationships. There are some speculations that CSF measurement of Aβ42 re-
flects the earliest amyloid changes, and that CSF Aβ42 and amyloid PET are
partially independent [102]. The soluble Aβ42 is a precursor for fibrillar amy-
loid plaques and is believed to be the cause of toxicity, either directly stemming
from oligomeric Aβ intermediates destined for aggregation into plaques or from
Aβ oligomers released from higher structure fibrils and plaques [317]. In CSF
soluble Aβ is measured and is believed to reflect brain soluble Aβ fraction [104],
however, there is no direct proof for that. A group from Washington University
used compartmental modeling of stable isotope labeling kinetic (SILK) [318]
in cognitively normal controls, and in patients with sporadic and autosomal
dominant AD (ADAD) to evaluate the production and turnover rate of Aβ
isoforms [319, 320]. They proved that in sporadic AD clearance rate of Aβ42
is 49% slower than in HC [319], and that in ADAD production rate of Aβ42 is
24% increased and its turnover rate relative to Aβ40 is 65% faster compared
with noncarriers [320]; explaining reduced Aβ42 concentration in CSF. These
experiments also shed light on different forms of soluble Aβ present in CSF
(monomers, dimers, oligomers, Aβ bound to larger structures) which currently
cannot be distinguished. If CSF truly represents brain soluble Aβ it seems
plausible that a middle age subject with a positive CSF Aβ42 finding and a
negative amyloid PET lies in the lag-phase where Aβ42 concentration is in-
creased for longer time until it reaches a threshold to initiate Aβ42 aggregation
[317]. Thus, theoretically CSF and PET could reflect different amyloid phases.
Nonetheless, this needs further investigation, the best is a longitudinal study
with near the same time acquisition of amyloid PET and CSF Aβ42 followed
by a neuropathological validation detecting aggregated and soluble Aβ pools.
The data presented in different chapters of this thesis are part of a study
to explore different aspects of amyloid deposition in the preclinical AD popu-
lation. In cognitively intact older adults we aimed at (1) investigating BDNF
and APOE polymorphisms’ effects on amyloid load (Chapter 3) and an asso-
ciation with the patterns of functional activation (Chapter 4), (2) comparing
performance of 18F-flutemetamol PET and 11C-PIB PET (Chapter 5) and CSF
(Chapter 6) biomarkers for the definition of preclinical AD, and (3) defining ge-
netic determinants of increased amyloid levels other than APOE (future work).
The cognitively intact older adults have been recruited from the community for
a total sample size of 180 subjects. At the time of recruitment, subjects were
stratified according to a factorial design with 2 factors per 5 year age bins:
BDNF (met allele present versus absent) and APOE (ε4 allele present versus
absent). The different cells of the factorial design were matched for the num-
ber of cases, gender, age, and educational level. Note that, we had to screen
a larger number of volunteers to find a sufficient number of the rare combina-
tion of BDNF met and APOE ε4 alleles. Since 2010 until the time of writing,
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741 volunteers underwent an on-site screening visit, which included an inter-
view about medical history, MMSE, and blood sampling for genotyping. Of
these, 298 volunteers underwent a detailed neuropsychological assessment and
172 proceeded to the full study procedures: 18F-flutemetamol PET, volumet-
ric MRI, FLAIR. In addition, 64 subjects underwent an fMRI, 32 received an
11C-PIB PET, and 38 received a CSF analysis for Aβ, total and phospho tau.
This doctoral research project revealed an interesting and novel finding.
In preclinical AD, the BDNF gene in interaction with the APOE gene mod-
ulated amyloid deposition (Chapter 3). This suggests that neuroplasticity-
related genes may also play a role in amyloid accumulation (see discussion in
the next section).
We also found that at the preclinical AD stage increased amyloid load was
associated with increased activity in the posterior temporal cortex during a
language task (Chapter 4). Such an increased activity may have a compen-
satory function against toxic effects of amyloid pathology (see discussion in the
next section).
To conclude, a significant proportion of the cognitively intact older adults
has increased amyloid deposition, and therefore could encompass the preclinical
stage of AD. It remains to be seen which subjects in our cohort will progress
to the symptomatic stage and over how long time period [311]. Most recent
findings indicate that subjects in preclinical stage 1-3 are at a greater risk for
cognitive decline [321] and progression toward symptomatic AD [57, 58]. A
longitudinal follow-up of the study participants will shed light on this issue.
7.2 Neuronal response to amyloid injury
Five years ago we started from a model in which BDNF polymorphism was
expected to affect functional changes in the language and semantic system
in response to amyloid deposition. Instead, we found that in interaction with
APOE polymorphism, it affects amyloid accumulation (Chapter 3). BDNF met
carriers intrinsically have worse neuronal plasticity and with at least one APOE
ε4 allele they are additionally predisposed to a higher amyloid deposition. It
has been suggested that APOE ε4 carriers with BDNF met cannot tolerate
amyloid toxicity to the same extent as APOE ε4 carriers with BDNF val form
[322]. In this group the neuronal survival mechanisms might be less efficient.
This is concordant with the neuronal plasticity failure theory, which has been
implicated as one of the potential mechanisms in AD [17, 323]. Neuroplasticity
is a concept where neurons throughout life undergo adaptive changes in order to
keep up with physiological needs and to cope with an injury or stress. It involves
upstream changes in regulatory processes at the neuronal body level, which
mediate downstream structural and functional changes of dendrites, axons, and
synapses [17]. In AD, processes such as amyloid accumulation, tau tangles, loss
of synapses and neurons, and cholinergic depletion, perturb normal neuronal
plasticity processes at downstream dendritic and synaptic sites. This triggers
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an extra upstream plasticity-related cellular activity to meet the higher needs
at the downstream sites. Initially this process is compensatory but when it is
active for a prolonged time it leads to maladaptive effects. This is influenced
by genetic and environmental factors [17]. Let us translate this theory to the
established interaction. In BDNF val carriers who carry an APOE ε4 allele,
properly functioning neuroplasticity processes would compensate for the toxic
effects of Aβ, by e.g. an induction of pro-survival BDNF signalling and a chain
of more complex plasticity-related reactions. In BDNFmet carriers with APOE
ε4, the pro-survival BDNF signalling would be less efficient e.g. owing to the
reduced BDNF secretion, and this would render neurons less resistant to the
surrounding Aβ toxicity. This would also negatively affect the normal neuronal
processes, such as synaptic and axonal signalling, protein transport, vesicular
trafficking, and clearance of intra and extra cellular debris. Potentially this
would lead to a faster amyloid accumulation among other detrimental processes.
It is important to mention that the reason we were able to detect this inter-
action was probably because of the genetic stratification for BDNF and APOE
prior to recruitment for scanning. The combined rare forms of BDNF met and
APOE ε4 within a same subject, were present only in 10% of all candidates
volunteering for the study after applying all non-genetic in/exclusion criteria.
After genetic stratification this rare combination was present in 25% of cases.
Therefore, we would probably miss this interaction if the study candidates
would not be matched for equal number of cases in each genotype group. If
one would like to replicate this findings, prior stratification might be a prereq-
uisite for the success of the study.
The biological effect of this double risk genotype (BDNF met/APOE ε4)
seems intelligible. The mechanistic underpinnings of this interaction, how-
ever, are more difficult to explain. The interaction between BDNF and APOE
will probably occur at the epistatic (gene-protein-gene) level or protein-protein
level, rather than direct gene-gene interaction. A recent study showed an
epistatic effect of APOE on BDNF [324]. Using human primary neuronal cells,
it was shown that APOE ε4 increased nuclear translocation of histon deacety-
lases 4 and 6 which reduced BDNF expression, whereas APOE ε3 increased
histon acetylation and increased BDNF expression [324]. This mechanism ex-
plained reduced BDNF expression, but did not take into account different gene
products of the val66met polymorphism. The BDNF met carriers may have
decreased activity-dependent secretion of BDNF protein, impaired dendritic
trafficking and synaptic localization, rather than impaired expression [183]. A
possible link in the cross-talk between BDNF and APOE could be SORLA pro-
tein (sorting protein-related receptor containing LDLR class-A repeats), which
is implicated in molecular pathways of both BDNF and APOE. SORLA is a
sorting receptor for the amyloid precursor protein and it regulates intracellular
trafficking and processing of amyloid peptides [325]. BDNF protein activates
transcription of SORLA [325]. Cellular uptake of amyloid provided by SORLA
is dependent on APOE isoforms [326]. Currently very little is known about pos-
sible pathways through which BDNF and APOE proteins could cross [327, 324],
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and even less is known about crossing of their genotype specific effects.
At the functional level, our current and previous findings suggest that the
activity in the posterior temporal language and semantic areas may follow a
characteristic temporal and spatial pattern in response to the amyloid injury
[133, 132]. At the beginning of the disease, the increased activity within left
posterior MTG, subserving higher demands for semantic control, may have a
compensatory role which maintains a normal cognitive performance despite the
present amyloidosis (Chapter 4). Next, consistent with the neuronal plasticity
failure theory, due to a breakdown of a prolonged increased neuronal activity,
a gradual degeneration of neuronal function may begin in areas more directly
involved in word processing as left posterior STS, and this may lead to the first
cognitive symptoms [133]. When a significant proportion of neurons is dam-
aged in the target left-sided areas, which are not able to sustain the function
any further, the homotopical right-sided regions may be recruited such as right
posterior STS [132]. The increased activity in left posterior MTG in response to
higher amyloid load was independent of BDNF val66met genotype. This may
seem surprising since BDNF met carriers would be expected to have somewhat
lower compensatory capacity against amyloid toxicity, according to the neuro-
plasticity theory. However, in light of our findings from Chapter 4, BDNF in
interaction with APOE may be involved at a different level of the pathophysio-
logical AD process. It may mediate amyloid aggregation rather than modulate
post-hoc response to amyloid toxicity. On the other hand, BDNF val66met is
known to affect episodic memory [181, 182, 183, 184, 185, 186, 187], therefore
it is as well possible that we did not pick up the effect of BDNF because we
focused on the language function. At a genetic level, current evidence for ge-
netic involvement of BDNF in AD is not clear (e.g. [328, 329, 330]) but there is
increasing evidence suggesting a role of BNDF in AD pathogenesis, e.g. based
on studies of BDNF serum levels [222, 331, 332] or animal studies [215, 216].
A similar pattern of stage-dependent fMRI activation changes can be ob-
served in the hippocampal formation during episodic memory tasks. In preclin-
ical AD [265, 266, 135] and early MCI [263, 264, 134], activity during memory
encoding in hippocampus is increased compared with controls. In the more
advanced disease stages, late MCI [258, 262] and probable AD [257, 258, 259,
260, 138, 261], activity is decreased compared with controls.
Elman et al. [136] investigated if such increased activation is truly com-
pensatory or rather an aberrant overactivation. Cognitively intact older and
young individuals encoded visual scenes during fMRI and afterwards they were
asked if the provided description matched previously viewed scenes (gist mem-
ory) and if the number of details matched a given scene (memory richness).
Older subjects received a 11C-PIB PET scan. They showed that older indi-
viduals with increased amyloid deposition have increased fMRI activity during
gist memory encoding in task-positive areas, and decreased deactivation in
task-negative areas. Amyloid-positive older subjects with increased activation
in task-positive areas could recollect more details about scenes. It was con-
cluded that increased activity in subjects with brain amyloidosis is beneficial
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and reflects neural plasticity and serves a compensatory function [136].
In a longitudinal study of MCI subjects, Huijbers et al. [134] investigated
fMRI activity during face-name encoding task over 3 years. MCI subjects
underwent a 11C-PIB PET scan at baseline and repeat MRI at 6 later time
points. They reported that amyloid-positive MCI subjects had increased hip-
pocampal activity during memory encoding compared with amyloid-negative
subjects. This activity did not significantly change over time. They suggested
that elevated hippocampal activity may have a compensatory function against
neurodegeneration or it contributes to amyloid deposition [134].
Taken together, we can conclude that increased activation in domain specific
areas (memory or language) at the early disease stages most probably have a
compensatory function. Significant associations with the behavioural measures
are reassuring, however, one must note that this conclusion was derived from
correlational analyses and between-group comparisons. An interventional study
would be necessary to further prove this compensatory function. For such
purpose, transcranial magnetic stimulation may be a useful technique, which
can transiently deactivate a region of interest to test its effect on behavioural
performance.
7.3 Clinical applicability
The remaining question is which amyloid measure is the most accurate to define
preclinical AD. This is especially important for the clinical trials of putative new
treatments for AD. The success of targeted molecular therapies may critically
depend on the presence of the drug target. Accurate ascertainment of amyloid-
positivity prior to inclusion may constitute one of the factors that determines
the success of trials in preclinical AD (importance of high specificity), as well
as the cost of screening (importance of high sensitivity). Moreover, amyloid
biomarkers may be used as surrogate endpoints to assess the efficacy of disease-
modifying treatments.
Despite some differences in the dynamic range, the three recently FDA
and EMA approved tracers 18F-flutemetamol [66], 18F-florbetaben [67], and
18F-florbetapir [68], and also 11C-PIB [105], clearly separate AD patients from
controls. Binding of the approved tracers to neuritic amyloid plaques has been
thoroughly validated in the pivotal phase 3 neuropathological studies [333, 226,
142] (Table 7.1). Compared with 18F-flutemetamol and 18F-florbetaben, 18F-
florbetapir has a lower slope for correlation with 11C-PIB, indicating a smaller
dynamic range [31, 69]. Diagnostic performance based on neuropathology as a
standard-of-truth is not available for 11C-PIB. However, generally 11C-PIB re-
tention correlates well with immunohistochemical measures of amyloid plaque
area [334, 141, 335]. Given its shorter half-life, use of 11C-PIB will be restricted
to research. According to the findings reported in Chapter 5, a method to eval-
uate the amyloid PET scan in preclinical AD is preferentially quantitative. The
quantitative approach offers several advantages: it is independent of reader sub-
General discussion 105
Diagnostic performance of FDA and EMA approved amyloid PET tracers
with neuropathological findings as a standard-of-truth
18F-florbetaben [333] 18F-florbetapir [226] 18F-flutemetamol [142]
Sensitivity % (95% CI) 98 (94 - 100) 92 (78 - 98) 86 (72 - 95)
Specificity % (95% CI) 89 (77 - 100) 100 (80 - 100) 92 (74 - 99)
AD (No) 57 29 30
MCI (No) 0 5 0
Other dementias (No) 9 13 17
HC (No) 8 12 21
∆t PET and autopsy ≤ 20 months ≤ 24 months ≤ 13 months
Readers (No) 3 5 5
Table 7.1: Scans were evaluated visually. Values in the table represent results
for majority reads. CI = confidence intervals. No = number. ∆t = time
between.
jectivity when evaluating images, and an identical quantification method can
be applied across stages of a longitudinal study and/or across different centres
[37]. In a part of the healthy older population with intermediate uptake values,
the quantitative method may outperform visual reads, which are difficult to
perform in such case. A reference region used to scale amyloid image is an
important methodological factor which may influence the subject classification
[37]. In our entire sample of 112 subjects, SUVRcomp with the cerebellar grey
matter as reference region correlated with SUVRcomp calculated using the pons
as reference region (Figure 7.2). When the pons was used as reference region,
analyses from Chapter 3 yielded the same results as those obtained with the
cerebellar cortex as reference region. In Chapter 4 using the pons generated
similar results to the main analyses but with much lower values of statistical
significance. In Chapter 5 the correlation between 18F-flutemetamol and 11C-
PIB SUVRs was weaker when the pons was used. In our cohort of cognitively
intact older controls, the pons as reference region does not preform better than
the cerebellar cortex, despite some suggestions from other studies [314, 298]. In
agreement with the neuropathological staging, which shows that the cerebellar
cortex is not affected by amyloid plaques until late AD stage [7], amyloid im-
ages of adults between 55 and 80 years of age can be scaled to a ligand uptake
in the cerebellar grey matter.
For the CSF-based definition of preclinical AD, if a high specificity is re-
quired, the use of Aβ42 over total tau or over Aβ40 is preferred, rather than
using Aβ42 alone (Chapter 5). This is in line with two recent studies showing
a better discrimination between AD and HC based on Aβ42/Aβ40 ratio com-
pared with Aβ42 alone [304, 303]. The added value of Aβ42/total tau ratio is
well established in clinical populations [336]. These ratios are also useful for a
differential diagnosis (see Section 6.5.1). A performance of the CSF measure-
ment is clinicopathologically validated, although only for the Aβ42 isoform.
Low Aβ42 levels are associated with fibrillar brain Aβ deposits postmortem
[83] and in cortical biopsies [84]. The sensitivity and specificity are in the
range of amyloid PET tracers, 92% and 86% respectively [83]. A limitation is
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Figure 7.2: Linear regression between 18F-flutemetamol SUVRcomp values with
cerebellar grey matter (X axis) and pons (Y axis) used as reference regions;
based on all included participants (n = 112).
the time interval between CSF collection and autopsy, which is much longer
than in the neuropathological studies of amyloid tracers.
The difference in utility between imaging and CSF biomarkers lies in the
metrics of the tests, i.e. between-centre and within-centre replicability, the
prevalence of intermediate values, and the between-reader variability in di-
agnostic interpretation of the values for amyloid imaging and CSF, respec-
tively. From the viewpoint of implementation in a clinical environment, CSF
biomarkers still have to go through the standardization steps that other diag-
nostic laboratory tests, e.g. for measuring protein levels in blood, have gone
through [337, 338]. The values measured for the same sample vary between
centres and the interpretation of a given CSF profile may also be centre- and
examiner-dependent. The factors that contribute to the between-centre and
within-centre variability of CSF measurements need to be better understood
and improved. The neuropathological validation studies of CSF performance
should be replicated in a prospective manner. In this sense, the strengths of
amyloid imaging compared to CSF at the time of writing seem to lie in its per-
formance in terms of replicability between and within centres, between-reader
replicability and standardization [31].
Summary
In this thesis we focused on brain amyloid deposition in a cognitively intact
older population: we described its dependence on the genetic polymorphisms
and its functional consequences on language and semantic processing. More-
over, we compared the performance of different amyloid biomarkers.
All participants included in this project were community recruited cogni-
tively intact older adults (52-74 years old Chapter 3 and 4 or 65-80 years old
Chapter 5 and 6) who underwent genetic stratification for APOE and BDNF,
conventional neuropsychological testing, volumetric MRI, 18F-flutemetamol
PET, and additionally for experiments in Chapter 3 and 4 associative-semantic
fMRI and neurolinguistic assessment, or for experiments in Chapter 5 and 6 a
second PET with 11C-PIB and lumbar puncture to collect cerebrospinal fluid.
In the first part of this work (Chapter 3), we examined whether the BDNF
codon 66 polymorphism affects β amyloid deposition and the relationship be-
tween β amyloid burden and cognitive scores, and how this relates to the effect
of APOE. Our study revealed two key novel findings. First, APOE ε4 carriers
exhibited a higher β amyloid load in the presence of one or two BDNF met
alleles compared to BDNF met non-carriers. This interaction was localized
to precuneus, orbitofrontal cortex, gyrus rectus, and lateral prefrontal cortex.
Second, an inverse relationship between Aβ load and episodic memory exists
in BDNF met/APOE ε4 carriers but not in any of the other subgroups. This
experiment highlights a potential role of the BDNF polymorphism in the pre-
clinical phase of β amyloid deposition and also suggests that the BDNF codon
66 polymorphism may influence resilience against β amyloid-related effects on
cognition.
In the second part of this project (Chapter 4), we examined whether amyloid
load affects the network for language and associative-semantic processing. We
found that a higher activity during associative-semantic processing in the pos-
terior left middle temporal gyrus, correlated positively with increased amyloid
load. This finding was based on a whole-brain search without prior restriction
of the search volume. According to a stepwise linear regression analysis, oﬄine
naming reaction times correlated positively with amyloid levels. In a secondary
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analysis based on a binary approach, the amyloid-positive group exhibited a
higher activity compared to the amyloid-negative group during associative-
semantic processing in the same region: the posterior left middle temporal
gyrus. We concluded that the left posterior temporal activity increase may
reflect higher demands for semantic control in the presence of a higher amyloid
burden at the preclinical AD stage.
In the third part of this project (Chapter 5), we compared two amyloid
imaging markers within subjects: 18F-flutemetamol and 11C-PIB. We found
that the concordance between binary classification based on 18F-flutemetamol
versus 11C-PIB according to semiquantitative assessment (SUVR) was 94%.
Concordance of blinded binary visual reads between tracers was 84%. The cor-
relation between 18F-flutemetamol and 11C-PIB SUVR values with cerebellar
grey matter as reference region, was 0.84, with a slope of 0.98. Correlations
in neocortical regions were significantly lower with pons as reference region.
Partial volume correction improved the correlation in two out of 9 investi-
gated regions: striatum and medial temporal cortex. This study provided
evidence that for the definition of preclinical AD based on 18F-flutemetamol,
concordance with 11C-PIB was highest using semiquantitative assessment with
cerebellar grey matter as reference region.
In the last part of this work (Chapter 6), we compared the diagnostic ac-
curacy of different cerebrospinal fluid Aβ isoforms, their ratios, total tau, and
Aβ42/ttau for detecting amyloid-positive individuals. For this purpose we per-
formed ROC analysis on cerebrospinal fluid analytes with 18F-flutemetamol
amyloid PET as classifier. Seven out of 38 subjects (18%) were assigned to the
amyloid-positive category based on the PET cut-off. Aβ42/ttau, Aβ42/Aβ40,
Aβ42/Aβ38, and Aβ42 had the highest accuracy to identify amyloid-positive
subjects (AUC ≥ 0.908). Aβ40 and Aβ38 had significantly lower discriminative
power (AUC = 0.571). When specificity was fixed at 90% and 95% Aβ42/ttau
had the highest sensitivity, 85.71% and 71.43%, respectively. This experiment
showed that for the CSF-based definition of preclinical AD, if a high specificity
is required, our data support the use of Aβ42 over total tau rather than using
Aβ42 in isolation.
Samenvatting
In deze thesis lag de focus op het meten van amyloidneerslag in een populatie
van cognitief intacte, oudere vrijwilligers. We konden een verband beschrijven
met genetische polymorfismen en de functionele gevolgen hiervan op het vlak
van taal en semantische verwerking. Daarenboven hebben we de performantie
van verschillende amyloid biomerkers vergeleken en beschreven.
Alle cognitief intacte, oudere vrijwilligers, werden gerecruteerd voor dit
project uit de algemene bevolking (52-74 jaar oud Chapter 3 en 4 of 65-80
jaar oud Chapter 5 en 6) Deze cohorten werden vervolgens genetisch gestrat-
ificieerd voor APOE en BDNF polymorfismen en ondergingen conventionele
neuropsychologische testen, een volumetrische MRI en 18F-flutemetamol PET.
Een deel van deze vrijwilligers heeft deelgenomen aan experimenten (Chap-
ter 3 en 4) met een associatieve-semantische fMRI en neurolinguistische taken,
of aan experimenten (Chapter 5 en 6) met een tweede (11C-PIB) PET scan en
tenslotte een lumbale punctie voor hersenvochtanalyse.
In het eerste deel van dit werk (Chapter 3), onderzochten we of het BDNF
codon 66 polymorphisme de β amyloidneerslag kan beïnvloeden en hoe β amy-
loidpathologie de cognitieve scores kan beïnvloeden, met betrekking tot effecten
van het APOE gen. Onze studie kon twee belangrijke bevindingen rapporteren.
Ten eerste vertoonden APOE ε4 dragers een hogere graad van β amyloidneer-
slag wanneer zij ook drager waren van een of twee BDNF met allelen vergeleken
t.o.v. BDNF met non-carriers. Deze interactie is gelocaliseerd in de precuneus,
de orbitofrontale cortex, gyrus rectus, en de lateral prefrontale cortex. Ten
tweede, hebben we aangetoond dat er een inverse relatie bestaat tussen Aβ
pathologie en performantie op testen die het episodisch geheugen onderzochten
in de BDNF met/APOE ε4 dragers. Dit verband kon niet worden aangetoond
in de andere subgroepen. Dit experiment wijst op een mogelijke rol van het
BDNF polymorphisme in de preklinische fase van β amyloidneerslag en sug-
gereert ook dat het BDNF codon 66 polymorfisme de veerkracht/weerstand van
het brein tegen β amyloid-gerelateerde effecten op cognitie kan beïnvloeden.
In het tweede deel van dit project(Chapter 4), hebben we onderzocht of amy-
loid pathologie het taalnetwerk en het netwerk voor associatieve-semantische
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verwerking beïnvloedt. We konden aantonen dat een hogere activatie gedurende
associatieve-semantische verwerking in de linker posterieure midden temporale
gyrus, correleerde met een hogere graad van amyloidneerslag in dit gebied. Deze
bevinding was gebaseerd op een analyse van het gehele brein zonder beperk-
ing van het zoekvolume. Volgens een stapsgewijze, lineaire regressie analyse,
correleerden de oﬄine reactietijden voor het benoemen van objecten met een
hogere graad van amyloidneerslag. In een secundaire analyse, gebaseerd op een
binaire classificatie, bleek dat de amyloid-positieve groep een hogere activiteit
vertoonde vergeleken met de amyloid-negatieve groep gedurende associatieve-
semantische verwerking in dezelfde regio: de linker posterieure midden tempo-
rale gyrus. We kunnen dus besluiten dat de verhoogde activiteit in de linker
posterieure temporale gebied mag een hogere semantische controle vereist, wan-
neer er amyloidpathologie aanwezig is in het preklinische stadium van AD.
In het derde deel van dit project (Chapter 5), vergeleken we twee amyloid
beeldvormingsmerkers in dezelfde subjecten: 18F-flutemetamol PET en 11C-
PIB PET. We vonden een concordantie van 94% tussen de binaire classificatie
van 18F-flutemetamol PET versus 11C-PIB PET gebaseerd op een semiquanti-
tatieve berekening (SUVR). De concordantie van de geblindeerde visuele lezin-
gen van de twee type PET scans was daarentegen 84%. De correlatie tussen
18F-flutemetamol en 11C-PIB SUVR waarden, met de cerebellaire grijze stof
als referentie regio, was 0.84, met een richtingscoefficient van 0.98. Correlaties
in neocorticale regio’s waren significant lager wanneer we de pons als referentie
regio gebruikten. Partieel volume correctie verbeterde de correlatie in twee van
de 9 onderzochte regio’s: het striatum en de mediale temporale cortex. Deze
studie bevestigde dat voor de definiëring van preklinische AD 18F-flutemetamol
gebruikt kan worden en dat de concordantie met 11C-PIB het hoogste was voor
de semiquantitatieve berekening van tracer opname met cerebellaire grijze stof
als referentie regio.
In het laatste deel van dit werk (Chapter 6), vergeleken we de diagnostische
accuraatheid van merkers in het hersenvocht: verschillende Aβ isovormen, de
ratios, totale tau, en Aβ42/ttau om amyloid-positieve subjecten te kunnen on-
derscheiden van amyloide-negatieve subjecten. We maakten hiervoor gebruik
van ROC analyse op de hersenvochtmerkers met 18F-flutemetamol amyloid
PET als ’classifier’. Zeven van de 38 subjecten (18%) werden ingedeeld in de
amyloid-positieve categorie gebaseerd op de PET grenswaarde. Aβ42/ttau,
Aβ42/Aβ40, Aβ42/Aβ38, en Aβ42 waren het meest accuraat in het identifi-
ceren van amyloid-positieve subjecten (AUC ≥ 0.908). Aβ40 en Aβ38 had-
den minder discriminerende waarde (AUC = 0.571). Wanneer de specificiteit
beperkt werd tot 90% en 95%, dan had Aβ42/ttau de hoogste sensitiviteit
(85.71% and 71.43%, respectievelijk). Dit experiment toont aan dat voor
de hersenvocht-gebaseerde definitie van preklinische AD, een hoge specificiteit
vereist is en dat het gebruik van Aβ42 in combinatie met total tau een betere
diagnostische waarde heeft dan Aβ42 op zich.
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